Evaluation of proteomic and transcriptomic biomarker discovery technologies in ovarian cancer by Coveney, CRE
  
 
 
EVALUATION OF PROTEOMIC AND 
TRANSCRIPTOMIC BIOMARKER DISCOVERY 
TECHNOLOGIES IN OVARIAN CANCER. 
 
 
CLARE RITA ELIZABETH COVENEY 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements of the 
Nottingham Trent University for the degree of Doctor of Philosophy 
 
 
October 2016 
 
 
 
  
  
Copyright Statement 
 
“This work is the intellectual property of the author. You may copy up to 5% of this work for 
private study, or personal, non-commercial research. Any re-use of the information contained 
within this document should be fully referenced, quoting the author, title, university, degree 
level and pagination. Queries or requests for any other use, or if a more substantial copy is 
required, should be directed in the owner(s) of the Intellectual Property Rights.” 
 
 
  
Acknowledgments 
 
This work was funded by The John Lucille van Geest Foundation and undertaken at the John 
van Geest Cancer Research Centre, at Nottingham Trent University. 
I would like to extend my foremost gratitude to my supervisory team Professor Graham Ball, 
Dr David Boocock, Professor Robert Rees for their guidance, knowledge and advice throughout 
the course of this project.  
I would also like to show my appreciation of the hard work of Mr Ian Scott, Professor Bob 
Shaw and Dr Matharoo-Ball, Dr Suman Malhi and later Mr Viren Asher who alongside 
colleagues at The Nottingham University Medical School and Derby City General Hospital 
initiated the ovarian serum collection project that lead to this work. I also would like to 
acknowledge the work of Dr Suha Deen at Queen’s Medical Centre and Professor Andrew 
Green and Christopher Nolan of the Cancer & Stem Cells Division of the School of Medicine, 
University of Nottingham for support with the immunohistochemistry. 
I am grateful for the colleagueship of the numerous and high-quality scientists, both staff and 
students I have had the opportunity to work alongside during this time. 
I am indebted for the unconditional and unknowing support of my partner, friends and family, 
especially my parents. 
Thank you. 
  
Contents 
 
 
CONTENTS 
 
FIGURES .................................................................................................................................... i 
TABLES .................................................................................................................................... iii 
Abbreviations and Glossary ...................................................................................................... iv 
HYPOTHESES ........................................................................................................................ vii 
Thesis Abstract ........................................................................................................................ viii 
1. Introduction ............................................................................................................................. 1 
1.1. General Concepts ............................................................................................................. 1 
1.1.1. Cancer ....................................................................................................................... 1 
1.1.2. Ovarian Cancer ......................................................................................................... 4 
1.1.3. Biomarkers .............................................................................................................. 10 
1.1.3.1. Essential and Desirable biomarker properties .................................................. 11 
1.1.4. The Need for Effective Screening Strategies .......................................................... 12 
2. Methodological Overview .................................................................................................... 18 
2.1. Proteomic Approaches to Biomarker Discovery and Onco-proteomics ........................ 18 
2.1.1. Proteomic Techniques for Cancer Biomarker Discovery ....................................... 18 
2.1.2. Analysis of the Serum Proteome ............................................................................. 19 
2.1.3. Mass Spectrometry and Tandem Mass Spectrometry ............................................. 22 
2.1.3.1. An Historic Summary ....................................................................................... 22 
2.1.3.2. Soft Ionisation: Matrix Assisted Laser Desorption Ionisation (MALDI) and 
Electrospray Ionisation (ESI) ......................................................................................... 24 
2.1.3.3. Mass Analysers ................................................................................................. 28 
2.1.3.4. Tandem Mass Spectrometry ............................................................................. 30 
2.1.4. Mass Spectrometry Approaches/Techniques used for Biomarker Discovery ......... 32 
2.1.5. Sample Fractionation and Liquid Chromatography ................................................ 33 
2.1.5.1. Reducing Sample Complexity .......................................................................... 33 
2.1.5.2. The Mechanics of and Sources of Variability in Liquid Chromatography ....... 33 
2.1.5.3. Deconvolution of Complex Biological Samples Using Liquid Chromatography
 ....................................................................................................................................... 36 
Contents 
 
 
2.1.6. Advantages or Disadvantages of Tagging in MALDI-TOF-MS. ............................ 38 
2.1.7. Label Free Quantitation Techniques ....................................................................... 38 
2.2. Transcriptomic Approaches to Biomarker Discovery and Onco-genomics ................... 39 
2.2.1. Gene Expression Profiling ...................................................................................... 40 
2.2.1.1. DNA Microarray Experiments .......................................................................... 40 
2.2.1.2. Next Generation DNA Sequencing ................................................................... 41 
2.2.2. Data Mining ............................................................................................................ 42 
2.2.2.1. Statistical Analysis for Omics Data .................................................................. 43 
2.2.2.2. Categorical and Continuous Variables in Omics Data ..................................... 44 
2.2.2.3. Analysis of Omics Survival Data ...................................................................... 44 
2.2.2.4. Machine Learning. ............................................................................................ 48 
2.2.2.5. Artificial Neural Networks (ANNs) ................................................................. 49 
2.2.3. Curated Data Repositories and Online Tools .......................................................... 54 
2.2.3.1. Data Sharing ..................................................................................................... 55 
2.2.3.2. Protein interaction databases ............................................................................ 55 
2.2.3.3. Ontological Databases ...................................................................................... 59 
2.3. Aims of the Project Overall ........................................................................................... 59 
3. Proteomic Evaluation: MALDI-MS Profiling Strategy for Biomarker Discovery in Ovarian 
Cancer ....................................................................................................................................... 60 
Chapter Abstract ................................................................................................................... 60 
3.1. Introduction .................................................................................................................... 61 
3.1.1. MALDI Mass spectrometry and ovarian cancer ..................................................... 61 
3.1.2 Aims and Hypotheses of the Chapter. ...................................................................... 67 
3.2. Materials and Methods ................................................................................................... 68 
3.2.1 Materials .................................................................................................................. 68 
3.2.1.1. Equipment used ................................................................................................. 68 
3.2.1.2. Reagents used: .................................................................................................. 69 
3.2.1.3. Stock Solutions Made and Used ....................................................................... 69 
3.2.1.4. Samples ............................................................................................................. 69 
3.2.2 Methods ................................................................................................................... 70 
Contents 
 
 
3.2.2.1 Sample Preparation and Data Acquisition ......................................................... 70 
3.2.2.2 Biomarker Panel Generation .............................................................................. 71 
3.2.2.3 Identification of m/z Values in the Biomarker Panel ......................................... 71 
3.2.2.4 ELISA ................................................................................................................ 72 
3.2.2.5 Additional Analyses ........................................................................................... 72 
3.3. Results ............................................................................................................................ 73 
3.3.1. Generation of Biomarker Panel from MALDI-TOF-MS Data ............................... 73 
3.3.2. Identification of the Peaks in the Biomarker Panel ................................................ 74 
3.3.3. Validation of the Peaks in the Biomarker Panel ...................................................... 76 
3.4. Discussion ...................................................................................................................... 78 
3.4.1. Samples ................................................................................................................... 80 
3.4.2. Identification of the Biomarker Panel Proteins ....................................................... 80 
3.5. Conclusion ..................................................................................................................... 81 
4. Proteomic Evaluation of LC-MALDI-TOF-MS as a Profiling Strategy for Biomarker 
Discovery in Ovarian Cancer .................................................................................................... 83 
Chapter Abstract ................................................................................................................... 83 
4.1 Introduction ..................................................................................................................... 84 
4.1.1 Need for Identification and Reproducibility of Biomarkers. ................................... 84 
4.1.2. Liquid Chromatography .......................................................................................... 85 
4.1.3. The need to Address Reproducibility to Progress with the Research in the Area... 85 
4.1.4. Sample Fractionation Techniques. .......................................................................... 85 
4.1.4.1. Millipore Zip Tips. ............................................................................................ 86 
4.1.4.2. Alkylation and Reduction. ................................................................................ 86 
4.1.5. Aims and Hypotheses of the Chapter ...................................................................... 88 
4.2. Materials and Methods ................................................................................................... 90 
4.2.1. Materials ................................................................................................................. 90 
4.2.1.1. Equipment used ................................................................................................. 90 
4.2.1.2. Reagents used: .................................................................................................. 91 
4.2.1.3. Stock Solutions Made and Used ....................................................................... 91 
4.2.2. Methods .................................................................................................................. 92 
Contents 
 
 
4.2.2.1. Production of the BSA Standard Curve. ........................................................... 92 
4.2.2.2. QC Serum Sample ............................................................................................ 92 
4.2.2.3. Multiple Workflows Tested for Optimisation .................................................. 93 
4.2.2.5 Alkylation and Reduction of Sera ...................................................................... 93 
4.2.2.6 Pre-digestion C18 ZipTip of Sera ....................................................................... 94 
4.2.2.7. Paired Comparisons .......................................................................................... 95 
4.2.2.8. A Model for use on Clinical Cohort of Samples .............................................. 97 
4.3. Results ............................................................................................................................ 99 
4.3.1. Semi-quantitative Nature of MALDI-TOF-MS ...................................................... 99 
4.3.2. Reproducibility of the Third Dimension; Retention Time of the Analytical Column
 ........................................................................................................................................ 101 
4.3.3. Reproducibility of Identities Acquired using LC-MALDI-TOF-MS/MS ............ 102 
4.3.4. Comparison of the Proteins Identified from each Workflow ................................ 103 
4.3.5. A Model for use on Valuable Clinical Samples .................................................... 106 
4.3.5.1. Measured Error. .............................................................................................. 106 
4.3.5.2. Investigation of Peaks Calculated to be Significantly Differentially Expressed 
Between the two Groups. ............................................................................................. 106 
4.4. Discussion .................................................................................................................... 108 
4.4.1. Semi-quantitative Nature of MALDI-TOF MS .................................................... 108 
4.4.2. Chromatographic Reproducibility ........................................................................ 109 
4.4.3. Reproducibility of Identities Acquired Using LC-MALDI-TOF-MS/MS ........... 110 
4.4.4. Comparison of the Proteins Identified from each Workflow ................................ 111 
4.4.5. A Model for use on Valuable Clinical Samples .................................................... 112 
4.4.6. Limitations of the Methods Tested ....................................................................... 113 
4.5. Conclusion ................................................................................................................... 115 
4.6 Review of Findings and Future Direction for Onco-proteomics in MS ....................... 116 
4.6.1. Future of Protein Mass Spectrometric Biomarker Discovery ............................... 117 
4.6.2. Future for Biomarkers for Ovarian Cancer ........................................................... 120 
5. Transcriptomics: Gene Expression Array Analysis as a Strategy for Biomarker Discovery in 
Ovarian Cancer ....................................................................................................................... 123 
Contents 
 
 
Chapter Abstract ................................................................................................................. 123 
5.1 Introduction ................................................................................................................... 123 
5.1.1. Known Influences on Survival time from Ovarian Cancer .................................. 124 
5.1.1.1 Platinum Resistance ......................................................................................... 124 
5.1.1.2 Epithelial to Mesenchymal Transition (EMT) ................................................. 125 
5.1.2. Aims and Hypothesis of the Chapter .................................................................... 127 
5.2 Materials and Methods .................................................................................................. 127 
5.2.1. Selection of Data Sets ........................................................................................... 127 
5.2.1.1. Array-Express Search Parameters for Sample Cohort Selection .................... 127 
5.2.1.2. Two Data sets used for Meta-analysis ............................................................ 128 
5.2.2. Pre-analysis Data Evaluation and Processing ....................................................... 130 
5.2.3. Analyses Applied .................................................................................................. 131 
5.2.3.1. ANN of Short versus Long Term Survival ..................................................... 131 
5.2.3.2. Cross Validation with Cox Univariate Survival Analysis .............................. 132 
5.2.3.3. Cross-comparison of Significant Genes ......................................................... 133 
5.2.3.4. T-tests .............................................................................................................. 133 
5.2.3.5 STRING Analysis ............................................................................................ 133 
5.3. Results .......................................................................................................................... 133 
5.3.1. ANN of Short and Long Term Survival ................................................................ 133 
5.3.2. Cox Univariate Survival Analysis ......................................................................... 134 
5.3.3. Cross-comparison of Significant Genes ............................................................... 134 
5.3.4. T-tests .................................................................................................................... 137 
5.3.5. STRING Analysis ................................................................................................. 138 
5.3.6. Interaction Intact Analysis .................................................................................... 139 
5.4. Discussion .................................................................................................................... 139 
5.4.1. Comparison of Results with the Data Source Publications .................................. 140 
5.4.2. Interpretation and Implications of Results ............................................................ 142 
5.4.2.1. Known Mechanisms of Resistance to Platinum Based Chemotherapy .......... 142 
5.4.3. Support of the Methods Used ............................................................................... 143 
Contents 
 
 
5.4.4. Criticisms of the methods used ............................................................................. 144 
5.4.4.1. The Availability of Additional Information .................................................... 145 
5.4.4.2. Challenges in Studying Ovarian Cancer ......................................................... 145 
5.4.4.3. The Array and Data Analysis Methodology ................................................... 146 
5.4.4.4. Downstream Analyses .................................................................................... 147 
5.4.5. Future work ........................................................................................................... 148 
5.5. Conclusion ................................................................................................................... 150 
6. Validation Strategies ........................................................................................................... 151 
Chapter Abstract ................................................................................................................. 151 
6.1. Introduction .................................................................................................................. 151 
6.2 Validation of Genes of Interest using Gene microarrays .............................................. 155 
6.2.1. KM Plotter Introduction ........................................................................................ 155 
6.2.2. Kaplan-Meier Methods / Utilisation Strategy ....................................................... 155 
6.2.3. Results and Discussion of KM Plotter Reports .................................................... 157 
6.2.3.1. Cautions and Caveats Considered when Interpreting KM Plotter Data ......... 161 
6.2.3.2. Indications for Further Research ..................................................................... 163 
6.3. Translational Validation Strategy using Immunohistochemistry ................................. 163 
6.3.1. Protein Verification of EDNRA in Ovarian Tissue ............................................... 176 
6.3.2. Immunohistochemistry Method ............................................................................ 176 
6.3.3. Results and Discussion of Immunohistochemical Staining of EDNRA in Ovarian 
Tissue. ............................................................................................................................. 178 
6.4. Discussion of Verification Strategies ........................................................................... 183 
6.5. Conclusion of Verification Strategies .......................................................................... 187 
7. Discussions for Future Work and Overall Conclusions ...................................................... 188 
7.1. Ongoing Unmet Clinical Need and Future Work Required ......................................... 188 
7.1.1. Targeted Protein Mass Spectrometry Based on Transcriptomic Discovery as a 
Strategy for Future Work. ............................................................................................... 190 
7.1.2. Clarity and Cohesiveness of Current Resources Challenge Future Work ............ 192 
7.1.3. Integration of Cross-Platform Data Challenges Future Work ............................... 193 
Contents 
 
 
7.2. Overall Summary and Conclusions ............................................................................. 194 
References ............................................................................................................................... 197 
 
 
Contents 
i 
 
FIGURES 
 
Figure 1. Personification of the Hallmarks of Cancer. ............................................................... 2 
Figure 2. Histological Anatomy of the Ovary ............................................................................. 5 
Figure 3. Stages in Ovarian Cancer ............................................................................................ 7 
Figure 4 The Complexity and Challenge of Studying the Human Proteome. .......................... 20 
Figure 5. The Basic Components of a Mass Spectrometer. ...................................................... 24 
Figure 6. Matrix Assisted Laser Desorption Ionisation (MALDI). .......................................... 25 
Figure 7. Electrospray Ionisation (ESI). ................................................................................... 27 
Figure 8. Linear and Reflectron Mode of the MALDI-TOF-MS. ............................................ 29 
Figure 9. Peptide Backbone Fragmentation. ............................................................................. 31 
Figure 10. Liquid Chromatographic Separation Coupled to Mass Spectrometric Detection. .. 37 
Figure 11. A Schematic Depicting how Genomic and Proteomic Data Represent a System at 
Different Perspectives. .............................................................................................................. 39 
Figure 12. A Typical Gene Array Experiment Workflow. ......................................................... 41 
Figure 13. Typical Multilayer Perception Artificial Neural Network Architecture. ................. 50 
Figure 14. A Representation of a Hidden Layer Node from a MLP ANN ................................ 51 
Figure 15. Population Chart of the Performance of the Biomarker Panel Discriminating Cancer 
from Controls. ........................................................................................................................... 74 
Figure 16. Boxplot of Transferrin Levels as Measured by ELISA. .......................................... 77 
Figure 17. Boxplot of Vitronectin Levels as Measured by ELISA. .......................................... 77 
Figure 18. Vitronectin Levels as Measured ELISA (ug/mL) and Peptide Peak m/z 1647.8 
Intensity. .................................................................................................................................... 78 
Figure 19. Multiple Analysis of one Serum Sample via Different Sample Preparation Workflows.
 .................................................................................................................................................. 88 
Figure 20. Flow Chart of Alkylation and Reduction of QC Sera and Control Workflow. ........ 96 
Figure 21. Flow Chart of Pre-digestion Zip-tip QC Sera and Control Workflow. .................... 97 
Figure 22. Increase of Peak Intensity with Increase in Concentration of Sample Loaded from a 
BSA digest. ............................................................................................................................. 100 
Figure 23. BSA Standard Curve from Peak Intensity. ............................................................ 101 
Figure 24. Retention Time Reproducibility. ........................................................................... 102 
Figure 25. Histogram of Protein Identity Occurrence. ........................................................... 103 
Contents 
ii 
 
Figure 26. Venn Diagram Comparing the Lists Protein Identities Acquired from the Alkylation 
and Reduction Sample Preparation Workflow and Control. ................................................... 104 
Figure 27. Venn Diagram Comparing the Lists of Protein Identities Acquired From the Pre-
digestion ZipTip Sample Preparation Workflow and Control. ............................................... 105 
Figure 28. Venn Diagram Comparing the Lists of Protein Identities from Peptide IDs Matched 
from MS-T-test. ....................................................................................................................... 108 
Figure 29. Number of Investigated Genes in Ovarian Cancer. ............................................... 122 
Figure 30. Histogram of Distribution of Survival Times of Two Cohorts of Patients with 
Ovarian Cancer ....................................................................................................................... 131 
Figure 31. Overview of Gene Microarray Meta-analysis Methodology. ................................ 135 
Figure 32. A Graphical Representation of the Order of Significance of the Genes of Interest.
 ................................................................................................................................................ 136 
Figure 33. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) Output 
Displaying known Associations Between the Genes of Interest. ............................................ 138 
Figure 34. The Biomarker Discovery to Validation Pipeline. ................................................. 153 
Figure 35. Kaplan Meier Plots of the Highest Ranking Genes of Interest. ............................ 160 
Figure 36. Verified GOIs Location in the Proteoglycans in Cancer pathway. ........................ 171 
Figure 37. Verified GOIs in the Pathways in Cancer pathway. .............................................. 174 
Figure 38. Range of Staining Intensity Observed in EDNRA Stained Ovarian Tumour Tissue 
from the Biomax OV6161 TMA............................................................................................. 178 
Figure 39. EDNRA Protein Expression in Ovarian Tissues of Different Stage. ..................... 179 
Figure 40. EDNRA Protein Expression in Ovarian Tissues of Different Grades. .................. 180 
Figure 41. EDNRA Protein Expression in Ovarian Tissues of Different Histology. .............. 181 
 
  
Contents 
iii 
 
TABLES 
Table 1. Past Potential Markers for Ovarian Cancer.. ............................................................... 14 
Table 2. A Summary of Globally Accessible Data Repositories and Resources. ..................... 58 
Table 3. A Summary of Similar Research.. ............................................................................... 63 
Table 4. Equipment Utilised for MALDI-TOF-MS .................................................................. 68 
Table 5. Reagents Utilised for MALDI-TOF-MS ..................................................................... 69 
Table 6. All stock solutions made and used for MALDI-TOF-MS .......................................... 69 
Table 7. Stepwise Analysis Generation of a Biomarker Panel. ................................................ 73 
Table 8. Potential Identities of the m/z values of the biomarker panel.. ................................... 75 
Table 9. Equipment Utilised for LC-MALDI-TOF-MSMS ..................................................... 90 
Table 10. Reagents Utilised for LC-MALDI-TOF-MSMS ...................................................... 91 
Table 11. All stock solutions made and used for LC-MALDI-TOF-MSMS ............................ 91 
Table 12. Dilutions made for production of a BSA standard curve. ......................................... 92 
Table 13. Summary of the Workflows Applied to Replicates of one Test Sample. .................. 93 
Table 14. Numbers of Cases in Short and Long or Short Term Survival Groups.  ................. 130 
Table 15. Summary of KM Plotter Analysis. .......................................................................... 158 
Table 16. Aliases of the Finalised Seven Genes of Interest. (GeneCards 2015) ..................... 165 
Table 17. KEGG Pathways found to be Associated with the Shortlisted Genes of Interest. .. 169 
Table 18. T-test Results Comparing the Significance of Protein Expression Differences Between 
Cancer Stages. ......................................................................................................................... 179 
Table 19. T-test Results Comparing the Significance of Protein Expression Differences Between 
Cancer Grades. ........................................................................................................................ 180 
Table 20. T-test p-values Comparing EDNRA Protein Expression Between Cancer Histologies.
 ................................................................................................................................................ 182 
  
Contents 
iv 
 
Abbreviations and Glossary  
ADF Array Design File 
AI Artificial Intelligence 
Albuminome All isoforms of albumin and bound proteins 
ANN Artificial Neural Network 
AOCS The Australian Ovarian Cancer Study 
Ascites Fluid accumulation in a peritoneal cavity 
Biomarker  
A naturally occurring molecule or characteristic from which 
a disease or condition can be identified 
Bucket Table  
The table of data bins defined within the Bruker software 
containing, compiled, aligned LC-MALDI-TOF data of 
mass, retention time and peak intensity. 
CA125 Cancer Antigen 125 
CAD (HPLC) Charged Aerosol Detection HPLC 
Cancer 
A disease resulting from the uncontrolled division and 
proliferation of cells.  
CEA Carcinoembryonic Antigen  
CHCA Alpha-Cyano-4-hydroxycinnamic acid  
CRUK Cancer Research United Kingdom 
CT Scan Computerised Tomography 
DCN Decorin 
DDA Data Dependent Acquisition 
hhH2O Deionised and distilled water 
DESI Desorption Electrospray Ionisation  
DHB 2,5-dihydroxybenzoic acid  
DIA Data Independent Acquisition 
EDNRA Endothelin receptor type A 
ELISA Enzyme Linked Immunosorbent Assay 
ELSD (HPLC) Evaporative Light Screening Detection HPLC 
EMBL-EBI  
European Bioinformatics Institute part of the European 
Molecular Biology Laboratory  
ESI Electrospray Ionisation  
FAIMS Field Asymmetric Ion Mobility Spectrometry 
FDA U.S. Food & Drug Administration 
FDR False Discovery Rate  
Gene Microarrays  
A group of techniques where short strands of nucleic acid are 
immobilised to an array and through complementary binding 
are used to ascertain and quantify the expression of target 
genes.  
Genomics The study of a genome  
GEO Gene Expression Omnibus 
GOI Genes of Interest 
HPLC  High-Performance Liquid Chromatography 
ICAT Isotope Coded Affinity Tagging  
Contents 
v 
 
ICPL Isotope-coded Protein Labelling  
IGF2 Insulin-like growth factor 2 
IHC Immunohistochemistry 
IMEX The International Molecular Exchange Consortium  
Immunoassays  Assays including immunoglobulins for antigen recognition  
InnateDB Immune Response pathway database. 
IntAct A molecular interaction database hosted by the EMBL-EBI 
iTRAQ Isobaric tagging for relative and absolute quantitation  
I2D Interlogous Interaction Database 
KEGG Kyoto Encyclopaedia of Genes and Genomes  
KNNs  Nearest Neighbour Analysis  
LC Liquid Chromatography  
LPA Lysophosphatidic acid  
MALDI Matrix Assisted Laser Desorption and Ionisation 
MatrixDB Extracellular Matrix Interaction Database 
MBInfo Mechanobiology database 
MCCV Monte Carlo Cross Validation  
MINT Molecular Interaction Database  
MLP Multilayer Perceptron 
MS Mass Spectrometry 
MS/MS / MS2 Tandem mass spectrometry 
NAV3 Neuron Navigator 3 
NCBI National Centre for Biotechnology Information  
NGS Next Generation Sequencing 
NHS National Health Trust 
NICE The National Institute for Health and Care Excellence 
OCAC Ovarian Cancer Association Consortium 
OCTIPS  
Ovarian Cancer Therapy Innovative Models Prolong 
Survival 
Oncogene A gene coding potentially carcinogenic traits 
OTTA Ovarian Tumour Tissue Analysis Consortium 
PCA Principal Component Analysis 
pI Isoelectric point.  
PIR Protein Information Resource  
PPFIB1 PTPRF interacting protein, binding protein 1 (liprin beta 1) 
PRIDE The Proteomics IDEntification database  
Proteomics The study of the proteome 
PSA Prostate Specific Antigen 
REIMS Rapid Evaporation Ionisation Mass Spectrometry 
RVM Relevance Vector Machines 
SDRF Sample and Data Relationship Format  
Shotgun 
proteomics 
A proteomic strategy aiming to measure the entire proteome 
and measure the difference between two groups 
SIBm Swiss Institute of Bioinformatics 
SILAC Stable Isotope Labelling with Amino acids in Cell culture 
Contents 
vi 
 
SPL Scheduled Precursor List 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins  
SVM Support Vector Machines  
Targeted Mass 
Spectrometry  
Mass spectrometric strategy aiming to quantify a 
predetermined set of proteins 
TCGA The Cancer Genome Atlas 
TMA  Tissue Microarray 
TMT Tandem mass tags  
TNFAIP6 Tumour Necrosis Factor, Alpha-Induced Protein 6 
TOF Time of Flight 
TP53 Tumour Protein 53 
Transcriptomics The study of the transcriptome 
UCL-BHF 
Cardiovascular Gene Annotation Initiative funded by the 
British Heart Foundation  
UFX Bruker UltrafleXtreme 
UKCTOCS 
United Kingdom Collaborative Trial of Ovarian Cancer 
Screening 
UV Ultraviolet 
WHO World Health Organisation 
WTAP Wilms Tumour 1 associated protein 
 
 
Contents 
vii 
 
HYPOTHESES 
Section  H1 H0 Page 
3.1.2 i 
Unique protein patterns expressed in the 
sera of ovarian cancer sufferers can be 
detected using MALDI-TOF-MS with 
ANNs and can be used to positively 
identify a blind validation set. 
MALDI-TOF-MS with ANN analysis 
will not be able to detect unique 
protein patterns expressed in the sera 
of ovarian cancer sufferers. 
67 
 ii 
The masses of the peptide peaks expressed 
differentially in the tested serum can be 
assigned a protein identity by linking the 
MS-MALDI data with LC-MALDI-
MS/MS data. 
The masses of the peptide peaks 
expressed differentially in the tested 
serum cannot be identified by linking 
data from LC-MALDI-MS with the 
MS profiles. 
67 
 iii 
Unique protein patterns expressed in the 
sera of ovarian cancer sufferers can be 
detected using MALDI-TOF-MS with 
ANNs and can be used to positively 
identify a blind validation set. 
No difference in expression will be 
noted of the proteins demonstrated to 
be expressed using MALDI-MS. 
68 
4.1.5 iv 
The signal intensity values of a detected 
protein are relative to the amount of protein 
loaded. 
There is no correlation between 
protein amount loaded for detection 
and the signal intensity of protein 
detected. 
88 
 v 
One sample preparation technique prior to 
LC-MALDI-MS will yield a greater 
amount of meaningful protein identities. 
All tested sample preparation 
techniques prior to LC-MALDI-MS 
produce equal amounts of meaningful 
protein identities. 
88 
 vi 
Differences will be seen in the LC-MALDI 
profiles of serum samples prepared under 
identical conditions. 
There will be no significant difference 
between the LC-MALDI-MS profiles 
of serum samples prepared under 
identical conditions. 
89 
5.1.2. vii 
Genes will be found to be consistently 
significantly associated with survival time 
when a complement of statistical strategies 
are applied in a meta-analysis approach to 
two separate cohorts of patients measured 
with two different microarray platforms 
None of the gene expression 
measurements from the in two cohorts 
will be found to be consistently 
associated with survival times from 
ovarian cancer when tested with a 
complement of statistical strategies. 
127 
6.2.1. viii 
Genes of interest will be verified to 
significantly associate with ovarian cancer 
survival time when  investigated on a wider 
sample cohort. 
None of the genes of interest found to 
significantly associate with ovarian 
cancer survival time will be verified to 
do so when investigated on a larger 
sample cohort. 
155 
6.3.1 ix 
Protein expression of EDNRA will be found 
to be different between different stages, 
grades and histologies of ovarian cancer 
samples. 
No difference in protein expression 
will be observed between different 
stages, grades and histologies of 
ovarian cancer. 
176 
 
 viii 
 
Thesis Abstract  
Novel, specific and sensitive biomarkers are prerequisite to improve diagnosis and prognosis 
of patients with ovarian cancer. Firstly, a proteomic bottom-up MALDI-TOF mass 
spectrometric profiling analysis was conducted on a cohort of sixty serum samples specifically 
collected for this purpose. An in-house stepwise Artificial Neural Network (ANN) algorithm 
generated a biomarker panel of m/z peaks which differentiated cancer from aged matched 
controls with an accuracy of 91% and error of 9%, identities were inferred where possible and 
validation conducted using ELISA on the same cohort. Lack of complete verification, or the 
ability to verify the full panel lead to an in-depth evaluation of the strategy used with the aim 
to repeat with an improved methodology. Following this, a feasibility analysis and evaluation 
was performed on the next generation of equipment for sample fractionation prior to analysis 
on multiple replicates of stock human serum collected in the same way as the ovarian cohort. 
The results of which combined with the limited amount of available ovarian cancer sample 
cohort altered the trajectory of the project to the mining of transcriptomic data acquired from 
an online data repository. A meta-analysis approach was applied to two carefully selected gene 
expression microarray data sets ANNs, Cox Univariate Survival analyses and T-tests were used 
to filter genes whose expression were consistently significantly associated with patient survival 
times. A list of 56 genes were refined from a potential 37000 gene probes to be taken forward 
for verification for which more freely available online resources such as SRING, Kaplan Meier 
Plotter and KEGG were utilised. The list of 56 genes of interest were refined to seven using a 
larger cohort of transcriptomic data, of the seven one, EDNRA, was selected for translational 
verification using immunohistochemistry of a tissue microarray of ovarian cancer specimens. 
Significant association is seen with cancer stage, grade and histology. The merits and flaws of 
the verification are discussed and future work and direction for research is suggested.  
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1. Introduction  
 
1.1. General Concepts 
 
1.1.1. Cancer  
 
Cancer will at some point effect most people in Western society (Scotting 2011), nearly 50% of 
the population will receive a cancer diagnosis in their lifetime (Ahmad et al., 2015) and the rest 
will most likely know someone directly affected. In the UK in 2012 there were 338,623 new 
cases of cancer diagnosed, and 161,823 consequent deaths (Cancer Research UK 2016). Fifty 
percent of people diagnosed in 2012 were predicted to survive for 10 years or more (Cancer 
Research UK 2016). It is the second most common fatal disease in the UK, following only heart 
disease (Scotting 2011). 
 
Cancer is a condition of a cell where it has lost its ability to regulate growth. Cancerous cells 
are able to migrate to other organs in the body where they may continue to proliferate 
uncontrollably, eventually interfering with homeostatic cell, system and organ function, until 
potential complete upheaval then malfunction of tissue function (Cooper 2000).  
Mutations in the genetic code can subtly alter genes coding for proteins essential for normal 
cell growth, regulation and homeostasis resulting in a traits indicative of cancer; oncogenesis. 
Cells containing oncogenes and translated onco-proteins exhibit cancerous phenotypes 
involved in the cell regulatory process resulting in uncontrolled growth. Malignant cells are 
morphologically, genetically and phenotypically distinguishable from normal tissue (Baba and 
Câtoi 2007).  
 
Cancer is primarily subcategorised by the origin site of a primary tumour. There are over 100 
types of cancer by this definition. However, common characteristics are noted between cancers 
of different origins and sometimes treated with the same therapy (Barretina et al., 2012). 
Equally, the diversity of pheno- and genotypes of cancers from one origin organ can be wide 
ranging and most subtypes are continually being defined/clarified, notably breast cancer is now 
able to be grouped by genotype into specific subtype for a more targeted treatment (Dent et al., 
2007, Banerji et al., 2012 and Caldas and Stingl 2007). 
 
A large proportion of people suffering from or affected by cancer are unaware of the complex 
and conflicting/ complex molecular mechanisms in play. Often human characteristics are used 
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to attain a lay understanding. Figure 1 is a personification of Hanahan and Weinbergs (2000, 
2011) widely used/known depiction of cellular attributes hallmarking cancer. Stickmen 
represent how cells within a cancer cell ‘act selfishly’ (Scotting 2011) making (cellular) 
environmental alterations for personal gain. The lack of programmed cell death, senescence or 
other noble self-limiting traits of non-cancer cells is in disregard to the (cellular) society they 
are in. Sooner or later the rebellious actions of the cells, like colonising other tissues; metastasis, 
altering existing resources and supply routes; angiogenesis, is destructive to neighbouring and 
non-adjacent organs. 
 
Figure 1. Personification of the Hallmarks of Cancer. An adaptation of Hanahan and Weinburg (2011) 
with Illustrated Health (2014)  
Each of the cell characteristics used to classify cancer are satirised into a bad human characteristic. The analogy 
being; cancer harms the body as some human characteristics do to a society. In the six sections key 
characteristics are represented by a pictograms: From the top centre and continuing clockwise: In green multiple 
stickmen represent limitless proliferation - overcrowding straining recourses, the hulk-like character in brown 
represents increased growth – greed or an inadvertent overpowering by size, in black the tank driver presents 
invasion – metastasis, in blue the infinity symbol represents the immortality – lack of a natural death, in red 
roadworks symbol a sign well associated with disruption of traffic infrastructure to redirect supply routes, 
finally, in grey a character performing a death defying stunt - resisting death. 
 
In 2000 and again in 2011 Hanahan, and Weinberg compiled cancer literature and defined six 
hallmarks of cancer, all cancer traits can be categorised as one or more hallmark, phenotypical 
of cancers; these are summarised below and a brief example outlined for each.  
 Uncontrolled cell proliferation, or the dis-regulation of cell proliferation. Cancer 
cells may display up-regulation of cell surface receptors to growth factors, typically 
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tyrosine kinases, the receptors themselves may be onco-proteins, altered, activating 
independently or change in tertiary structure increasing affinity to ligands, or cells may 
release the ligands growth factor themselves. Additionally, cancer cells have exhibited 
altered glycolic metabolism sometimes preferring aerobic glycolysis when oxygen is 
available. In multiple examples an altered/dysfunctional/onco-protein plays a key role 
in transmitting or receiving in a negative feedback loop in a cell growth system. Such 
examples include PTEN and mTOR kinase, both are normally transducers of a signal 
which in normal cell growth are triggered to signal for cessation of further growth. 
 Evading growth suppressors and un-controlled cell growth. A renowned, well 
characterised example of which is Tumour Protein 53 (TP53) protein, responsible for 
adjudicating the decision/molecular outcome as to whether a cell proliferates, undergoes 
senescence or apoptosis. Mutations in, or faulty production of, TP53 protein products, 
many of which have been characterised, results in a loss authority/governance within 
the system. 
 The ability to induce angiogenesis. Tumours over ~1cm display the ability to induce 
the growth of neo-vasculature from otherwise quiescent adjacent blood vessels. Like all 
cells the supply of nutrients and removal of waste products is requisite. Descriptively 
named -Vascular Endothelial Growth Factor-A (VEGF-A) and downstream effectors of 
it have been noted in numerous tumour types, it’s up-regulation is known to be triggered 
by hypoxia, a natural consequence of excessive tissue growth. 
 The ability to invade and metastasise to other organs/sites in the body. Metastasis 
is a multistep process sometimes referred to as the invasion-metastasis cascade. Cancer 
cells have been shown to release factors, Matrix Metalloproteases, which disrupt the 
extracellular cellular bonds and status quo. Further to this cancer cells enter the 
lymphatic system bloodstream where they are transported to distant parts of the body 
where they settle and continue to mitose/colonise/grow/duplicate.  
 The ability to evade immune detection. Cancer immunology is a wide and growing 
field. Cancerous cells are thus harder to detect by immune system than foreign invaders. 
Additionally, if triggered the immune system can exacerbate a cancerous environment 
if an inflammatory process is activated releasing cells/biomolecules/creating an 
environment to promote tumour growth, nurturing conditions for angiogenesis, cell 
growth and proliferation and invasiveness.  
 Replicative immortality or the lack of programmed cell death. Telomeres are 
comprised of repeating hexonuclotides cap each chromosome within a cell nucleus, as 
well as having a barrier protective role they are shortened every time the cell undergoes 
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mitosis. Telomerase is able to counter this shortening adding hexonucleotides 
lengthening the telomeres and increasing the number of mitotic events before 
irreparable damage of the DNA chromosome ends thus triggering apoptosis. Up-
regulation of telomerase has become a common trait in the immortalisation of cancer 
cell lines. 
Eleven years later Hanahan, and Weinberg (2011) narrate the following decades of cancer 
research to define two more emerging hallmarks and two enabling characteristics of cancer.  
The additional hallmarks are; deregulating cellular energetics and avoiding immune destruction. 
The enabling characteristics being genome instability and mutation and tumour promoting 
inflammation. The reader is referred to Hanahan and Weinberg (2000) and Hanahan and 
Weinberg (2011) for a detailed benchmarking definition and characterisation of the phenotypes 
of cancer. 
 
A poignant progression when the literature is summarised, is the change of emphasis from 
cancer cells alone, to put them in a scene of a cellular microenvironment, and the contribution 
of and communication with pericytes and paracrine signalling (Hanahan and Weinberg 2011).  
 
Identifying and understanding the specific molecular pathways and mechanisms responsible for 
the malevolent characteristics of malignant cells will expose ways to detect, treat and even 
prevent cancer. Under the premise that molecules such as proteins are secreted from, shed by 
or released in response to the tumour microenvironment into the circulation, cancer research 
endeavours to detect these molecules for use as a biomarker in serum samples. 
 
1.1.2. Ovarian Cancer  
 
Typical/normal ovarian function: Ovaries are almond shaped structures approximately 2 x 3 
x 4 cm located within the female pelvis at the top of the genital tract. Their role is to generate 
and release germ cells into the reproductive system. They are suspended in the opening to the 
fallopian tubes by ligament and connective tissues called the tunica albuginea, this is covered 
by the germinal epithelium which is a simple squamous mesothelium (Peckham et al., 2004). 
In the endocrine system, ovaries release oestrogen and progesterone and are stimulated by 
gonadotrophin which is released from the anterior pituitary. The ovary is the female gonad, and 
is the site of oogenesis within the ovary germ cells mature from Primordial follicles mature to 
Secondary, to mature then Graaffian Follicle phase to be released as into fallopian tube 
(Peckham et al., 2004). Other cells found within ovarian tissue include epithelium surrounding 
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the capsule and stroma creating structural foundation to the tissue. Ovum mature and are 
released from the ovary surface as part of the menstrual cycle, corpus luteum cyst is the term 
for an ovarian cyst that may burst around the time of menstruation, repair of this action can take 
up to 3 months (Adam et al., 2012) Follicular and/or Granulosa cells “are somatic cells of the 
sex cord that are closely associated with the developing female gamete” (Adam et al., 2012) 
The Anral follicle, also known as a Graafian follicle is the term for the mature ovum cyst prior 
to rupture and releasing the ovum into the fimbriae and the fallopian tubes, Folicular fluid 
surrounds the ovum and fills the ovum follicle (Adam et al., 2012) 
 
Figure 2. Histological Anatomy of the Ovary  
Annotated from (Peckham et al., 2004) A histological cross section of a human ovary. Stages in oogenesis are 
observed and in different locations within the section: Germ cells mature from Primordial follicles to Secondary, 
then Mature then Graaffian Follicle phase and are released into the phallopian tube 
 
A subtype of follicle epithelial cells known as border cells are of interest as a cancer model and 
have been used as a model in studies researching metastasis on account of their unique 
migratory characteristics and ability to invade adjacent tissue; a number of their characteristic 
genes have been identified in cancer cell lines (Naora et al., 2005). Primates are often used as 
an ovarian model as healthy human ovarian samples are in shorter supply (Adam et al., 2012) 
however cannot fully represent a human genome. 
 
Incidence. With approximately 136 new diagnoses each week in 2011 in the UK alone, ovarian 
cancer is the 5th most common cancer in the UK (Cancer Research UK 2015), it is the fourth 
most common cancer in US females aged 40-59 and 5th most in US females aged 60-79 (Siegel 
et al., 2013). 
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Survival. The key prognostic for the survival time is the stage and grade at diagnosis (Erickson 
et al., 2014). A 92%, 5-year survival can be expected from a Stage 1 diagnosis, this drops to 
22% at Stage 3. Little changed in 5-year survival rates between 1975 and 2008 (Vaughan et al., 
2012, Siegel et al., 2013). Unfortunately, due to the asymptomatic nature of the early stages, its 
insidious growth pattern of the disease and the lack of a sensitive screening tool, over half of 
ovarian cancer is diagnosed at Stage 3 or above (Cancer Research UK 2012).  
 
When diagnosed, ovarian cancer can be categorised by stage and grade to determine the 
prognosis and direct treatment. Tumour grade refers to cell morphology with the tumour and 
the Stage refers to the occurrence and distance of secondary tumours from the primary tumour 
site; metastasis. Figure 3 below illustrates the typical abdominal distribution metastasis of a 
Stage 3 ovarian cancer. The high morbidity of ovarian cancer is often attributed to the majority 
being diagnosed at a later stage. The ability to stratify patients with this heterogeneous disease, 
based on identification of molecular pathways, would enable precision treatment and improve 
prognosis. Hundreds of genes have been significantly associated with ovarian cancer yet few 
have been verified by peer research (Braem et al., 2011). 
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Figure 3. Stages in Ovarian Cancer 
Adapted from Naora et al., (2005); cancer cells are confined to one (1a) or both (1b) ovaries and may also be 
present on the surface of the ovary or ascites (1c). Stage 2; local metastasis where the cancer lesions are also 
found in the fallopian tubes or womb (2a), other local organs such as bladder or bowel (2b) and may also be 
present in ascites (2c). Stage 3; abdominal metastasis, cancer cells (3a) or larger visible lesions (3b) are found on 
the lining of the abdomen, or in the lymph nodes and upper abdomen and or groin (3c). Stage 4; distant 
metastasis, tumours found outside of the peritoneum or inside other organs for example within the liver or lungs. 
 
The underlying reason for late stage diagnosis is the asymptomatic nature of the early stage 
disease. Few if any symptoms are expected from Stage 1 and 2 disease and indicators of the 
later stages often at best vague and easily miss-attributed to general less serious complaints 
including; back or abdominal pain, bloating or abnormal menstrual patterns. 
 
Currently, factors known to influence a patients’ survival time from ovarian cancer include but 
are not limited to the histology and grade of the tumour (Matuzaki et al., 2015), distance of 
metastasis or stage and, if the cancer displays resistance to chemotherapy. Some chemo-
resistant molecular pathways, mainly involved in DNA repair have been demonstrated in some 
ovarian cancer cell lines (Marchini et al., 2013) but this has not yet been extrapolated to apply 
to the general population. Specific pathways are discussed at molecular level in (Chapter 5). 
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Cytology. As yet, there is no defined pre-malignant stage, as there is in cervical or prostate 
cancer (cervical/ prostate intraepithelial neoplasia). 
 
Prognosis. Only 22% of patients diagnosed at Stage 3 are expected to live for 5 or more years, 
this is improved to 92% if diagnosed at Stage 1. Other than the increase in reported incidence 
in the early part of the 20th century nothing to date has made a dramatic impact on the death 
rates from ovarian cancer (Siegel et al., 2013). 
 
Currently there is no screening tool with a performance specific or accurate enough to be 
implemented to the general population.  
 
Current Treatment. Despite the continuing study of ovarian cancer cell lines and patient 
material with numerous publications implicating novel genes associating with its incidence, 
little has changed in the treatment and expected outcome of patients presenting with ovarian 
cancer. Platinum based chemotherapy sometimes administered with an adjuvant. A response to 
which is seen in approximately 70% of patients, however most will develop a resistance to the 
therapy and experience a recurrence of tumour some more aggressively than others (Miller et 
al., 2009). Repeated cycles of platinum therapies are administered for most recurrent disease, 
however, typically the length of progression free survival shortens due to chemo-resistance until 
the disease is terminal (Marchini et al., 2013). Additionally, not all patients diagnosed with the 
disease are eligible for treatment (Erickson et al., 2014) 
 
Chemotherapy. Platinum based chemotherapies act by binding directly to DNA strands and 
disrupting the cells ability to divide. Historically cisplatin was the original platinum therapy 
this was replaced with Carboplatin which is less toxic to other organs, more recently Oxaplatin 
was developed which is still considered an analogue but has been shown to be effective were 
resistance to Carboplatin or cisplatin has occurred (Martin et al., 2008). This treatment pathway 
yields 50% 1.5-year progression free survival of patients diagnosed with Stage 3 ovarian cancer 
20-30% of these patients will progress after this with 10-year survival rates as low as 10% 
(Marcus et al., 2014). 
 
More recent therapies target the tumour microenvironment, such as Bevacizumab which 
inhibits the angeogenic pathway (Kim et al., 2012). Bevacizumab has been administered as an 
adjuvant in disease recurrence after resistance to platinum chemotherapy has occurred with 
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some improvement in survival, it has also been trialled as an adjuvant to first line therapy 
alongside cisplatin in platinum-sensitive cases (Vaughan et al., 2012). However, resistance to 
anti-VEGF agents such as Bevacizumab have been reported (Vaughan et al., 2012). 
 
Preliminary studies have identified some success using immune therapies, were by antigenic 
stimulation of T-cells the body’s natural anti-tumour response and can be stimulated to 
recognise and eliminate tumour (Vaughan et al., 2012). Immunotherapy strategies are 
developing quickly for many cancers, however, identifying the immunogenic biomarker is a 
key prerequisite to this. 
 
Metastatic Pattern, Nomenclature and Peritoneal Cancer. Ovarian cancer metastatic pattern 
is distinctive from other cancers in that, although spread is seen and defined by its presence in 
local and distant lymph nodes and blood vessels it also ‘seeds’ in to adjacent organs via aescetic 
fluid to form numerous lesions across the abdominal cavity (Naora et al., 2005, Vaughan et al., 
2012) as seen in Figure 3. For this reason, the presence of aescitic fluid is associated with a 
poor prognosis (Rosanò et al., 2011). Surgical removal of innumerable tiny lesions requires 
radical surgery at least and could be considered near-futile, thus debulking and adjuvant 
chemotherapy is the best possibility.  
 
It has been agreed among experts that what falls under the label ovarian cancer could originate 
from a number of tissues of vastly differing in histology. It has been suggested that the term 
ovarian cancer replaced with “pelvic” or “peritoneal” but it was agreed to be too confusing to 
change the meanings (Vaughan et al., 2012).  
Research has shown that metastatic spread is not a random event and that cancer cells can also 
be directed by factors such as a chemokine gradient (Scotton et al., 2001). 
 
Immune response in the tumour microenvironment. There is a strong body of evidence 
uncovering the role of chemokines and the immune system in orchestrating angiogenesis, 
metastatic patterns as well as directing T-cell directed anti-tumour responses and inhibition of 
apoptosis in the tumour microenvironment, which is of use for sub-typing and identifying 
targets for therapies (Obermajer et al., 2011, Balkwill et al., 2004, Vaughan et al., 2012). 
 
Risk Factors.  
 First degree female relative with ovarian cancer 
 Tobacco smoking 
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 A postmenopausal status 
 age of >50 years 
 BRCA1 and BRCA2 mutations 
 Years of oral contraceptive use 
 Other pre-existing conditions such as polycystic ovarian disease 
 Parity (number of times a woman has given birth to a foetus with a gestational age of 
24 weeks or more) 
 
1.1.3. Biomarkers 
 
A biomarker is defined as “a naturally occurring molecule, gene or characteristic by which a 
particular pathological or physiological process, disease, etc. can be identified” (Oxford 
Dictionaries 2015). Or, a measurable factor that is used to represent a clinical end point (Strimbu 
et al., 2011). 
 
In this context, a biomarker is defined as a measurable biochemical found in bodily tissue 
believed to be produced by, or in response to, diseased tissue in the body. The objective of 
biomarker discovery research is to identify non-invasive methods to detect specific, sensitive 
and accurate markers of disease. A specific, sensitive, reliable biomarker may be applied as a 
screening tool for the general population to detect early stage disease, or to known sufferers of 
a disease to stratify the most appropriate treatment or monitor the progression or reoccurrence. 
 
In a standard clinical setting, biomarkers can be grouped as either:  
 Diagnostic: The presence or absence of the biomarker can be used a classifier, to 
diagnose a disease or clinical condition.  
 Prognostic. The presence or absence of the biomarker can be used to assign a likely 
cause of a disease or clinical condition.  
 Predictive. Predictive biomarkers can be used to categorise subpopulations of patients 
and used as a marker of risk or likely hood of an event. For example, a likely response 
to a given therapy. 
 
Biomarker discovery experiments aim to stratify patients according to clinical parameters or 
therapeutic response, it can also be the optimal scenario that they also are appropriate target 
genes / proteins for therapeutic intervention. For example, in breast cancer an overexpression 
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of the Her2/neu receptor correlates with poor prognosis and likelihood of metastasis (Carmen 
et al., 2008). It is also the target of therapy, trastuzumab (Herceptin). HAGE (DDX43) has been 
shown to be overexpressed in sarcoma, testis and breast solid tumours (Abdel-Fatah et al., 
2014), and, has also shown immunogenic potential with view to be used as an 
immunotherapeutic target (Mathieu et al., 2007). 
 
1.1.3.1. Essential and Desirable biomarker properties 
 
A biomarker is only able to progress from scientific discovery to clinical implementation firstly 
though extensive scientific peer reviewed research, followed by the rigour of all stages of 
clinical trials (de Gramont et al., 2014, Henry et al., 2012 and Goossens et al., 2015), for this 
reason there are few new fully approved biomarkers. Anderson (2010) reports the rate at which 
novel protein analytes are introduced has stabilised and remained the same for 15 years, at an 
average of 1.5 per year.  
 
A clinically useful biomarker test must be: 
 Biochemically stable. 
 Specific and sensitive enough to minimise the number of false positives and false 
negatives respectively. Specificity of >99% and positive predictive value of 10% 
(Hays et al., 2010). Jacobs et al., (2004) state most researchers in the area agree at no 
more than 1 false positive for every nine true positives and a 99.6% specificity. 
A clinically useful biomarker would ideally be: 
 Detectable from sample attained from a non-invasive method i.e. urine or blood 
sample, not tumour biopsy or exploratory surgery. 
 Unaffected by natural variations caused by circadian rhythm, seasonal rhythm, diet, 
lifestyle, sex and race. 
 In the case of a combination of biomarkers compiling a clinical test, the biomarker 
panel must contain no more than four or five biomarkers to make it a marketable tool 
(NBDA 2016). 
 
The specificity and sensitivity of a biomarker is needed to calculate the risk to potential patients. 
In a clinical setting, false positive results cause unnecessary harmful exploratory surgery or 
treatment, false negatives result with disease going undiagnosed or untreated and therefore 
likely to worsen. 
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Biomarkers currently used in clinical practice to detect or monitor progression of cancer include 
Cancer Antigen 15.3 (CA15.3) for breast cancer, Cancer Antigen 19.9 for pancreatic cancer, 
Prostate Specific Antigen (PSA) for prostate cancer, Cancer Antigen 125 (CA125) for ovarian 
cancer and Carcinoembryonic Antigen (CEA) for colorectal and other cancers (Engwegen et 
al., 2006, Hanash et al., 2008). 
 
The predictive performance can sometimes be improved by concurrent measurements, a 
biomarker panel. However, less than half of FDA approved biomarkers have more than one 
protein analyte (Anderson 2010). Screening strategies may be based on other factors, such as 
cytology of a collected specimen for pap smear tests for cervical cancer.  
  
Existing monitoring of ovarian cancer progression or recurrence assays the levels of circulating 
Cancer Antigen 125 (CA125) and carcino-embryonic antigen (CEA) in blood, however these 
tests are flawed by the natural variation and fluctuations of these proteins resulting in false 
positives and unnecessary explorative surgery. 
 
Strimbu et al., (2011) critiques the current conceptual status of biomarkers as clinical diagnostic 
tools and identifies room for vast improvement. In clinical settings and studies the use of a 
biomarker is often necessary to make a clinical endpoint measurable, however is a reductionist 
view and does not allow for consideration of wider influences to the measured system. Strimbu 
et al., (2011) concludes that we will only be able to use biomarkers to represent clinical 
endpoints when we fully map out and understand all of the biomolecular interactions within 
normal physiology which is not currently the case. This notion is also outlined by Hanahan and 
Weinburg (2011), who in their decennial review of cancer explain how fully mapping 
heterotypic as well as atypical cellular molecular circuits is central to the understanding of 
cancer and future personalised or now more realistically “precision” (Goossens et al., 2015) 
medicine. They predict that over the next decade mapping of cellular mechanisms will “eclipse” 
current knowledge. These advances should increase the confidence in the measured 
biomolecules chosen to represent a clinical endpoint. 
 
1.1.4. The Need for Effective Screening Strategies  
 
Nearly 50 years ago the World Health Organisation (WHO) identified the number one priority 
for ovarian cancer as being a screen for early stage ovarian cancer in the asymptomatic 
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population (Wilson and Junger (1968) in Nossov et al., (2008)), however, one with the required 
specificity or sensitivity is yet to be verified. 
 
Many currently used diagnostic biomarkers and biomarker panels listed above are not specific 
or sensitive enough to be implemented as a screening tool; this poor performance also events 
in misdiagnosis and false positives which further risks the lives of patients. For example, CA-
125 has a sensitivity and specificity of (85-90%) and is less sensitive to detection the early, 
asymptomatic stage ovarian disease where treatment has an enormously greater impact on 5-
year survival, or specific enough to distinguish many benign from malignant growths leading 
to unnecessary and harmful investigative biopsy procedures (Timms et al., 2011, Buys et al., 
2011). CA125 is only elevated in 60-80% of ovarian cancer patients, it is more sensitive to the 
later stage and serous cancers, however does not perform as well to detect Stage 1 (50% 
sensitivity), or other histological subtypes such as mucinous (Marcus et al., 2014). For every 
100 patients with an ovarian cancer screened for CA125 either as follow up for a previous 
cancer or for suspected new cancer, 15 will not have a serum CA125 level above the normal 
distribution, thus leaving 15 cancer patients with false negative screen and potentially untreated. 
Currently, a “high” CA125 blood level (above 35IU/ml) followed by a ultrasonogram indicating 
ovarian cancer - a positive biomarker screen, would most likely need to be investigated by 
explorative surgery to attain a biopsy for a conclusive diagnosis (NICE, 2016). Due to the 
location of the ovaries all surgery, even laparoscopic, has associated risks including general 
anaesthetic.  
 
Prostate Serum Antigen (PSA) is an example of an unstable biomarker. PSA is a kallikrein 
protease expressed exclusively in the epithelial cells of normal, benign and malignant prostate, 
(Oesterling et al., 1991). Its measurable presence in the serum make it a convenient biomarker 
to detect and monitor prostate cancer and is the main tool utilised for this by the NHS today. 
Unfortunately, both false negatives and false positives are common, PSA serum levels are 
increased in benign prostatic hyperplasia, in certain ethnic groups, bacterial prostatitis, and 
acute urinary retention, all common conditions. Further to this, PSA binds to other circulating 
serum proteins so is present in multiple forms bound and unbound (Catalona et al., 1996) only 
the non-bound molecule will be measured. Hence PSA is not accurate enough to rely on alone 
to monitor cancer progression or recurrence. An invasive biopsy is the only route more 
conclusive diagnosis, although, often still hold question. It is important to identify accurate 
biomarkers or biomarker panels to improve diagnosis, monitor progression and predict a 
patient’s response to a therapy. 
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Other serum biomarkers investigated as potential ovarian cancer screening tools include CA72-
4 or TAG72, CA125, LASA, CA15-3, CA19-9, CA54/61, Serum macrophage colony-
stimulating factor (M-CSF), Monoclonal antibody OVX (OVX1), Lysophosphatidic acid (LPA), 
Prostasin, Osteopontin, HE4 (Homosapiens epididymis specific 4, Inhibin, and various 
Kallikreins (Jacobs et al., (2004), Nossov et al., (2008)). Table 1 below, summarises some 
investigated promising biomarkers of interest from a comprehensive review (Jacobs et al., 
2004). The reader is referred to Jacobs et al., (2004) for a full review on investigating novel 
biomarkers, panels combining existing biomarkers and other screening strategies tested in 
ovarian cancer worldwide. 
 
Table 1. Past Potential Markers for Ovarian Cancer. Summarised from Jacobs et al., (2004) lists some 
select past potential markers for ovarian cancer. 
Abbreviation  Summary  
CA72-4 or 
TAG 72 
Cancer antigen 72 (CA72-4) also known as tumour-associated glycoprotein 72 (TAG 72) is a 
glycoprotein surface antigen found in gastric, colon, and ovarian cancer.  
Higher expression has been observed in mucinous tumours. 
It has been investigated as marker panel with CA125 but no conclusive data. 
M-CSF 
Serum macrophage colony-stimulating factor (M-CSF) is a cytokine released by normal as 
well as neoplastic ovarian epithelium. Elevated levels have been demonstrated in 68% ovarian 
cancer compared to 2% of those classified as healthy controls. M-CSF has been shown to be 
sensitive in ovarian cancer cases where CA125 is not elevated. 
OVX1 
Monoclonal antibody OVX1 specifically binds an antigenic determinant found in ovarian and 
breast cells. Combining OVX1 and M-CSF with CA125 yields a higher sensitivity for the 
detection of earlier ovarian cancer than CA125 alone. However, the methodology used to 
conclude this is susceptible to sample handling instability. 
LPA 
Lysophosphatidic acid (LPA) is a bioactive phospholipid has mitogenic potential its functions 
with similarity to growth factors. LPA has been shown to stimulate the growth of cancer cells. 
Plasma levels of LPA are under investigation as a biomarker of ovarian as well as other 
gynaecologic cancer. Increased LPA levels were detected in the plasma 9 of 10 Stage 1 
ovarian cancer as well as the later stage disease. This performed with a higher specificity than 
the cohort tested. 
Prostasin 
Prostasin is a serine protease found in prostate gland secretions. Identified as a biomarker after 
discovery from microarray platform. RNA of Prostatsin was found to be overexpressed in 
ovarian cancer pooled from ovarian cancer and normal human ovarian surface epithelial cell 
lines. The sensitivity of both CA125 and prostasin is improved when used in conjunction. 
Osteopontin 
Osteopontin is secreted phosophoprotein. Also, discovered from gene expression profiling. 
Increased levels of osteopontin were found to be cancers from patients with epithelial ovarian 
cancer compared with healthy controls, ovarian disease, and other gynecologic cancers 
Inhibin 
Serum inhibin, a natural ovarian product decreases to levels below detection in post-
menopausal women. Some cancers (mucinous, sex cord stromal tumours and granulosa cell) 
have been shown to secrete Inhibin hence it’s the basis for a diagnostic test for serum. 
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Different forms of Inhibin have been found in serum; free, dimer subunit assays that are able 
to detect both forms have shown promising specificity and sensitivity.  
Kallikrein 
Kallikreins are serine proteases, there are 15 identified members of the human kallikrein 
family. One of note is Prostate Specific Antigen (PSA) also known as hK3. Two reports have 
suggested that hK6 and hK10 have potential a serum biomarkers of ovarian cancer diagnosis. 
 
Several biomarkers for ovarian cancer have been found to be inflammatory markers, such as 
chemokines and their receptors, though they have been shown to have the sensitivity to detect 
disease, they lack the specificity to distinguish cancer from benign disease, infection or simple 
inflammation. For example, overlap has been observed between panels of potential ovarian 
cancer and other polycystic ovarian syndrome (Galazis et al., 2012). Furthermore, 
inflammatory markers/inflammation is a characteristic that can exacerbate the cancer 
environment, tumour cells typically release or stimulate the production of inflammatory 
cytokines and as a consequence, avoid detection and elimination by the immune system 
(Vaughan, et al., 2012).  
 
Ultrasonography can be used to visualise the ovaries, malignant growths have distinctive 
asymmetric, irregular morphology. Doppler imaging can also be used, as reduced blood 
flow/pressure is commonly observed in malignant growths due to the lack of smooth muscle in 
the endothelium of blood vessels, formed by cancer-induced angiogenesis. Both have been 
investigated as a potential screen of the early detection of ovarian cancer. Jacobs et al., (2004), 
Nossov et al., (2008). However, ultrasonography is subject to inter-observer variability of the 
radiologists, a study described in (Marcus et al., 2014) found only 25% agreement between 
radiologists to identify the focal point of the ovarian cancers and 15% variability in 
measurements. This error may be exacerbated by the diverse morphological and metastatic 
patterns, tumours surrounded by ascites are viewed more clearly using a CT scan. 
 
Tumour vascularisation has also been used as a prognosticator of survival (Brown et al., 2000). 
By simply counting the number of blood vessels in tumour sections, it has been shown that an 
increased number of blood vessels correlates with decreased survival. However, this requires a 
tumour section and such is thus not suitable for a detection of early disease. 
 
Using combinations of existing screening tools or targeting screening to a high-risk population 
is believed to reduce the number of false positives and reduce exposure to the associated harms 
from medical procedures (Buys et al., 2011). A multimodal trial incorporating more than 
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ultrasonography together with CA125 monitored over several time periods termed the Risk of 
Ovarian Cancer algorithm (ROC) has been shown to increase detection of the diseases (Jacobs 
et al. 2004), but none have as yet proved sensitive or specific enough to change NICE guidelines. 
For a full historical review of ovarian cancer screening strategies investigated worldwide, 
including number of cancers per positive screen, the reader is referred to Jacobs et al. (2004), 
the author of which is a key investigator on the United Kingdom Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS) trial (discussed below). 
 
There is also a mandate for an effective tool for the monitoring of disease progression or 
recurrence of treated patients (Marcus et al., 2014), identification of low volume metastasis, 
and, detection of cancer grade (Vaughan, et al., 2012). However, again, currently CA125 and 
ultrasonography are the best available tool for this, however, their performance is poor. A small 
study described in Marcus et al., (2014) of 80 patients undergoing a “second look” surgery, 
found no correlation between CA125 levels and tumour burden. They also found little or no 
evidence to show that screening for recurrence using CA125, or physical examination strategies, 
improves survival over a patient waiting for symptoms (Marcus et al., 2014). Preliminary 
reports from a United States based screening trial based on CA125 and ultrasonography as a 
screening strategy, show that screening for detection of early disease does not improve overall 
survival, due to the high risk involved in following up a positive test resulting from screening 
tools with such low accuracy, i.e. a positive high CA125 level or irregular ultrasonogram was 
followed up by a explorative surgery which itself holds significant risk to the said target 
population (Vaughan, et al., 2012). One such sizeable US study testing screening strategies in 
the general population in fact found a higher mortally rate in the screening arm (Buys et al., 
2011). Buys et al., 2011 attributes an increased mortally to the increased exposure to the 
associated harms from medical procedures. 
 
It is accepted that ovarian cancer is a relatively rare yet genotypically diverse disease, in fact 
the term ovarian cancer has been described as “a general term for series of molecularly and 
etiologically distinct diseases that simply share the same anatomic location” (Vaughan et al., 
2012). A tangible risk of screening a general population with a screening tool of dissatisfactory 
accuracy has been demonstrated at the cost of those screened (Buys et al., 2011). Cooperation 
and sharing of sample material, data and technology worldwide will speed up the progress of 
research, Worldwide organisations-supporting such research include: Ovarian Cancer 
Association Consortium (OCAC), The Cancer Genome Atlas (TCGA), United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), The Australian Ovarian Cancer 
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Study (AOCS), OCTIPS (Ovarian Cancer Therapy Innovative Models Prolong Survival) and 
Ovarian Tumour Tissue Analysis Consortium (OTTA). It is hoped that these efforts will 
generate novel biomarkers that are prerequisite to an effective screening strategies and have 
paved the way to access appropriate sample and data cohorts to evaluate emerging biomarkers 
on a wide scale across the variety of populations.  
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2. Methodological Overview 
 
2.1. Proteomic Approaches to Biomarker Discovery and Onco-proteomics 
 
2.1.1. Proteomic Techniques for Cancer Biomarker Discovery 
 
Due to the heterogeneity of all types of cancer, and the numerous number of molecular changes 
that occur in a tumour, it is reasonable to assume that the expression level of one molecule alone 
would not provide an indication of cancer status with sufficient sensitivity and specificity. It is 
more logical to assume there will be a change in a combination of protein expressions from, or 
in response to, a tumour. However, detection and confirmation of multiple smaller changes in 
protein expression is a far more complex task (Hanash et al., 2008). 
 
Proteomic biomarker discovery workflows can be segregated into two approaches; top-down 
proteomics or bottom-up proteomics. Bottom-up proteomic biomarker discovery workflows 
entail recording as much information about a samples proteome as possible (proteome 
mapping), then comparing and contrasting the recorded proteomes of two sample groups to 
observe the identifiable differences. A bottom-up approach is most fitting to detect the multiple 
yet minute changes expected in protein expression, and general biomarker discovery. Top-down 
approaches are a targeted methodology focusing on changes in the expression of one or more 
markers of interest, the majority of the information on the samples proteome is disregarded to 
focus on the changes in presence of this or these key proteins, top-down proteomics is 
commonly seen in verification and validation stage experiments.  
 
Protein mapping/profiling studies have evolved since the 1930’s. The number of proteins 
identified in serum has exponentially increased as the technology to separate and de-convolute 
the proteome has become available (Anderson and Anderson 2002). These studies began with 
separating proteins based on their mass using ultracentrifugation. Electrophoretic separations 
in liquid, paper, agarose, starch then polyacrylamide followed. The first two dimensional 
separation of plasma were published in 1977 (Anderson and Anderson 1977); the number of 
proteins isolated and identified from 2D gel electrophoresis steadily increased since then as it 
has been coupled with other sample fractionation methods including immune-depletion, size 
exclusion, lectin binding, ion exchange and hydrophobic interaction (Anderson and Anderson 
2002). 
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Identifying proteins using mass spectrometry to measure and match a proteins fragment masses 
to those known or calculated in databases of protein amino acid sequences, has become 
fundamental to proteomics (Nesvizhskii 2007). Mass spectrometers have evolved dramatically 
since their invention yet since their application to proteomics the reliability and accuracy of 
mass spectrometry has been unparalleled by any other proteomic identification technique at any 
given time (Jennings 2012). Firstly, for the quantification and identification of proteins isolated 
using other techniques such as 2D gels or immuno-precipitation. But also for the discovery/ 
generation of biomarkers themselves. 
 
Current NICE approved biomarker detection tools used in the NHS are mainly based around 
the use of labelled antibodies to specifically bind and signal the presence of known biomarkers. 
A review of the currently used FDA approved diagnostic assays based on protein measurement 
are predominantly immune-assay (approximately 80%) with the remainder being enzyme assay 
or in one case a coagulation assay (Anderson 2010). Two key examples include; Enzyme Linked 
Immunosorbent Assay (ELISA) analysis of blood or Immunohistochemistry (IHC) on sections 
of biopsy sample. Mass spectrometry is accepted mostly as a research and discovery tool, 
however, there are a few instances where mass spectrometry and database matching is applied 
in clinical laboratories, namely the Bruker BioTyper from Bruker Daltonics. This is used to 
classify strains of bacteria (Buchan et al., 2012). Potential future clinical applications protein 
biomarkers and mass spectrometry include the iKnife© currently in phase II clinical trials or 
Rapid Evaporation Ionisation Mass Spectrometry (REIMS) where the vapour from the cuts of 
an electric surgical knife is used as the ionisation source and directly fed in to a mass 
spectrometer for near real time detection of cancer biomarkers from tumour reduction surgery’s 
(Balog et al., 2013). Immuno-based techniques such as ELISA and IHC are tried, tested and 
trusted to measure the presence their known biomarker target protein/s however do not offer 
the same scope, speed or accuracy or type of measurement of the targeted mass spectrometric 
techniques mentioned. Incorporation of mass spectrometers to clinical laboratories would 
require investment in capital equipment and the patient benefit would need to be deemed to 
offset this cost by appropriate authorities. 
 
2.1.2. Analysis of the Serum Proteome 
 
Blood serum and plasma are a popular source for biomarker discovery investigations as they 
can be easily sampled non-invasively to a patient. It is logical to expect abnormal or altered 
expression levels of molecules released from tumours to spread into the circulation, carried 
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around the body and be detectable at lower levels in the blood. Although a higher concentration 
of a biomarker released from a tumour would be expected nearer the tumour site and diluted 
levels in the general circulation. Few biomarkers though have currently been first identified in 
tumours and then shown to be present in serum (Hanash et al., 2008). 
The study of the serum proteome is challenged by the huge dynamic range and size of its 
constituent proteins and the natural inter- and intra- variation in people (Timms et al., 2011). 
 
 
Figure 4 The Complexity and Challenge of Studying the Human Proteome. 
A) The Wide Dynamic Range and Mass of Proteins in Serum. Abundance of measured proteins range over 13 
orders of magnitude; the graphics of albumin verses cytokines are approximately to scale. B) Complexity of the 
Proteome Compared to the Genome. Splice variants and post translational modifications such as glycosylation 
or phosphorylation exponentially increase the possible number of protein species to detect. C) The Increase in 
Protein Species Resolved and Identified in Plasma over a 70-Year Period. Adapted from Anderson and 
Anderson (2002) Illustrates how the number of protein species has increased, as new sample preparation 
methodologies became available. 
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In contrast to the calculated number of coding genes in the human genome, which has been 
steadily decreasing discovery (Harrow et al., 2012) the number of proteins being postulated and 
discovered in the human proteome is larger and increasing.  
As Figure 4a indicates, the abundance of proteins known to be present in the serum, span over 
thirteen orders of magnitude, further to this, a plethora of potential splice variants and post 
translational modifications increase the size of the possible protein species in the proteome 
exponentially. As Figure 4 (inspired from Anderson and Anderson 2002) depicts, the final 
count/ exact number of proteins in serum is remains unknown and the estimated number is 
expected to steadily increase as the tools to detect them have become more and more sensitive 
(Anderson and Anderson 2002).  
 
Any person’s serum proteome is a moving target. Measurable clinically relevant chemical 
analytes in serum, including proteins, have been shown to vary to differing extents both, 
between different patients within the same demographic group (age and sex) and within an 
individual when repeat samples are taken at multiple time points (Harris et al., 1970, Williams 
et al., 1978). Inter and intra individual variability poses a huge challenge to biomarker discovery 
and validation. This highlights the need for including large numbers of appropriate samples into 
a cohort to suitably represent the natural variation of any measured component across a 
population, and, if at all possible repeat measurements could be used to establish intra-variation. 
However, experimentally the logistics of sampling such appropriate control or comparator 
groups is sometimes not possible and as close a match as possible is used instead. This can limit 
the ultimate utility of the biomarkers. A biomarker needs to be robust enough to detect a disease 
state despite the noise of sample variation to be clinically applicable. 
 
Gil et al., (2015) identified data management to be the current bottle neck in progression of the 
omic research. It is still not foreseeably possible to fully enumerate or catalogue the human 
plasma/serum proteome. Each generation of discovery platform offers increased sensitivity and 
specificity, exponentially advancing computer processing and software provide the capacity to 
compile and combine measurements with both existing databases and measurements from other 
platforms. For example, Sciex have created the OneOmics Cloud data processing platform 
(Sciex 2016, Illumina 2016), where, both gene and protein measurements are compiled from 
the same samples. 
The holistic aim to study ‘omics’ encompasses the aim to map the full proteome as the ability 
to do so into a wider body of data emerges (Gil et al., 2015). This approach holds promise to 
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confront the long-held challenges of proteomics of the wide range in size and abundance of 
proteins present, and the innumerable permutations of post translational modifications. 
 
Post translation modifications such as ubiquitination or a proteins activation-state i.e. 
phosphorylation or glycosylation can be investigated by extracting phosphopeptides or 
glycoproteins using commercially available kits prior to protein identification (Jensen 2004, 
Thermo Fisher Scientific 2016). 
 
Many initial biomarker studies searching for biomarkers for ovarian cancer, to distinguish 
cancer from control, applied mass spectrometry to search for differences in the expression of 
low molecular weight serum proteome by preparing their samples onto specialised surfaces 
(SELDI) described more fully in Chapter 3 (Petricoin et al., (2002); Kozak et al., (2003); 
Vlahou et al., (2003); Zhang et al., (2004); Yu et al., (2006); Zhang et al., (2006) Kong et al., 
(2006)). An et al., 2006 focused on glycans in sera not proteins (An et al., 2006).  
 
2.1.3. Mass Spectrometry and Tandem Mass Spectrometry 
 
A mass spectrometer is an instrument designed to measure the mass of electrically charged 
molecules; ions, see Figure 5. Mass spectrometry can be used to quantify known molecules, 
identify unknown molecules and further elucidate their chemical structure and properties.  
Molecules need to be charged, either positively or negatively, in order to be measured by a mass 
spectrometer (Greaves and Roboz 2014).  
 
2.1.3.1. An Historic Summary 
 
It could be said that mass spectrometry was an incidental discovery by Physicist J. J. Thomson 
whilst researching cathode rays in the late 1800s (1889). The first “mass spectrometers” were 
invented whilst attempting to prove the existence of electrons, and later to investigate the 
masses of charged atoms. Since then the technology of the mass spectrometry field has evolved 
and the breadth of application widened unimaginably (Griffiths 2008). 
 
Fundamentally, all molecules have an electromagnetic characteristic/charge. By applying 
electromagnetic fields to molecules trapped within a vacuum it is possible to trap or direct 
/control their trajectory. Hence mass spectrometry is used to separate molecules based on their 
mass to charge ratio (m/z). In lay terms, molecules are weighed using mass spectrometers.  
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Key developments that advanced the field include:  
The development and application to wider fields than physics by Alfred Nier (1911-1994), who, 
amongst countless accomplishments developed the 60° sector field instrument, the first widely 
used mass spectrometer, and as a spontaneous collaboration, separated the 255Uranium isotope 
prompting researchers in the Manhattan Project, which began the nuclear age (Nier (1991), 
Griffiths 2008). 
Increased resolution. Marshall and Camiasow in the 1970’s were the first to apply furrier 
transform (FT) method, a mathematical function, and altered the ion path at detection to 
enhance deconvolution of wave data to interpret and vastly increase the resolution of recorded 
MS data (Griffiths 2008). 
Identification of unknown compounds. The concept and development of identification of 
unknown compounds using database matching by McLafferty, Beinman and Djerassi in the 
1960’s and 70’s where systematic experiments data-basing/recording the fragmentation 
characteristics of each class of organic molecule thus opening the field to the identification of 
unknown molecules (Griffiths 2008). 
Inclusion in proteomics. Most relevantly to this document, the introduction of soft ionisation of 
analytes via either MALDI or ESI, opening the technique to large organic molecules, proteins, 
DNA and complex carbohydrates.  
It was in the 1980’s when the two methods of soft ionisation (section 2.1.3.2) were developed 
that mass spectrometry was opened to and advanced biology and proteomics (Fenn 2002, 
Hillenkamp and Karas 2000). Mainly because it enabled the analysis and identification of 
protein opening the technology to biology - proteomics (Griffiths 2008). Prior to the advent of 
soft ionisation MS was mostly applied to small organic molecules. Larger organic molecules, 
proteins, oligonucleotides, lipids and complex carbohydrates were of interest however suffered 
excessive fragmentation or degradation prior to analysis during the ionisation into a gaseous 
phase (Griffiths 2008). 
ESI came from Fen in the US Fenn (2002). The matrix assisted element of MALDI came from 
Hillenkamp and Karas of Germany (Hillenkamp and Karas 2000) and the laser desorption part 
from Tanaka in of Shimadzu Corp (Japan). Although Fenn and Tanaka, not Hillencamp were 
credited with the 2002 Nobel Prize for soft ionisation techniques (Griffiths 2008). 
 
The fundamental components of MS are as follows: source, analyser detector. Analytes are 
ionised in the source prior to separation in the mass analyser, the detector counts/senses the 
frequency of ions as they contact it and converts this information into a digital output.  
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Figure 5. The Basic Components of a Mass Spectrometer. 
A schematic diagram of a typical mass spectrometer: samples are introduced in a gaseous phase in at the source, 
separated based on m/z in the mass analyser and counted at the detector the process happens under vacuum and 
the system is controlled by an online PC. 
 
2.1.3.2. Soft Ionisation: Matrix Assisted Laser Desorption Ionisation (MALDI) and 
Electrospray Ionisation (ESI) 
 
Matrix Assisted Laser Desorption Ionisation (MALDI): 
 
When using MALDI, the analyte is mixed with a chemical matrix, and dried to a crystal on a 
metal target plate, a high-power laser is then fired at the crystal, the energy is preferentially 
absorbed then transferred through chemical matrices causing excitation and ionisation of the 
matrix-analyte crystal into a gaseous phase plume ready for separation and detection. A 
progression from the original application of laser desorption method for biological molecules 
developed by Tanaka et al., 1988, analyte was dissolved in a mixture of glycerol and metal 
nano-particles to convey the laser energy (Griffiths 2008). The vast majority of MALDI uses 
matrix the most common of which are 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), 
α-cyano-4-hydroxycinnamic acid (CHCA, alpha-cyano or alpha-matrix) and 2,5-
dihydroxybenzoic acid (DHB) respectively for small medium and large organic molecules. 
 
In the example of serum proteome analysis using MALDI-TOF-MS, small amounts of sera are 
combined with the matrix and spotted on to a specialised steel target plate. SA can be used for 
analysis of intact proteins whereas CHCA can be used for digested peptides. 
 
The matrix-sample amalgam is then pipetted into a small spot and left to dry. Upon close 
inspection, the spot will have a crystalline formation. The crystal formation is closely related to 
the amount, concentration, distribution, dissolution and nature of the proteins in the sample. 
Depending on the make and model of the MS, the target plate can contain any number of spots 
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(up to hundreds of spots), each spot potentially containing a separate sample. The target plate 
is then inserted into the mass analyser through an air lock and the source area brought to vacuum. 
 
An ultraviolet laser is fired in pulses at each sample location in turn. Each firing of the laser 
separately desorbs the sample from its crystallised matric into a tiny gaseous plume. It is 
assumed that for each desorbed ion will acquire one proton from the matrix mixture. Thus, all 
ions are singly charged in a positive state. As the samples are separated on their mass to charge 
ratio (m/z) if all the molecules of the analytes carry a single positive charge the only property 
that will cause them to have different flight paths down the flight tube will be their mass.  
 
 
Figure 6. Matrix Assisted Laser Desorption Ionisation (MALDI). 
A schematic diagram depicting sample-matrix crystal of one of multiple spots on a steel target. Sample is ionised 
via a UV laser exciting transferring energy through the chemical matrix. One positive charge is transferred to 
each ion.  
 
Ions generated from MALDI are all predominantly singly charged (=+1), however occasionally 
a second or third proton is imparted. This simplifies and almost negates the need for calculation 
mass using the m/z ratio (Perkel 2012).  
 
Surface Enhanced Laser Desorption Ionisation (SELDI), such as Cyphergens’s ProteinChip © 
arrays are a version of MALDI, in which, a sample/analyte/protein is prepared directly onto the 
specialised surface on a chip platform (Tang et al., 2004). The chip coating is comprised of a 
factor such as a receptor ligand, antibody, hydrophobic, hydrophilic, cationic or anionic 
substance to immobilise specific components for analysis. Only components of the 
sample/analyte/protein complementary to the chip surface will be retained during a wash phase. 
Examples include Hydrophobic ProteinChips, Weak Cation exchange ProteinChips (WCX2), 
Strong anion exchange ProteinChips (SAX2), Immobilised metal affinity ProteinChip surfaces 
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(IMAC) or Immobilised copper ProteinChip surfaces (IMAC3 ) (Roboz 2005) which will bind 
different analytes/proteins with greater or less affinity depending on the properties of their 
constituent amino acids. 
 
Hillencamp, a pioneer of MALDI (Hillenkamp and Karas 2000), views MALDI to be 
“competing and complementary” to ESI (Griffiths 2008), some experiments could be conducted 
using either a MALDI or ESI source, however some would be better suited to one. Some 
molecules would not be identified using one or the other. As analytes are dried using MALDI, 
it is more tolerant of contaminants such as salts. ESI is better suited to coupling to liquid 
chromatography increasing the directionality, and data acquired from an experiment (Griffiths 
2008). Multiply charged ions are thought to fragment better if singly charged (Perkel 2012), 
making MALDI a more challenging platform for fragmentation and consequently protein 
identification. Further to this, the possibility of multiply charging ions provided by ESI, 
increases the likelihood of detection of those on the cusp of the detection range in their singly 
charged state. Thus, ESI enhances the analysis of larger molecules (Perkel 2012). Researchers 
are challenged to choose an instrument best suited to their individual work demands, ESI and 
MALDI have been the two main soft ionisation options for many years. However, an increasing 
number of ambient sources are being development for bespoke purposes. 
 
Electrospray Ionisation (ESI): 
 
ESI, was a modification of a current high voltage ionisation where non-volatile solutes analytes 
such as proteins were first dissolved in solvents (Griffiths 2008). A high voltage is applied to a 
spray of the solution creating charged micro droplets. The solvent evaporates leaving the 
gaseous analyte with one or more charges. As depicted below, during the evaporation of the 
solvent, analyte molecules can be left with varying number of positive charges, multiply 
charged species of the same molecule may exist +1, +2, +3. The speed an ion will travel through 
the mass analyser is reduced as the charge it holds increases.  
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Figure 7. Electrospray Ionisation (ESI). 
A schematic diagram adapted vastly from (Gates 2009) depicting ESI, high voltage is applied to the exterior of a 
probe through which an analyte dissolved in a solvent is being sprayed. A gaseous plume of droplets is created in 
front of the inlet to the MS. Solvent evaporates leaving a gas phase analyte which has retained one or more 
charges. 
 
Ambient Sources 
 
During the popularity and common usage of ESI or MALDI in a biological/proteomic research 
lab setting, alternative ionisation techniques have continued into emerge, especially in the 
context of clinical setting and precision medicine. A key goal in the applicability of these 
technologies is the ideal that a clinical sample could be analysed with minimal or no sample 
preparation and fed directly into the mass analyser. For this reason, they can be grouped as 
“ambient” sources, these include:  
 Desorption Electrospray Ionisation (DESI), where an electro-statically charged mist is 
passed over a liquid sample and the pneumatic perturbation of the surface, fires sample 
particulates into the analyser inlet (Takáts et al., 2014). 
 Acoustic mass spectrometry, where sound waves are used to eject a droplet from a wave 
and disrupt it into a spray with partials fine enough to effectively release analyte 
molecules into the mass analyser (Ho et al, 2011). 
 Rapid Evaporative Ionisation Mass Spectrometry (REIMS) where a sample heated and 
the vapour from a sample is directed into the mass analyser. One such example is the 
iKnife© described above (Balog et al., 2013). 
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2.1.3.3. Mass Analysers 
 
Separation of ions occurs in the mass analyser, after ionisation and before detection. Separation 
of ions is done using at least one of the following; Time of Flight (TOF), Quadrupole, 
Quadrupole ion Trap (QTrap), Ion Cyclotron Resonance (ICR), Electrostatic Sector Mass 
Analyser or a Magnetic Sector Mass Analyser (Greaves and Roboz 2014). 
 
TOF, Quadrupole and ion traps are most commonly seen in proteomics/clinical research 
laboratories and will be summarised below. 
 
Time of flight (TOF): 
Using TOF, gas phase ions are accelerated down a flight tube. If all the ions carry the same 
charge their kinetic energy will be equal and the only thing effecting their velocity is mass. Ions 
with a lower mass will reach the end of a flight tube faster than ions with a larger mass and 
equal charge. Thus, they have a lower m/z ratio (Greaves and Roboz 2014).  
 
Most TOF analysers can be run in linear or reflectron mode. In linear mode, desorbed ions 
travel down a straight flight path to a detector located at the opposite end to the source. In 
reflectron mode, an ion mirror at the end of a linear flight tube deflects their trajectory toward 
a detector in a different location, this may be at an <90° angle flight tube or back at the base of 
the flight tube near the source. Reflection is applied to extend the flight path enabling better 
resolving power. The separation distance between ions of a similar mass will increase the 
further their flight path, the longer the flight tube the higher the resolution and sensitivity to 
smaller masses. 
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Figure 8. Linear and Reflectron Mode of the MALDI-TOF-MS. 
A schematic diagram of the ion mirror increasing the flight path in reflectron mode allowing amplified 
separation then analyses of the smaller molecules. 
 
The laser of the MALDI-TOF-MS is often fired in a raster (at regular points across the dried 
spot of sample) to ensure even sampling from all areas of the spot. Alternatively, some models, 
including the Bruker UltrafleXtreme offer an auto-quality function, in which, the areas of the 
crystallised sample that yield the highest signal ‘hot spots’ are automatically ascertained and 
the laser is focused on these locations for data acquisition. Spectra acquired in auto-quality 
mode will have lower background noise and higher intensity signal in comparison to that 
acquired in Rasta mode, where data is acquired from evenly spaced locations across the sample 
spot. A good signal to noise ratio is necessary to distinguish low intensity peptide species. 
 
Magnetic and electrostatic sector field mass analysers are similar to TOF in that ions are 
directed down a flight tube with a detector at the far end. However, in this case the flight tube 
is not straight, a magnetic/electric force is applied at the bend of the flight tube. The force will 
affect each ion differently depending on its m/z. Only ions of a specific m/z flight path will be 
altered at the correct trajectory to reach the far end and hit the detector (Greaves and Roboz 
2014). 
 
The principal of using specific electric forces to direct and separate ions by influencing their 
flight path is key to most mass analysers. 
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Quadrupoles: As its name suggests a quadrupole is structure of four steel poles positioned 
longitudinally and equidistant along an ion flight path. Electrical currents are applied to the 
poles and surrounding environment to separate ions based on their mass and charge properties. 
A DC is applied at the base of the poles to give the ions a forward trajectory down the centre of 
the four poles. The quad of poles act as two pairs, each pole is twinned with the one on the 
opposite side of the ion flight path. Specific electrical currents are applied to each pair and 
alternately switched from positive to negative creating two sinusoidal electrical fields at a 180-
degree orientation as they oscillate create a circle of electrical force. Ions will have a spiral 
motion path as they are attracted to and repelled from each pole as they pass. The amount the 
poles voltage influences the flight path of the ion is dependent on its m/z charge. At any given 
set of voltages, only ions of a specific m/z will be directed to the end of the flight path without 
hitting the edge or being thrown out. Thus, the quadrupole selectively filters out ions that are 
not the intended m/z (Greaves and Roboz 2014). 
Ion traps work using the same principal where instead of directing in ions along forward path, 
the electrical fields trap them in repeating shape or orbit (Greaves and Roboz 2014). 
 
2.1.3.4. Tandem Mass Spectrometry  
 
Within a mass spectrometer, ions can be deliberately broken down/fragmented to measure the 
masses of their resulting fragments (McLafferty 1981, Hoffman 1996, Greaves and Roboz 
2014). The masses of these fragments can then be used to ascertain the chemical makeup and 
infer the identity of the parent ion (Hoffman 1996, Nesvizhskii 2007). For small molecule ions 
or short peptide ions the fragment masses can only be matched (within an appropriate tolerance) 
to the known mass of one or more element/compound. Thus, making its identity unequivocal. 
For larger molecules and the majority of protein/peptide experiments, this needs to be done by 
best matching the mass difference between fragment peaks to known masses of elements and 
compounds and incrementally compiling these in the order the parent ion fragmented them. 
This method is based on assumptions such as; the ion has been successfully and thoroughly 
fragmented to create a fragment at each stage of destruction/deterioration of the parent ion, or, 
in a peptide experiment that the beginning and end fragment is signified by a peak difference 
the same mass as the amino acid cleavage site target of the proteolytic enzyme used 
(Nesvizhskii 2007).  
Ions are fragmented within a mass spectrometer by different means depending on the model 
and type of the mass spectrometer. These include, an increased laser power when using laser 
desorption ionisation, within the vacuum of the mass spectrometer a high voltage can induce 
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fragmentation to ions isolated along the flight path, or ions can be directed through a "collision 
cell” where ions traveling along the flight path current collide with molecules of a known gas 
which inhabits the collision cell, the force physical force of the collision fragments the ions 
(McLafferty 1981, Hoffman 1996, Greaves and Roboz 2014). Additionally, ions may be 
inadvertently fragment at the source, ion source decay. 
 
For MALDI-TOF-MS/MS ions are desorbed from the target using a significantly higher laser 
power than that used for the spectra of parent ions. Once desorbed the fragmented MS/MS ions 
are detected the same was as they are in MS some designs include devices to boost detection of 
fragment ions. The Bruker Ultraflex III utilises such technology, where a "LIFT" cell is inserted 
into the ion flight path in MS/MS mode to add velocity to fragment ions, their improved 
acceleration increased the number that reach the detector for measurement (Suckau et al., 2003). 
In tandem mass spectrometry, each peak detected has two identifying features; its mass, and the 
parent mass from which is was fragmented. 
 
 
Figure 9. Peptide Backbone Fragmentation.  
A schematic diagram depicting ion fragmentation. Coloured lines depict where the molecule would fragment and 
the common nomenclature for the fragment ions until they are matched to a known mass and assigned an 
identity. 
 
Figure 9 (above) depicts a peptide ion, the coloured lines depict where the peptide would 
fragment in the mass spectrometer. Until they are matched either manually or automatically to 
a known entity the common terminology for the fragmented ions is from the carboxyl terminus 
from “z, y, x” and from the N terminus “a, b, c” A consensus between the distance of each of 
the “b” ions and each of the “y” ion is used to measure assign the unique amino acid identity.  
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2.1.4. Mass Spectrometry Approaches/Techniques used for Biomarker Discovery 
 
Since its development in the 1980's MALDI mass spectrometry has been applied to protein 
samples to separate them based on their mass to charge ratio. Identifying proteins using mass 
spectrometry relies on databases of hypothetical protein masses derived from genomic sequence 
information.  
 
Protein Identification Using Mass Spectrometry. Inside a mass spectrometer charged ions, 
for example enzymatically digested peptides, can be isolated and fragmented further i.e. to the 
amino acid level. The identity of the amino acids sequence can be derived from the fragment 
masses and possible protein identity calculated using online databases such as Mascot (Perkins 
et al., 1999). 
 
ESI and MALDI, are the two MS techniques applicable to biological molecules, they work on 
different concepts, variation in the properties of analyte fragment ions mean some are better 
detected using one platform than the other, thus their results are complimentary. 
 
MALDI: Popularity of biomarker discovery via MALDI or SELDI-MS peaked in early to mid-
2000s; numerous groups published mass values of peptides identified from mass spectra that 
were significantly differentially expressed in ovarian cancer, control or benign (see Table 3 
section 3). Failure to reproduce findings or give meaning to the mass values of ions that 
discriminated the cancer cohorts damaged the image and trust/confidence in its use. This is 
reflected by a drop in the number of publications from MALDI-TOF-MS data (Albrethsen 
2011). To confirm any potential novel biomarker findings results must be reproduced on either 
or both of; a second technological platform and a separate sample cohort. 
 
MALDI mass spectrometers do not produce numerically quantitative data. Amino acids behave 
differently in the ionisation and desorption phase depending on their efficacy to transfer energy 
when excited. Consequently, some proteins will ionise and be detected more easily than others 
depending on their amino acid composition (Benk and Roesli 2012). However, the data can be 
treated as relatively quantitative. 
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2.1.5. Sample Fractionation and Liquid Chromatography 
 
2.1.5.1. Reducing Sample Complexity 
 
Fractionating a serum sample, prior to a bottom-up analysis, allows access to identify lower 
abundant proteins (Faca et al., 2007), the total protein content of each fraction will be lower 
than the whole sample thus decreasing the overlap of proteins in any one dimension, which 
potentially masks lower abundant proteins which share the same properties. In mass 
spectrometry, this is termed “ion suppression" (Mallick et al., 2010). The strength of the signal 
from detection of highly abundant proteins, expressed at several orders of magnitude more than 
lower abundant proteins, masks the detection of the latter. Fractionating samples reduces the 
complexity of each fraction of a sample to be analysed, thus increasing the potential to see the 
proteins expressed in smaller amounts. However, fractionation reduces the sample throughput. 
Firstly, due to the time taken to perform the fractionation steps to the sample and, secondly each 
fraction then needs to be analysed separately.  
 
Albumin, the most abundant protein in human serum, can be extracted using commercially 
available kits (Margulies and Shevack 1996). This vastly reduces signal suppression of lower 
abundant proteins allowing their investigation, evaluation and analyses. However, anything 
bound to the albumin fraction is lost, some researchers have chosen to focus on the albumin 
and its bound proteins; the albuminome (Gundry and Cotter 2007, Gundry et al., 2007) 
 
Other fractionation techniques used to deconvolute a sample include; immunodepletion of the 
high abundance proteins (Tang et al., 2013), separation by pI isoelectric focusing (Stein et al., 
2013), this can be done to whole proteins after proteolytic digestion and most commonly reverse 
phase liquid chromatography using C4, C18 or strong or weak cation exchange (SCX WCX) 
media packed into a column or pipette tip (Chen et al., 2009).  
 
2.1.5.2. The Mechanics of and Sources of Variability in Liquid Chromatography 
 
Liquid chromatography (LC) or liquid chromatographic gradients are often employed upstream 
of mass spectrometric analysis as a means to fractionate or deconvolute samples. As defined by 
the International Union of Pure and Applied Chemistry (IUPAC) Chromatography is “a physical 
method of separation in which the components to be separated are distributed between two 
phases, one of which is stationary and the other moves in direction” (Ettre 1993). High 
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Performance Liquid Chromatography (HPLC), developed in the 1970s (Hager 2008), is a 
process where analytes are passed through a column packed with microscopic particles with a 
deliberately engineered surface chemistry; the stationary phase. The column is washed through 
with an analyte followed by solvents of differing strengths/properties; the mobile phase. The 
components of the analyte interact with the particle surfaces and retains components with 
affinity, changes in the composition of the mobile phase as it is washed through alters the 
chemistry of the environment surrounding the interactions. Components within the analyte are 
separated based on their affinity to bind in the altering environment. Polar compounds prefer 
the mobile phase environment whereas non-polar compounds favour the stationary phase, the 
mobile phase flow may be isocratic or a gradient of continuously increasing solvent. As the 
solvent concentration of a mobile phase increases it becomes a favourable environment for 
more of the molecules bound to the surface, thus components of the analyte are separated based 
on their differential interactions between the mobile and stationary phase. The chromatographic 
separation does not need to be coupled to a mass spectrometer, detection of the eluted sample 
may also be via UV, fluorescence, Refractive Index, Conductivity, Evaporative Light Screening 
Detection (ELSD) and Charged Aerosol Detection (CAD). The retention time (tR) of a 
compound is the measured time from injection of the sample into the system to the elution of 
the peak at its highest point. Retention factor (k), is the amount of a molecule that remains 
bound in the solid phase in proportion to that eluted into the mobile phase. A goal of liquid 
chromatography is for all identical molecules within an analyte to elute from the column with 
the same tR both within one experiment and when measured on multiple occasions; a 
reproducible tR. Factors effecting tR variation include: the differing length of possible route 
identical molecules take around and through the packed particles in the column known as "the 
multipath" effect or Eddy Diffusion, the dispersion via random molecular diffusion of identical 
molecules within the mobile phase after they have eluted, the strength of the interactions from 
the particles surface chemistry and temperature (Snyder, Kirkland and Dolan., 2010).  
 
Since the 1970's technological developments in column production, namely the engineering of 
silica particle attributes, have made HPLC a robust and reproducible platform with wide 
reaching applications. Purity of the silica from metal ions, associated with the production 
process, has steadily improved since the 1980s. Regulation of particle size and consistency 
minimise the multipath effect by standardising the path lengths taken by compounds within an 
analyte as they travel through the column thus increasing the reproducibility of their tR. The 
move to solid core/ superficially porous silica particles has the same result, analyte will only 
travel the prescribed distance throughout the outer layer of the particle. Designing the terrain 
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of the particle surface to make be a smooth sphere with pores of regulated shape can firstly, 
further standardise the path lengths and number of interactions between the analyte and 
stationary phase and secondly, as a means to filter analyte based on size exclusion. Compounds 
too large to enter the pores are unable to bind with the surface within them. Smaller particles 
increase the overall column surface, as does pore size. The pores throughout silica particles 
provide over 99% of the surface area. The longer the column length the larger the 
chromatographic effect and distance between different molecules within an analyte. Column 
ovens regulate column temperature ensuring the consistency of the environment sample 
injections. Increasing flow rates minimises the opportunity for identically eluted molecules to 
spread by random molecular diffusion. Ultra-HPLC (UHPLC) describes the use of HPLC at a 
lower volumes and higher pressure to increase sensitivity and resolution for working with 
smaller volumes. The van Deemter Equation (van Deemter et al., 1956) is used to compute all 
the potential factors effecting retention time spread, and column efficiency. Efficiency is 
measured in Theoretical plates (Snyder, Kirkland and Dolan, 2010) 
 
The van Deemter Equation: 
Theoretical Plate Height = Eddy Diffusion (multi-path effect) + (random molecular diffusion / 
velocity) + (mass transfer between phases x velocity) 
 
Theoretical plates are a model to measure column efficiency and performance. The various 
factors effecting a columns efficacy and the result can be calculated and conceptualised as 
layers within the column, theoretical plates. The more plates the column has the greater its 
efficacy at separating compounds within a sample.  
 
Different modes of HPLC include: reversed-phase where the sample is bound to and then eluted 
from a column, ion exchange where the bonds between the analyte require and anion or cation 
exchange, size exclusion, Hydrophilic Interaction Chromatography (HILIC) where surface 
chemistry is added to another to encourage water molecules to the surface for a hydrophilic 
environment, Chiral, Affinity, Hydrophobic Interaction. Ion pairing is when an intermediate 
chemical with a higher affinity to an analyte of interest is used to bind to the column and act as 
an intermediary (Majors 2012). However, reverse-phase is the most commonly used by far 93% 
(Majors 2012). Hydrocarbon chains of 18, 8 or 4 are a commonly used surface chemistry for 
the solid phase. Majors 2012 states C18 to be the most commonly used (38%), followed by C8 
(22%), Phenyl (16%), CN (10%), Fluorinated (6%), C4 (4%), Graphitised carbon (2%) and 
longer than C18 (2%).  
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2.1.5.3. Deconvolution of Complex Biological Samples Using Liquid Chromatography 
 
In a typical proteomic reverse-phase C18 LC-MS experiment aiming to fractionate a complex 
biological protein extract, a complex sample is passed through the analytical column containing 
C18 media, molecules with a corresponding surface chemistry i.e. hydrophobic peptides bind 
with varying degrees to the resin within the column. The proteins bind to, and are eluted from, 
the column at increasing concentrations of an organic solvent within the mobile phase. More 
relevantly, using LC, proteins within a serum sample can be bound to and then separated from 
a C18 column based on their affinity to bind to the chains of 18 carbons attached to the surface 
of the silica in the presence of a solvent such as acetonitrile or methanol. 
Depending on the downstream analysis the column eluate can either be monitored in real time 
or in periodical fractions collected and analysed, now at a greater detail than the original sample.  
 
LC systems are often coupled to an electrospray mass spectrometer for a continuous mass 
spectral analysis of the sample as it is eluted at an increasing concentration from the column. 
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Figure 10. Liquid Chromatographic Separation Coupled to Mass Spectrometric Detection.  
a) a representation of a complex protein sample containing proteins of varying sizes and biochemical properties 
represented by their size and dotted/dashed/solid border; b) depicts how the peptides are first separated to fractions 
based on their biochemical properties by their affinity to a solid phase inside an LC column c) in the mass 
spectrometer fractionated proteins within the sample are separated by mass d) Heat map generated by Bruker 
software of a serum sample analysed by LC-MALDI-TOF. The 384 fractions spotted over an 80-minute gradient 
of increasing solvent eluting proteins from a C18 solid phase is plotted on the Y axis, mass to charge ratio is plotted 
on the X axis, brighter colours represent a higher intensity. e) is a MS/MS spectrum of a peptide fragmentation 
with annotations assigning amino acid identities derived from the fragment masses, these could be imagined as the 
Z dimension of the heat map in d. See also Figure 9. 
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When using LC-ESI a sample analyte is in liquid form and is directly fed into the mass 
spectrometer as it ionises at the source inline/online as it is eluted from the analytic column. 
This is different to LC-MALDI as the sample needs to be mixed with a chemical matrix and 
dried to a crystal as a spot on a MALDI target plate first, this is prepared separately to entering 
the mass spectrometer so can be referred to as an offline separation. 
 
2.1.6. Advantages or Disadvantages of Tagging in MALDI-TOF-MS. 
 
Proteins can be labelled before MALDI analysis to enable a quantitation of results. These 
methods include: Isotope tagging, isotope coded affinity tagging (ICAT) late 1990s (Benk and 
Roesli 2012), Stable isotope labelling with amino acids in cell culture (SILAC), Isobaric 
tagging for relative and absolute quantitation (iTRAQ), Isotope-coded protein labelling (ICPL), 
Tandem mass tags (TMT).  
 
Other than the obvious advantage that tagging produces exact quantitation of peaks proteins, 
tagging protocols also have high reproducibility as samples are normally pooled to be analysed 
Christoforou and Lilley 2011). On the other hand, not only are the tagging systems listed above 
costly, there e is a limit of how many comparisons can be made in one experiment. Pooling 
samples is disadvantageous as it dilutes signal from each sample. Labelling protocols increase 
sample handling which gives opportunity for variation, error and loss of sample material. 
Isobaric tagging has been shown to decrease accuracy if not incorporated into methods 
appropriately (Christoforou and Lilley 2011). 
 
2.1.7. Label Free Quantitation Techniques 
 
Quantitative mass spectrometry data from methods not using labelling has been gathered using 
one of two approaches (Benk and Roesli 2012): 
 Area under the curve (AUC) of precursor ion peaks. This approach assumes that the 
amount of protein present for detection from a sample is directly correlated with the 
amount detected. 
 Methods counting MS2 spectra of parent ions calculated to belong to one protein. Again, 
this makes the assumption the amount of protein detected is correlated with the amount 
of sample loaded, and, the time the spectra is collected for. 
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A trade-off of a more accurate quantitation in exchange for less sample processing, lower costs 
and no limit on the amount of possible protein identities and comparisons is made. 
 
2.2. Transcriptomic Approaches to Biomarker Discovery and Onco-genomics 
 
Above, methods of recording protein expression, a gene’s translated information is described. 
Transcriptional information from mRNA is also mined from biomarker discovery. 
  
 
Figure 11. A Schematic Depicting How Genomic and Proteomic Data Represent a System at Different 
Perspectives. 
The difference between transcriptional and translational data is depicted. A transcriptomic measurement is of a 
biologically upstream factor and is therefore less complicated by the possibility of posttranslational modifications. 
The current common method to measure each proteins is by database matching of measured masses whereas genes 
are measured via specific complementary binding. 
 
Figure 11 depicts the difference between transcriptional and translational data. Firstly, a 
transcriptomic measurement is of a biologically upstream factor and therefore is less 
complicated by the possibility of downstream modifications. Secondly, the current common 
methods to measure each; proteins are currently measured by database matching of their 
measured masses whereas genes are measured via specific complementary binding. Proteomic 
data measures only what is active in a system at a given time and it is complicated by a plethora 
of potential posttranslational modifications (PTMs) such as glycosylation or phosphorylation. 
Genomic data (i.e. of mRNA fragments) can be less ambiguous yet still not conclusive due to 
splice variation or other factors controlling transcription.  
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2.2.1. Gene Expression Profiling 
 
2.2.1.1. DNA Microarray Experiments  
 
DNA Microarray experiments, also referred to as RNA transcriptomic, mRNA chip, 
GeneChip® DNA array microarray and gene expression array, allow determination of the 
expression of large numbers of genes in nucleic acid extracted from biological samples. 
Expression patterns of entire genomes, known splice variants, Single Nucleotide 
polymorphisms (SNPs) or collections of genes are generated and compared (Heller 2002). Early 
versions of the technique were first reported in the 1980’s (Taub et al., 1983) 
 
Fundamentally, microarrays consist of short sections of single stranded nucleic acid (referred 
to as oligonucleotides or probes) immobilised to a glass or Nylon surface which are used as bait 
to bind and measure genetic material with a complementary sequence extracted from a 
biological sample. The oligonucleotide probes are designed and manufactured to be 
complementary in sequence to the coding regions of genes, and in some cases exons, the 
expression of which are to me measured (Koboldt et al., 2013, Life Technologies 2013). 
 
In a typical microarray experiment, genetic material is extracted from a biological sample, 
fragmented using restriction enzymes, labelled and hybridised to a gene chip to assign an 
expression value to each probe representing a transcribed gene. The immobilised 
oligonucleotide probes are complimentary in sequence to their target coding gene and will 
therefore bind to a corresponding sequence of mRNA if present in the analysed genetic material. 
A well-designed gene chip has multiple probes corresponding to each gene (Life Technologies 
2013, spread at random locations across the surface to minimise experimental bias. Microarrays 
can contain probes for a small number of genes or a represented portion of an entire genome. 
As long as the sequence is known (Koboldt et al., 2013, Life Technologies 2013).  
 
Figure 12 below summarises the fundamental steps in the generation of microarray data: RNA 
is extracted from a biological sample such as a tumour tissue lysate, it is then transcribed into 
cDNA and labelled with a fluorophore; more than one fluorophore is used for comparative 
studies. The labelled cDNA is hybridised with the microarray, cDNA binds with the 
corresponding single stranded DNA probes. The remaining unbound tissue labelled material is 
removed and a reading is taken. Each probe is assigned a value depending on the fluorescence 
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emitted which will be higher the more corresponding cDNA has bound to the complimentary 
probes (Life Technologies 2013). 
 
 
Figure 12. A Typical Gene Array Experiment Workflow. 
Adapted from Life technologies 2013.Tissue containing genetic material is collected in vivo (as above) or grown 
in vitro, from this RNA is extracted cut in specific locations, restriction sites, using restriction enzymes (depicted 
above with scissors). The resulting short strands of RNA are amplified using polymerases strands with a 
complementary nucleotide sequence. The cDNA strands are fluorescently labelled at the signature beginning/end 
sequence used to cut them. The cDNA is then hybridised against a gene chip array consisting of specifically 
designed short strands of nucleotides called probes or oligo’s which are positioned in specific locations across a 
surface. After a wash step a fluorescent reading is taken the location of any fluorescent emission is inferred as the 
presence of a cDNA with a specific sequence match to the probe. Multiple probes are used to constitute a 
representative proportion sequence of a gene. 
 
2.2.1.2. Next Generation DNA Sequencing 
 
Aptly termed, Next-generation DNA sequencing (NGS), is a more recently developed 
methodology for sequencing DNA or RNA (EMBL-EBI 2015). Instead of binding the cDNA 
sample to probes of denoting predetermined known genes sequences, the DNA is cleaved into 
shorter strands approximately between 100 bp and 1 kb, the strands are then annealed to a 
position on a platform, the probes are then exposed to a mix of nucleotides, a DNA polymerase 
and a terminator which ensures only one nucleotide is bound at a time. The first nucleotide is 
bound and its character recorded, the terminator is unbound, and the process repeated. The exact 
method of recording what nucleotide varies depends on the platform used; Illumina anneal the 
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probes to a slide, then fluorescently label each nucleotide with a different colour, the colour 
emitted from each location is recorded each cycle. In 454 Sequencing the DNA fragments are 
bound to beads and the beads are immobilised into wells on a platform, the slides are flooded 
with one nucleotide species at a time (A or G or T or A) which emit a light for detection, the 
strength of the light signal emitted from each location denotes how many of that nucleotides 
base pair is next in the sequence. For example, if the slide was washed with a Guanine species 
bead location X a recodes a signal of 1 out of 4 and bead location Y records a signal of 4 out of 
4, the next part of the sequence for bead location X is T (thymine) and bead location Y is TTTT 
(thymine, thymine, thymine, thymine) (Life Technologies 2013). 
 
Ion Torrent or Proton sequencing is similar to Illumina and 454 in that DNA is fragmented and 
one end is then immobilised to a slide, however it does not record emitted signal with light. 
When a nucleotide species is bound to its counterpart the reaction releases a hydrogen ion (H+) 
thus changing the pH within the well. The pH change is measured for each probe between each 
wash to determine the strength of signal i.e. how many nucleotides were bound after that wash. 
Like 454 sequencing the slides is washed in one nucleotide species at a time and the strength 
of signal emitted recorded (Life Technologies 2013).  
 
NGS sequencing is preferable to using microarrays as it more accurately reveals the genomic 
sequence within each sample (EMBL-EBI 2015). The use of microarrays limits researchers to 
detection of predetermined probes. This is sufficient to interrogate a sample of presence/ 
absence or changes in expression of known genes. Whereas NGS allows a wider scope for 
investigation of single nucleotide polymorphisms, mutations and more (Koboldt et al., 2013) 
thus are a closer biological representation of any a given disease state.  
 
None the less, gene microarrays are able to report the presence or absence of a gene within 
biological samples and assign a quantitative value thus are still popular investigative tool 
(Koboldt et al., 2013, Life Technologies 2013). 
 
2.2.2. Data Mining  
 
Gene microarray, protein profiling and many omics protocols produce highly dimensional noisy 
data requiring in-depth bioinformatics approaches to interpret (Lancashire et al., 2009). 
Moreover, prerequisite data pre-processing steps such as alignment, normalisation, baseline 
subtraction or feature extraction add to an expanding maze of possible data processing 
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workflows (Allison et al., 2006). Suppliers of omic technology platforms commonly integrate 
a data processing workflow within their software, however, interrogation of complex 
multidimensional data using different bioinformatic processes can yield different answers. 
Often researchers merit from re-exploration of such data by alternative analyses. Combine these 
challenges with the often-limited sample numbers and wide heterogenetic inter-sample 
variation from biological samples. The challenge of data mining in biomarker discovery is to 
filter through the meaningless variation between samples from natural biodiversity and identify 
only those relating to the disease (Allison et al., 2006). 
 
2.2.2.1. Statistical Analysis for Omics Data 
 
After the overall research goal, the parameters/variables available with clinical samples 
primarily dictate the appropriate analyses for any given data set. Common examples of 
controlled variables from cancer research include 
 Paired categorical: - cancer verses control 
 Categorical: – Stage 1 verses 2, 3 and 4. 
 Continuous: – time to event data time until relapse or death after a particular 
treatment, commonly referred to as survival data. 
In a clinical research setting, it can occur that the ideally desired information to answer the 
research question is not available and has to be accommodated for post analysis during result 
data interpretation. 
 
For each data type, there are numerous statistical analyses that would be considered appropriate, 
each with benefits and disadvantages and each yielding slightly, or not so slightly, different 
findings from the same data (Allison et al., 2006). An ongoing scrutiny of published data and 
debate as to what is the most appropriate set of analyses for each data set encourages evaluation 
of statistical methodologies and encourages development of new or more widely accepted data 
handling procedures (Allison et al., 2006). One could argue a robust approach would 
incorporate more than one type of data analysis, focuses on results common between the two 
and evaluates the reasons behind differing results. 
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2.2.2.2. Categorical and Continuous Variables in Omics Data  
 
T-test 
Used for over a century the T-test is a widely-accepted test to assign a significance to the 
difference between two populations of data. For example, the differential expression of a gene 
across two cohorts. Incorporated into most software packages of omics technology platforms a 
T-test can be applied to thousands of inputs simultaneously.  
Limitations of using T-test include that they only compute two-dimensional data, and do not 
account for sample variation, or noisy data which inherent problems of large omics data sets. 
With respect to biomarker discovery, a T-test is a rudimentary assessment. 
 
False Discovery Rate (FDR) control such as the Benjamini Hochberg or the more stringent 
Bonferroni are normally applied to multiple hypothesis testing procedures of data sets with 
large variables compared to sample sizes. The purpose is to minimise the number of falsely 
rejected null hypotheses; Type 1 errors (Devlin et al., 2003). 
 
Principal Component Analysis (PCA), is another analysis/algorithm often written into the 
software of omics technology platforms. PCA identifies which variables of a data set to plot the 
sample cohort against to explain the maximum variance. The top principal components are 
separated recorded and the process is repeated thus finding the successive combinations of 
variables which best separate a sample cohort. PCA can be applied to biomarker discovery 
where in two sample subpopulations are identified when the data is separated on its principal 
components (Ringnér 2008). 
 
Cluster analyses is an exploratory grouping analysis applied to group samples within a cohort 
with similar expression patterns of particular subsets of variables. This is done by identifying 
similar attributes between samples. Most commonly in gene microarrays this would be applied 
to ontology or pathway categories when these descriptors are available (Eisen et al., 1999). 
 
2.2.2.3. Analysis of Omics Survival Data 
 
Time to event data in the biomedical research setting is commonly termed survival data. 
Survival data is continuous numeric unpaired data. The demand for analysis of survival data is 
predominantly from medical data were the measurement of time to event, often death is 
poignant (Machin, Cheung and Parmar 2006). Referring to the following particular set of 
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collections of statistical analysis as ‘survival analyses’ is believed to have become popular from 
the mid-20th century with an increase in commercial interest into safety (Singh and 
Mukhopadhyay 2011).  
 
The statistical methods used to analyse survival data are constantly evolving as the availability 
of increasingly powerful software is developed to handle data of escalating size and 
dimensionality (Machin, Cheung and Parmar 2006). 
 
Numerous software packages including SPSS and Statistica enable non-statisticians to perform 
survival analysis without needing to know the mechanics of the calculations. 
 
A life table is a rudimentary way to look at survival data (Singh and Mukhopadhyay 2011). The 
survival results are divided displayed separated by their variables and set time intervals. From 
this, further calculations can be made; the proportion of samples not survived/ failed, the portion 
surviving, the hazard function and the hazard ratio.  
 
The hazard function is the calculated probability that the event will happen at any particular 
given time point. The hazard ratio is the proportional difference between the calculated hazard 
function between two groups.  
 
Regression Analysis for Survival Data 
Regression analysis is applied to investigate the relationship between risk factors and various 
events, logistic regression for categorical variables and linear regression for continuous 
variables like survival data. A correlation plot of time versus continuous variable Y, the potential 
risk factor, can be plotted, the distance between each data plot and the line of best fit, the 
residual value is used to assess the fit of the correlation i.e. the strength of the association, or, 
the likely hood that the risk factor influences the survival time. Basic regression models cannot 
compute survival time as a viable or censored data (Singh and Mukhopadhyay 2011). 
 
Censored data is incomplete survival data. Censoring is problematic to survival data analyses, 
however commonly occurs in the biomedical setting for the following reasons; if the study ends 
before all the participants experience the measured event, if something happens so a participant 
is unable to experience the measured event or if a participant leaves the study. Respective 
examples for a study of patient survival after a test treatment; if a patient outlives the study 
period, if a patient dies of a reason irrelevant to the study and if a patient chooses to leave the 
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study. Censoring can have a left or right bias termed left censored or right censored data. In 
biomedical research, right censoring is more common as after a deliberately designed study 
start event is almost always known the end date may not be not be possible to collect due to 
reasons listed above (Singh and Mukhopadhyay 2011).  
 
Kaplan Meier plot  
A Kaplan Meier plot is survival table data graphically depicted as a Kaplan Meier plot (Kaplan 
and Meier 1958). Time is seen on the X axis and Y axis is the number of survivors usually as a 
percent. A line is plotted for each sample group which decreases/increases at every point an 
event occurs, often taking the appearance of a set of stairs with varying sized steps. The 
difference between the two groups plots can be observed. Visualisation of the survival on a 
Kaplan Meier Plot can be more informative than a test statistic from a set time point, or a 
comparison of overall influence of the risk factor on survival as these will not illustrate or work 
calculate indicate a lower significance if the survival curves may cross at any point or if there 
is a far greater difference in survival within one sub time period. 
 
The Cox Proportional Hazard (Cox 1972), followed by the Log-rank Test and Wilcoxen Rank 
test are the most common survival analyses used in the biomedical setting. The Cox 
proportional is the most popular as it is accommodating of censored data (Singh and 
Mukhopadhyay 2011). 
 
The Log-rank Test 
The Log-rank test is commonly implemented to compare survival data of two or more groups 
(Peto and Peto 1972). Using ovarian cancer survival data as the example, the Log-rank 
calculation tests the null hypothesis that there is no difference between the probabilities of a 
death occurring at a time point between two groups of patients: The calculation compares the 
difference of the observed and expected survival values and X2 is used to assign a significance 
value: 
For each group the following calculation is made at each event time point, where A is the 
number of patients in each group, B is the number of events that has occurred and C the number 
still alive.  
A(B/C) 
 
The sum of the observed (O) and expected (E) values for each group from all event time points 
are compared  
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(O1 - E1)2/E1 + (O2 - E2)2/E2 
 
This value and the degrees of freedom, which is the number of groups minus one, is applied to 
a X2 distribution table to return a p-value describing the significance of the difference between 
the two groups (Bland and Altman 2004).  
The advantage of the Log-rank test is it takes the trend of the entire follow up period into 
account which can be a more representative analysis compared to looking at survival rates at a 
particular time point, for example 3 or 5-year survival rates.  
Alone, the limitation of the Log-rank test is it only describes the significance of the difference 
between the two groups. Hazard ratios need to be incorporated to comment on the size and trend 
of the differential (Bland and Altman 2004). It is not essential to visualise the shape of the 
survival curve to perform a Log-rank Test, however may be beneficial to understand the trends 
of the data, the Log-rank test is less likely to find significance if the survival curves overlap. 
Overlapping survival cures are common in medical research trials with surgical intervention as 
the surgery itself has a high risk within a small time interval (Bland and Altman 2004). Bias 
can occur if censored data is not evenly distributed between the two groups. (Bland and Altman 
2004) 
 
A limitation to parametric methods is that assumptions are made about the data. Both the Log-
rank Test and the Kaplan Meier make the following assumptions about the data to which they 
are applied 
 Censoring has no effect on prognosis 
 Cases recruited at the beginning and the end of the study have the same survival 
probabilities as those at the beginning 
 That the time periods recorded are accurate (Bland and Altman 2004) 
 
Cox Proportional Hazard Regression Model 
The Cox proportional hazard regression model measures and compares the length of time 
between two marked events in two or more cohorts of samples. Introduced in 1972 (Cox 1972), 
it is a regression model applied to survival data, it can be used with data with and without 
censoring (Singh and Mukhopadhyay 2011). It compares the difference between the group’s 
measurements and assigns a significance, whilst at the same time accounting for influential 
covariates, i.e. censored data. Most commonly this is the time from the commencement of 
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observation to and event of relevance namely death, disease recurrence or recovery, hence the 
name ‘survival analysis’ (Singh and Mukhopadhyay 2011). 
 
Cox model assumes two parameters; that the hazard ratios of each data point/ patient are 
independent of time, and are only for time-independent covariates (Singh and Mukhopadhyay 
2011).  
 
2.2.2.4. Machine Learning. 
 
Machine learning, is a division of artificial intelligence (AI) relating to the creation and 
development of pattern recognition algorithms. The use of AI in place of conventional 
parametric linear based statistics is believed to improve the probability of identifying novel 
biomarkers from omics data via iterative processes that are designed to accommodate highly 
dimensional, noisy data. Data derived from nature is inherently ‘fuzzy’ (Lec and Guĕgan 2000), 
AI such as ANNs allow computational biologists to create a bespoke interrogation method for 
each data set, that will accommodate the non-linear relationships between variables. 
 
Lancashire et al., (2009) reports omics data to be considered be challenging due to the high 
number of input variables and limited number of cases, an inherent characteristic of biological 
data sets. Yet, in an in-depth comparison of MLP-ANNs with other statistical methods applied 
to large, multidimensional non-linear omics data sets was found to be the optimal analysis to 
apply, mainly due to their architecture giving ability to cope with highly dimensional or noisy 
data (Lancashire et al., 2009). This however may not apply to all data sets/ data types. 
 
The overall goal of machine learning or AI applied to data mining is to identify and interpret 
meaning from large highly dimensional data sets that it would be impossible to calculate 
manually. AI is applied to feature extraction and data pre-processing stages of omics data as 
well as the key applications which include supervised learning, such as relevance vector 
machines (RVM), decision trees, neural networks and Support Vector Machines (SVM). 
Decision trees are a predictive model used to make predictions of data based on sequential 
observations of a model data set. SVMs are an AI model used to find an optimal 
multidimensional line, a hyper-plane, to define subgroups or clusters of multi-dimensional data 
as if data were plotted in an artificial highly dimensional space (Dreiseitl et al., 2001). RVMs 
are akin to SVMs however include probability into the classification (Tipping, 2001).  
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“The Curse of Dimensionality” a term coined by Richard E. Bellman (1966) is a phrase used to 
acknowledge the complexity of studying large data with numerous variables using algorithms, 
where the dimensionality of the data has the potential to mask the key features driving the 
structure of the data. 
 
2.2.2.5. Artificial Neural Networks (ANNs) 
 
ANNS, the most popularly used AI in medicine and molecular biology (Lec and Guĕgan 2000) 
are a statistical application of AI that can be applied in classification or predictive modelling. 
“A neural network consists of an interconnected group of artificial neurons, and it processes 
information using a connectionist approach to computation” (Caudil 1987). The term neural 
network is used in reference to biological neurons in that, the conditioned plasticity of synapses 
dictate future behaviour. 
 
Multilayer feed-forward neuronal networks, also known as back propagation or multilayer 
perceptron (MLP) neural networks were first described by Rumelheart et al., (1986). Who, 
details a then new procedure where connections within networks of neurone like processing 
units were continually being adjusted based on the measurements performance in comparison 
to an output vector. 
 
MLP ANNs are a form of supervised learning, meaning that a training step is required from a 
set of model data with known outputs. The association between the input and output layer needs 
to be derived from training information or example data. A relevant example would be using 
measured gene or protein levels as input and the categorisation of cancer or control as output. 
 
The work described below will focus on multilayer perception (MLP) ANNs, a basic form of 
ANN used for generalisation. 
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Figure 13. Typical Multilayer Perception Artificial Neural Network Architecture. 
A fixed number of input and output neurons and hidden layer intermediating communication. A calculation made 
in each hidden layer node tailors the output based on learned information from each set of inputs. 
 
Figure 13 displays an example architecture of an ANN. Each circle represents a calculation 
centre, also termed a node. MLP-ANNs consist of three layers of nodes; an input layer, an 
output layer and a hidden layer. Or, two layers of variables sandwiching a layer of calculation 
neurons. The input nodes represent predictor variables, the hidden layer nodes are where the 
weighting for each variable is calculated and the output layer is the calculated predicted 
outcome. The MLP-ANNS used below are tailored for categorical data (i.e. cancer vs control), 
however the output is in a decimal place format ranging from 0 to 1, anything above 0.5 is 
rounded up and below is rounded down to create a categorical output. The input and output 
variable nodes will vary depending on the nature of the data under scrutiny, a basic example 
model would be where the input variables are genes from an expression microarray derived 
from cancer or control tissue.  
The ANN is perceived to ‘learn’ when pattern recognition algorithms in the hidden layer 
calculate the relative importance of one input/output node in relation to another, then, assigns 
the connection between them a respective weighting i.e. the strengthening or weakening of the 
in silico synapse.  
MLP-ANNs can have an internal training, testing and validation phase, used to prevent 
overfitting. Sample cases of data sent to the ANN are allocated, often randomly, to train test or 
validate the network in a process termed cross validation. 
 
Data used to train the ANN is not blinded, hence this is termed supervised learning. Weighting 
of the network is attributed to the input/output node connections, based on the two variables 
correlation. In the example of microarray data from cancer and control samples, if one genes 
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expression is consistently high in the cancer group and consistently low in the control group the 
algorithm in the hidden layer node will increase the weighting of this genes outbound influence, 
thus giving it more influence for the test and validation stages. During the testing stage the now 
trained model is applied to the test sample cohort predicting what their output would be based 
on the training set. The measured error between the test groups predicted and actual output is 
determined, and the error is fed back into the model to adjust weightings. The adjusted model 
can then be applied to the validation set, the performance of the model can be assessed on its 
ability to correctly categorise the data from the blind validation set. 
 
Within each node is a sigmoidal activation function which calculates whether to feedback 
positively or negatively, either increasing or decreasing the weight of the preceding in-silico 
synapse.  
 
 
Figure 14. A Representation of a Hidden Layer Node from a MLP ANN 
Adapted from Lec and Guĕgan (2000). Each input synapse value (xi) is associated with a weight (wji). The output 
(xj) is calculated in the node. The node may be connected to more than one output, this diagram has only one 
output to signify the node is only able to produce one output value per input.  
 
Figure 14, adapted from Lec and Guĕgan (2000), depicts how the MLP ANN node mirrors the 
physiology of a biological neuron. Signal is received from dendrites converging from multiple, 
separate locations or inputs (x), the information is processed and transduced in the cell body or 
calculation node (Neuron j) and one single output signal is emitted, which may create a positive 
or negative feedback loop.  
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The weight of the effect of the ith neuron to the jth neuron is represented wij. The formula is 
expressed as: 
 
Aj = ∑wjixi+Ɵj 
 
Where; i is the totalled count of nodes in the preceding layer. Ɵj is a bias term, this influences 
the calculations horizontal offset. If Ɵj is used as the weight from the modified output unit Lec 
and Guĕgan (2000). After the association between the input and output layer is established, the 
predictive error, the output value is determined. 
 
Not only can MPL-ANNs be implemented in different ways, the calculations can be extracted 
at different stages for interpretation as needed. In the example of an MLP-ANN applied to a 
gene microarray to classify cancer samples from control, the ANN can be used in a stepwise 
manner to generate a biomarker panel or simply to rank genes in order of their significance. To 
generate a biomarker panel, the MLP-ANN can be used in a stepwise manner wherein after one 
cycle of training, testing and validation the most influential gene is selected based on the lowest 
error, the data relating to that gene is set aside and the training stage is repeated. At the validation 
stage of the second loop the predictive performance is measured on all the top ranking from this 
training cycle together with those of all preceding cycles. This process is repeated until the 
performance of the model stops increasing, thus yielding a panel of the most predictive markers. 
Alternatively, the genes can be ranked based on their predictive performance in the first cycle, 
or an average performance over several cycles to assign a predictive value to all genes 
 
Benefits of using MLP-ANNs include: 
- They are able to perform generalisation that is that they can be used to make predictions 
of new data based on training data. 
- They are able to handle highly dimensional data and do not rely on a normal data 
distribution. 
- Calculations or results can be extracted at several junctures for an in-depth and flexible 
analysis. These are 1) analysis of the interconnecting network weights 2) sensitivity 
analysis and 3) rule extraction 
- They are able to process complex non-linear relationships or interactions within data 
that are too complex to de-convolute using conventional linear methods. 
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- The detrimental effect of noisy data is dampened by the redistribution of samples across 
multiple cycles of training i.e. they are fault tolerant.  
 
The limitations and caveats of using MLP-ANNs include:  
- They are limited by the quality of their training data. The inherently wide heterogeneity 
found in biological samples will hinder the ability to isolate potential biomarkers from 
noisy inputs. Predictive algorithms, modelled from poor quality data, with poorly 
controlled extraneous variables will perform badly at validation. 
- They can take a long time to complete the training stage calculations. The higher the 
number of hidden layers the longer the model can take to train. The number of hidden 
layers required is determined by the number of data features needing to be captured i.e. 
the complexity of the data. 
- Over fitting (Hawkins 2004) can occur and will be detrimental to performance at the 
test and validation stage. Over fitting is a ‘memorisation’ of the training data and is most 
commonly caused by a small training data set, a common challenge with clinical data 
sets.  
- ANNs, and other AI have been dis-affectionately labelled “black boxes” as the 
calculations and algorithms within them are often not seen or available for scrutiny. The 
MLP-ANNs utilised in the following work were created specifically with intent to apply 
to omics data from biomedical sample cohorts and successfully applied as such 
(Lancashire et al., 2008, Dhondalay et al., 2011 Kafetzopoulou et al., 2013) and a 
researcher familiar with their programming oversaw their application to the following 
work.  
- Another common adage associated with analyses of complex, fuzzy high noise data 
‘rubbish in rubbish out’ refers to the propensity of models to perform poorly if the 
quality of the training data is poor or high in extraneous variables. This highlights the 
necessity to control any extraneous variables everywhere possible. A specific example 
is seen in the reporting of MALDI-TOF based studies into novel serum biomarkers of 
ovarian cancer. Subsequent acclaimed novel biomarker panels were later accused as 
being an artificial product of not controlling sample handling extraneous variables prior 
to a predictive modelling analysis thus producing potentially artefactual interpretations 
See section 3.1.1. (Petricoin et al., 2002, Baggerley et al., 2005, Vaughan et al., 2012). 
Hence standardised sample handling and quality control and data pre-processing 
protocols must become part of data prep (Tong et al., 2012, Allison et al., 2006).  
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ANNs can also be applied to visual spatial data such as ultrasonography (Jacobs et al. 2004) to 
do this measurements and image intensity is broken down to numerical format. 
 
The reader is referred to Lancashire et al., (2009) for a full evaluation of MLP-ANNs against 
other machine learning approaches such as support vector machines, logistic regression, nearest 
neighbour analysis (kNNs) and other computational strategies for analysing large 
multidimensional data sets. 
 
2.2.3. Curated Data Repositories and Online Tools 
 
Sharing of information is key to progress scientific knowledge. Establishing databases of 
scientific measurements/information/sequence enables for peer critique/review allows for 
dispute/conflicting interpretations to be addressed and resolved the ease and speed this can 
happen will dictated the maturity and reliability of the data within. Ultimately/eventually/ 
eventuating in libraries of trusted/widely accepted almost-facts.  
One potentially problematic observation explored below is when multiple databases of the same 
information exist. This will naturally happen in the event novel types of information, or curation 
of existing information, creating a need for novel databases, these will most likely begin at a 
small scale potentially in parallel timescale with peer researchers at different institutes.  
A simple example of this and how this problem is resolved with the time/evolution of a database 
is that of Uniprot a world-wide trusted library of proteins sequence data. The need for a 
proteomics database was first identified and published in 1969 (Dayhof 1969). In the prevailing 
40 years, the creation of various databases of protein knowledge has evolved with discovery 
and demand for their use. Uniprot, is now comprised of a consortium of three major institutes 
the European Bioinformatics Institute (EBI), the Protein Information Resource (PIR) and the 
Swiss Institute of Bioinformatics, each are responsible for a key aspect of Uniprot. These were 
previously separately available containing contrary sequence data and annotation priorities. 
 
A more complex example of this is databases of protein interaction, several exist and are 
explored below. Although some draw their source information from multiple sources, a 
consortium of all protein interaction database providers does not currently exist, multiple are 
available. Some are painstakingly manually curated by researchers, others are created using 
algorithms searching and matching key words from literature. The former contains a qualitative 
data that has been read and interpreted in the context it was meant, however, may not be as 
comprehensive as a search performed by a computer. The latter is a more comprehensive search 
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however the data must be considered with the caveat that is the way that is was created – without 
human thought. 
 
2.2.3.1. Data Sharing 
 
Array Express 
The European Bioinformatics Institute, part of the European Molecular Biology Laboratory 
(EMBL-EBI) website hosts ArrayExpress; an online database of functional genomic 
experiments. All publications using gene arrays are encouraged to upload data generated for 
fellow researchers to scrutinise and attempt to validate published findings.  
 
Regulations enforcing the availability details of each published experiment are in place. Details 
of the samples source, collection protocol, and arrays used data acquisition protocol and data 
normalisation and must be listed to ensure as meaning full interpretation as possible can be 
made (ArrayExpress 2013). 
 
Gene Expression Omnibus (GEO) hosted by the National Centre for Biotechnology Information 
(NCBI) is the US counterpart to Array Express (Gene Expression Omnibus 2015).  
 
There is a crossover between Array Express and GIO, most importantly data submitted to either 
must meet the Minimum Information About a Microarray Experiment (MIAME) guidelines. 
Having this template as a basis means that incomplete data cannot be uploaded, and that 
variables are not recorded in an ambiguous, confusing or misleading format. This is essential 
as the purpose of sharing the data is for peer scrutiny, it is essential that the way the data was 
collected and recorded is clear.  
 
The Proteomics IDEntification database (PRIDE), also hosted by EMBL-EBI is a database of 
proteomic mass spectrometry data experiments where data from such experiments can be shared 
among peers for reanalysis (Vizcano et al., 2016).  
 
2.2.3.2. Protein interaction databases 
 
STRING 9.05 
Search Tool for the Retrieval of Interacting Genes/Proteins 9.05 (STRING) (Snel et al., 2000) 
is a user friendly online resource containing listings of proteins linked by; localisation, 
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homology, text-mining, databases, experiments, co-expression, co-occurrence and gene fusion. 
Lists of gene or protein identifiers can be entered and interactions between those listed are 
generated and displayed diagrammatically. Filters can be applied to control the nature of the 
interactions listed (STRING 2013). 
 
Reactome 
Reactome is a freely available curated database of protein interactions from EMBL-EBI (Croft 
et al., 2010). It prides itself on being manually curated and peer reviewed. Stringent regulation 
of what qualifies as a protein interaction allows for a higher confidence to be put in any 
interaction identified via Reactome compared to that of an automated, non-curated database 
such as STRING or IMEx. However, any new, missed or misinterpreted interactions by the 
curation team will not be identified.  
 
IMEX  
The International Molecular Exchange Consortium (IMEx) is another project to centralise 
knowledge of protein interactions IMEx (Orchard et al., 2012), it sources its information from 
curated databases however itself does not state to be manually curated. The constituent 
collaborators of IMEx include; Cardiovascular Gene Annotation Initiative funded by the British 
Heart Foundation (UCL-BHF), The SIB Swiss Institute of Bioinformatics (SIBm), Uniprot, 
Molecular Connections plc, , Extracellular Matrix Interaction Database (MatrixDB), 
Interlogous Interaction Database (I2D), Molecular Interaction Database (MINT), Database of 
Interacting Proteins (DIP) an immune response pathway database (InnateDB), a 
mechanobiology database (MBInfo) and IntAct the molecular interaction database hosted by 
EMBL-EBI (Orchard et al., 2012). Although IMEx is of a larger collaboration than STRING, 
search results are links to the origin database thus necessitating a deeper, analytical review of 
search results to use. Both STRING and Reactome facilitate searches of multiple terms.  
 
IntAct is a database of molecular interactions, it is hosted by EMBL-EBI and is curated by their 
web-based curation tool (Kerrien et al., 2012). 
 
MINT is a manually curated protein-protein interaction database with a focus on experimentally 
proven interactions (Licata et al., 2012). 
More recently, considerations have been made to combine IntAct and Mint for a more 
comprehensive database (Orchard et al., 2014). 
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I2D (Brown and Jurisica 2007) is a database of experimental, predicted and known protein-
protein interactions. It was developed in the Ontario Cancer Institute.  
 
UniProtKB Interactions is a search tool subpage of UniProt that facilitates searching for 
interacting proteins. Its information is derived from IntAact and is updated monthly. However, 
it is limited to binary interactions, and, when tested on two known interacting proteins IGF2 
and IGF2BP, a value of “no match found” is returned.  
 
Genes and proteins commonly have multiple aliases, formatting of search terms for each 
database is different and information can be lost by mislabelling a search term especially when 
databases are searching each other. 
 
KEGG 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) is a database curated of genomic and 
molecular level information, containing schematic diagrams of systems and pathways that were 
manually created using bespoke software and algorithms (Kanehisa and Goto 2000, KEGG 
2016) 
 
More Pathway data bases can be found on  
 Qiagen 
 Tocris from R&D systems.  
 Thomson Reuters pathways, also known as METACORE Life Science Research 
 
Other protein interaction or pathway databases services that are not freely available include  
 Cell Signalling Technologies (CST), a curated pathway database from CST 
 Extra Cellular Matrix Database Interaction Database (Matrix DB) (faulty website) 
(Matrix DB, 2015) 
 Qiagen Pathways, a curated pathway database from Qiagen 
 Pathway guide and iPathwayGuide from Adviata,  
 NextBio Research from Illumina 
 BioSystems pathways, incorporates NCBI, Entrez and KEGG, no fee but a membership 
credentials are required for use. 
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Table 2 (below), summarises the nature of the contents and key features in the curation of some 
widely used major data repositories and resources. For a full, detailed report on currently 
available data resources in the context of cancer the reader is referred to Pavlopoulou et al., 
(2014), who, highlights how, in the area of cancer alone, the production of exponentially 
increasing amount of data from studies focused on genes, proteins, immunomics protein-protein 
or gene-gene interactions are being compiled into various repositories. There are repositories 
available for individual cancers these include lung, breast, osteosarcoma, pancreatic, renal, 
cervical prostate but most relevantly ovarian (Ganzfried et al., 2013).  
 
 Table 2. A Summary of Globally Accessible Data Repositories and Resources. 
Type  
Database 
name 
Description Curation 
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Repository PRIDE 
Archive - proteomics data 
repository Manual Y 
    
Repository Array Express 
Database of functional 
genomic experiments Manual   Y       
Repository GEO 
The Gene Expression 
Omnibus  
  
Y 
   
Resource STRING 
Search Tool for the Retrieval 
of Interacting Genes/Proteins Algorithm Y Y 
 
Y Y 
Resource Reactome 
Reactome Database of Protein 
Interactions Manual Y     Y Y 
Resource IMEX 
The International Molecular 
Exchange Consortium  Algorithm Y Y 
 
Y 
 
Resource IntAct 
Molecular interaction database 
hosted by EMBL-EBI Algorithm Y     Y   
Resource MINT 
Molecular interaction database 
hosted by EMBL-EBI Manual Y 
  
Y 
 
Resource I2D 
Database of experimental, 
predicted and known protein-
protein interactions Hypothetical           
Resource KEGG 
Kyoto Encyclopaedia of 
Genes and Genomes ?   Y   Y Y 
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2.2.3.3. Ontological Databases 
 
Databases annotating classifications of genes, gene products and sequences have been evolving 
in parallel with gene and protein characterisation. Two examples are the Protein ANalysis 
THrough Evolutionary Relationships (PANTHER) Classification System, where proteins are 
grouped by subfamily/family, molecular function, biological process or a pathway (Thomas et 
al., 2003, PANTHER 2016). Or, the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (Huang et al., 2008, DAVID 2016) which hosts tools to annotate and 
visualise refined gene or proteins result lists based on function, functional classification, 
biological theme, interactors, and more (Huang et al., 2007, DAVID 2016).  
Importantly, large scale centralised collaborative efforts exist (Gene Ontology Consortium 2004) 
however, in the case of ontology although source data needs to be clarified and not duplicated, 
there is more of a justification to have multiple, individual niche tools which may focus on a 
specialist classification. The categories listed between the two examples above are similar yet 
notably different. 
 
2.3. Aims of the Project Overall 
 
 To identify novel biomarkers that can improve the prognosis of ovarian cancer suffers. 
 To discover novel protein biomarkers detectable in serum using MALDI-MS that 
could be used as a screening tool for the early detection and monitoring of progression 
of disease. 
 To find a reproducible sample preparation and MALDI-MS workflow which enables 
identification of novel protein biomarker/s in serum. 
 To identify genes that are associated with the progression and survival of ovarian 
disease. 
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3. Proteomic Evaluation: MALDI-MS Profiling Strategy for Biomarker 
Discovery in Ovarian Cancer 
 
Chapter Abstract 
 
The work described in this chapter aims to identify novel serum protein biomarkers using 
MALDI-TOF mass spectrometry. A MALDI-TOF MS profiling comparison was conducted and 
detailed. Briefly; MALDI-TOF-MS profiles were acquired from serum samples collected from 
30 patients with ovarian cancer and 30 age matched controls. Tight regulations were applied to 
the sample collection and processing to address criticisms of previous similar studies and 
prevent the degradation of proteins within the serum. MALDI-TOF-MS data was generated, 
processed, exported to Excel and analysed using Artificial Neural Networks (ANN’s). A 
biomarker panel of five peptide masses was found to differentiate cancer from aged matched 
controls with an accuracy of 91% and error of 9%. To assign a protein identity to each of the 
five peptide mass values to a protein identity a pool of cancer serum samples and a pool of the 
age matched controls were created. The two sample pools were separated by liquid 
chromatography (LC) on a C18 column into 384 fractions. Tandem mass spectrometry of the 
384 fractions produced a matched peptide sequence to every possible mass value present across 
the two samples (LC-MALDI-MS/MS). These masses values of the biomarker panel were cross 
referenced with those of the LC-MALDI-MS/MS sequence data to assign an identity based on 
the matched mass. This produced a list of several possible identities for each peptide value of 
the biomarker panel and for some no potential identities were matched. The lists of possible 
identities of the biomarker panels were cross-referenced with literature, two selections were 
made to attempt a validation of finding on a separate platform. ELISA was used to assay the 
expression of these two proteins, Transferrin and Vitronectin, in the serum. The expression 
patterns seen in the ELISAs did not correlate with the trends observed in the MS data and 
literature.  
On evaluation of the available data it was noted that, although the best available option, an 
ELISA assay of two proteins is an inadequate to validate the biomarker panel of the five protein 
identities generated via ANN analysis. Individually, the peptide identities held little statistical 
significance. Unfortunately, not all peptide mass values were able to be matched to a possible 
protein identity, thus it was not possible to attempt to fully validate the panel  
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Further to this, the use of the immunological approach assumes the link between the peptide 
and the whole protein. The statistical significance of identifying a peak based only on its mass 
is questionable.  
In conclusion, more information on identity of mass values significantly differently expressed 
between cancer and control groups would be needed for this data to be successfully validated. 
 
3.1. Introduction 
 
The aim of the following work was to identify novel protein signatures of serum proteins that 
could be used as a diagnostic or prognostic tool in ovarian cancer.  
 
3.1.1. MALDI Mass spectrometry and ovarian cancer 
 
Matrix Assisted Laser Desorption and Ionisation Time of Flight Mass Spectrometry (MALDI-
TOF-MS) is (was – when this work was conducted) a potentially powerful novel biomarker 
discovery tool in bottom-up proteomics and is introduced in section 2.1.3.2. Briefly, an analyte 
of interest such as blood serum containing complex mixture of proteins is combined with an 
acid matrix and dried to a crystal on a target, inside a mass spectrometer a laser is fired on the 
crystal, laser energy is transferred through the matrix and into the protein sample, ionised 
proteins are desorbed from the target and travel through a vacuum towards a detector, over the 
length of a flight tube proteins are separated massed on their mass; smaller molecules will have 
a shorter flight time than larger ones. Signal from the detector is commonly presented as spectra, 
a graph with time of flight convert to mass to charge ratio on the x-axis plotted against the 
intensity of signal detection at the time. Using MALDI-TOF-MS hundreds of samples can be 
spotted to one target, unique profiles of from all generated simultaneously and compared. Using 
this bottom-up approach minimises experimental bias as data from all samples for a comparison 
is acquired in a small time frame. Due to the sensitivity of the instrumentation MALDI-MS is 
susceptible to bias introduced from the variation in sample preparation and handling. 
 
Popularity of biomarker discovery via MALDI/SELDI-TOF-MS peaked in early to mid-2000s; 
numerous groups published mass values of peptides identified from mass spectra that were 
significantly differentially expressed in ovarian cancer, control or benign (see Table 3). Failure 
to reproduce findings or give meaning to the mass values of ions that discriminated the cancer 
cohorts damaged the image and trust/confidence in its use. This is reflected by a drop in 
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publications from MALDI/SELDI-TOF-MS data. To confirm any potential novel biomarker 
findings results must be reproduced on either or both of; a second technological platform and a 
separate sample cohort. 
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Table 3. A Summary of Similar Research. An overview of the sample selection, preparation, purification, methods and data analysis used by researchers investigating specific 
proteomic fingerprints in the sera of ovarian cancer patients. Numerous mass to charge values found to be significantly linked to ovarian disease detection. Few mass values are assigned 
to a protein identity. 
Researcher Sample source 
Mass to charge ratio (m/z) 
(or mass in Da where indicated) 
values where significant 
differences in peak amplitude 
occurred in ovarian disease 
vs control spectra 
Sample purification 
technique utilised 
Data analysis technique used Statistical significance attained. 
Petricoin et al., 
(2002) 
The National Ovarian 
Cancer Early Detection 
Program Clinic at 
Northwestern University 
Hospital (Chicago) (n=100) 
Simone Protective Cancer 
Institute (Lawrenceville) 
(n=17) 
534Da, 989Da, 2111Da, 
2251Da, 2465Da. 
C16 Hydrophobic 
interaction ProteinChip. 
Genetic algorithms combined 
with cluster analysis. 
 
Samples divided into training 
and validation. (no test set) 
100% sensitivity, 95% specificity, 
positive predictive value of 94% 
 
Sorace and Zhan 
(2003) 
Three sets from The 
Clinical Proteomics 
Program Databank: 
(Data set 2-16-02 used in 
Petricoin., et al., (2002), 4-
3-02 consist of the same 
samples but run on WCX2, 
and 8-7-02 a different data 
set) 
n=469 
2665.397, 3969.46, 3991.844, 
4003.645, 4027.3, 4056.967, 
4744.889, 6801.495, 7786.054, 
8349.266, 14796.14, 15955.47, 
17034.05 
 
1st set Ciphergen H4 
ProteinChip array (since 
discontinued). 
 
2nd and 3rd set Ciphergen 
weak cation exchange 2 
ProteinChip array (WCX2) 
Nonparametric statistics. No 
baseline subtraction. Wilcoxon 
test; then Wilcoxon with 
stepwise non-discriminant 
analysis. 
100% sensitivity and specificity 
Baggerly et al., 
(2003) 
As above 
435.46, 465.57, 2760.67, 
3497.55, 6631.70, 14051.98, 
19643.41 
As above 
Peak alignment, the 506 most 
frequent peaks were selected for 
two-sample T-test analysis, 15 
were significant. 
94% Correctly classified samples. 
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Zhu et al., 
(2003) 
National Institutes of 
Health and Food and Drug 
Administration Clinical 
Proteomics Program 
Databank web site (Ovarian 
Data Set 4-3-02 and 
Ovarian Data Set 8-7-02) 
167.8031, 321.4157, 322.4204, 
359.6322, 385.5688, 413.1668, 
433.9079, 434.6859, 444.4690, 
445.2563, 1222.1849, 
1528.3431, 3345.7995, 
3449.1503, 3473.3084, 
3528.5266, 6101.6299 and 
6123.5190 
Weak cation exchange 
protein chip (WCX2) 
Smoothing via Gaussian filters, 
pointwise two sample t/z test 
between groups of the training 
set, random field theory to 
identify the threshold and 
validated using the l-nearest 
neighbour method which also 
attains the sensitivity and 
specificity. 
Sensitivity and specificity of the test are 
both 100%. The 95% confidence intervals 
for sensitivity and specificity are (93%, 
100%) and (95%, 100%), respectively. 
 
Vlahou et al., 
(2003) 
Division of Gynecologic 
Oncology, University of 
Texas, Southwestern 
Medical Center. 
n=139 
5.54, 6.65, and 11.7  kDa 
(detected on the IMAC chip) 
4.4 and 21.5 kDa (detected on 
the SAX surface form the main 
splitters). 
Strong anion exchange 
(SAX) and immobilised-
copper (IMAC) chip 
surfaces. 
Samples separated to learning 
and test set. Five peaks were 
selected by the BPS algorithm to 
discriminate cancer from the 
non-cancer groups. 
A specificity of 80% and sensitivity of 
84.6% were obtained from the cross-
validation set. 
Kozak et al., 
(2003) 
Gynaecological Oncology 
Group and Cooperative 
Human Tissue Network. 
n=184 
3.1 kDa, 4.5 kDa, 5.1 kDa, 7.8 
kDa, 8.2 kDa, 16.9 kDa, and 
18.6 kDa (increased expression 
in the cancer group) 
13.9 kDa, 21.0 kDa, 28.0 kDa, 
79.0 kDa, 93.0 kDa, and 106.7 
kDa contrary 
Strong anion-exchange 
(SAX2) 
(Ciphergen Biosystems). 
 
Univariate and multivariate 
statistical analysis applied to 
protein-profiling data 
The individual proteins in the malignant 
biomarkers group had values for ROC 
area ranging from 0.617 to 0.851, 
sensitivities from 48.1% to 81.5%, 
specificities from 66.1% to 88.1%, and 
accuracies from 61.3% to 79.3%. 
Zhang et al., 
(2004) 
M.D Anderson Cancer 
Centre, Duke University 
Medical Centre, Groningen 
University Hospital, 
Netherlands, The Royal 
Hospital for Woman, 
Australia. (Four different 
medical institutes) n=503 
12828Da 28043Da (decreased 
expression in cancer group) 
3272Da contrary 
Bound in triplicate with a 
randomised chip/spot 
allocation scheme to 
IMAC3-Cu, SAX2, H50 
and WX2 
 
Divided into test and training set 
for the derivation and testing of 
non-linear unified maximum 
separability analysis. Then 
further analysed using Mann-
Whitney U-test or Krusckal-
Wallis test 
Sensitivity 83% 
Specificity 94% 
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Yu et al., (2005) 
Serum banks of Guangxi 
Medical University. 
n=61 
5881Da, 7564Da, 6044Da 
(increased expression in the 
cancer group) 
2085 Da, 9422 Da contrary 
Hydrophobic surface (H4) 
Tenfold cross-validation support 
vector machine established a 
diagnostic pattern. 
estimated specificity of the test sets was 
96.7%, the estimated sensitivity was 
96.7%, the estimated positive predictive 
value was 96.7% 
An et al., (2006) 
UC Davis Medical Centre 
Clinical Laboratories 
n=10 
788.545Da and 899.690Da. 
(peptide peaks) 
Dialysed with Pierce 
Slidealyzers, MWCO 7000-
10000 for glycan analysis 
but some peptises 
identified. 
n/a 
n/a 
 
Kong et al., 
(2006) 
Gynaecology and Obstetrics 
Hospital, Fudan University 
in Shanghai, China, from 
October 2002 to November 
2003 
n=195 
7676_21, 11463_8, 11545_9, 
11681_2,11706_6, 13790_8, 
15908_3). 
Immobilised metal affinity 
capture arrays (IMAC3) 
 
ProPeak software. Calculates and 
ranks the contribution of each 
individual peak toward the 
separation of the two groups. 
Unified maximum separability 
analysis (UMSA) combined with 
CA 125 
Combining the three biomarkers and 
CA125 produced sensitivity and 
specificity of 97%. 
Zhang et al., 
(2006) 
125 samples from 
Department of Obstetrics 
and Gynaecology, Qilu 
Hospital of Shandong 
University, China Between 
Apr 2004 and April 2005 
6195Da, 6311Da, 6366Da 
(decreased expression in cancer 
group) 
11498Da contrary 
Weak cation exchanger 
(WCX2) 
 
A decision tree algorithm. The 
receiver operation characteristic 
curve found most significant 
peaks. Candidate biomarkers 
evaluated by Mann Whitney-U 
test or Kruskal-Wallis test. 
Sensitivity of 87% 
Specificity of 95% 
 
Current Study 
120 serum samples 
collected from Derby City 
General Hospital, England 
Between September 2005-
2008 
1647.8, 1219.6, 3312.2, 1493.8, 
and 1820. 
Millipore C18 ZipTips 
before and after a tryptic 
digest.  
ANN used to compare the 
peptide profile of digested cancer 
serum verses age matched 
controls.  
Accuracy (test performance) 91% Error 
(test error) (9%) 
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A number of the studies detailed in Table 3 use a SELDI approach and could be criticised for 
doing so, SELDI data only represents the proteome of protein species complementary to the 
ProteinChip© utilised. Vlahou et al., (2003) demonstrates this by generating multiple 
biomarker panels from repeating the analysis of one set of samples with two SELDI platforms. 
A processed or purified sample is not representative the full serum proteome, which, biomarker 
discovery experiments would ideally aim to represent. For this reason, the data of many of the 
studies in Table 3 cannot be used to verify, validate or refute each other’s generated biomarker 
panels. 
 
Zhang et al., (2004) attempted this by using a combination of four SELDI surfaces in a 
randomised layout. Another approach explored below would be to minimise or negate sample 
preparation with an aim to best represent the entire proteome. In this chapter sample preparation 
is kept minimal and MALDI is employed to attempt to measure a larger portion of the proteome 
as possible. 
 
A common criticism of studies in Table 3, namely Petricoin et al., 2002 is that they are biased 
by artefacts in sample collection and processing (Baggerly et al., 2005, Vaughan et al., 2012). 
For example, Petricoin et al., 2002 tested samples and control samples were collected from 
different sources. The importance of control and standardisation of collection and storage of 
serum and plasma have been reviewed in Engweden et al., 2003. Alterations of known serum 
cancer biomarkers has since been demonstrated to be altered by diet (Ong et al., 2009). The 
sera for this study were collected in a tightly controlled manner with this in mind.  
 
Though it should be fairly noted that supporting evidence for the peptidomic signature 
published in Petricoin et al., (2002) was later reported (Conrads et al., 2004) as summarised in 
Nossov et al., (2008). The exact overlap in results is not specified in the original paper. Conrads 
et al., (2004) begins by noting that the low resolution TOF-MS used to generate the initial 
intriguing results is reproducible within runs and over small intervals of time, however week-
to-week and machine-to-machine variation was at an unacceptable level for work in a clinical 
setting. The study expands by applying a higher resolution instrument and several 
bioinformatics approaches for interpretation of, quality control, and analysis of the data on an 
expanded double-blinded cohort to yield four models with 100% sensitivity and specificity.  
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Sample collection was another theme in the critique of this methodology. Protein signatures 
may be affected by any part of the sample collection procedure. Namely, the about of time 
samples are stored and at what temperature. Data sets have now become available online, 
including one of ovarian cancer tumour samples, collected with a 0, 5, 30 and 60 min delay 
between collection and freezing for storage (National Cancer Institute 2015). However, 
measuring the effect of degradation is an ambiguous task, as measuring the potential biomarkers 
themselves, lack of confirmed identity assigned every peak or a quantitative measurement 
prohibit this clarification. It has also since ben argued that a large enough sample size, though 
rarely available, should dampen the effect of outliers from unwanted inter-sample variation 
(Dun et al., 2011). These critiques can be pre-empted by collecting both control and test samples 
under as similar conditions as is possible. 
 
3.1.2 Aims and Hypotheses of the Chapter. 
To identify peptide masses and identities that are significantly differently expressed in the serum 
of ovarian cancer patients compared to the serum of benign condition and control patients. 
 
H0-i: MALDI-TOF-MS with ANN analysis will not be able to detect unique protein patterns 
expressed in the sera of ovarian cancer sufferers. 
 
H1-i: That unique protein patterns expressed in the sera of ovarian cancer sufferers can be 
detected using MALDI-TOF-MS with ANNs and can be used to positively identify a blind 
validation set. 
 
If H0-i above is rejected: To identify the peaks found to be present in significantly different 
amounts in the tested serum by matching by matching LC-MALDI-MS/MS of a pool of the 
samples to MALDI-MS data. 
 
H0-ii: The masses of the peptide peaks expressed differentially in the tested serum cannot be 
identified by linking data from LC-MALDI-MS with the MS profiles. 
 
H1-ii: The masses of the peptide peaks expressed differentially in the tested serum can be 
assigned a protein identity by linking the MS-MALDI data with LC-MALDI-MS/MS data. 
 
To reproduce the difference in expression observed using a different platform; immunoassay.  
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H0-iii: No difference in expression will be noted of the proteins demonstrated to be expressed 
using MALDI-MS. 
 
H1-iii: That unique protein patterns expressed in the sera of ovarian cancer sufferers can be 
detected using MALDI-TOF-MS with ANNs and can be used to positively identify a blind 
validation set. 
 
3.2. Materials and Methods 
 
3.2.1 Materials 
 
3.2.1.1. Equipment used 
 
Table 4. Equipment Utilised for MALDI-TOF-MS 
Equipment Supplier 
Bruker UltrafleXtreme Matrix Assisted 
Laser Desorption Ionisation-Time of Flight 
Mass Spectrometer (MALDI-TOF) 
Bruker Daltonics 
Desktop computers with use of SpecAlign, 
Excel, Statistica and Bruker Software 
which comprises of: FlexControl 3.3, 
FlexAnalysis 1.3 
Bruker Daltonics 
384 spot MALDI-TOF targets  
(Grounds Steel 384) 
Bruker Daltonics 
Automated pipetting machine FluidX 
Sonicator VWR Ultra Sonic Cleaner 
-80˚C freezer New Brunswick 
37˚C Incubator Heraeus 
Vortex Scientific Industries 
10 μL Millipore ZipTips C18 pipette tips Millipore 
Polypropylene bottles for reagent storage Nalgene F.E.P. 
1.5 mL Eppendorf Eppendorf 
1 mL pipette Gilson 
200 mL pipette Gilson 
2 mL pipette Gilson 
0.2-1 mL tips Gilson 
20-200 μL tips Gilson 
0.5-10 μL tips Gilson 
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3.2.1.2. Reagents used: 
 
Table 5. Reagents Utilised for MALDI-TOF-MS 
Reagent Supplier Grade 
Acetone Sigma LC MS 
Acetonitrile (ACN) Sigma LC MS 
Alpha-Cyano-4-hydroxycinnamic acid (CHCA) Bruker Daltonics 
MALDI-TOF-
MS 
Ammonium bicarbonate Sigma Laboratory 
Distilled water 
Barnstead 
Diamond 
nano pure 
Methanol Sigma LC MS 
Peptide Calibrant II Bruker Bruker Daltonics MS  
Trifluoroacetic acid (TFA) Fisher Scientific HPLC  
Trypsin – Trypsin Gold, Mass Spectrometry Grade Promega MS  
Tryptic Digest of Bovine Serum Albumin  Bruker Daltonics MS  
 
3.2.1.3. Stock Solutions Made and Used 
 
Table 6. All stock solutions made and used for MALDI-TOF-MS 
Reagent Composition 
0.1% TFA in H2O 
(50 mL) 
50 µL TFA 
49.95 mL – Distilled water 
0.1% TFA in Acetonitrile 
(50 mL) 
49.95 mL – Acetonitrile 
50 µL TFA 
80% ACN diluted with 0.1%TFA 
(50 mL) 
40 mL – ACN 
10 mL - 0.1% TFA solution 
Trypsin solution 0.5 mg/mL 
(200 uL) 
100 mg – Trypsin Gold, Mass Spectrometry Grade 
200 mL – 100 mM ammonium bicarbonate 
NH4HCO3 
Iodoacetamide 200 mM 
(1 mL) 
36 mg Iodoacetamide 
1 mL of 50 mM ammonium bicarbonate 
Dithiothreitol (DTT) 200 mM 
(1 mL) 
30 mg DTT 
1 mL 50 mM ammonium bicarbonate 
 
3.2.1.4. Samples  
 
Two hundred serum samples were selected and categorised by a consultant gynaecologist from 
a bank of serum samples ethically collected from patients in a Derby City General Hospital 
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Gynaecology ward between 2004 and 2007 (Southern Derbyshire Local Research Ethics 
Committee: REC reference number: SDLREC Ref 0205/495). 
 
The four categories were age matched as closely as possible 
30 Cancer. (1 Clear cell carcinoma,14 endometrioid adenocarcinoma, 1 mucinous 
cystadenocarcinoma, 1 mucinous papillary cystadenocarcinoma, 1 poorly differentiated 
adenocarcinoma, 6 serous adenocarcinomas, 2 serous cystadenocarcinomas, 4 serous papillary 
cystadenocarcinoma). 
 30 Cancer controls. Treated in the gynaecology ward but not for ovarian malignancy or 
benign condition aged matched to the cancer group. 
 20 Benign (4 mucinous cystadenoma, 2 serous cysts, 3 serous cystadenofibromas, 18 
serous cystademonas and 3 serous papillary cystadenomas. 
 20 Benign controls. Treated in the gynaecology ward but not for ovarian malignancy or 
benign condition age matched to the benign group cohort. 
 
A full analysis between each group was conducted, however for this report only cancer vs 
cancer control will be reported. 
 
3.2.2 Methods 
 
3.2.2.1 Sample Preparation and Data Acquisition 
 
Two hundred serum samples were defrosted on ice, diluted 1 in 20 in 0.1% TFA and refined 
using Millipore C18 ZipTips and an automated pipetting robot. Trypsin was manually added to 
each sample for an overnight 37°C digestion then the automated pipetting robot was used to 
repeat the C18 ZipTip clean up and spot to the ground steel target for MALDI-MS analysis (as 
described in the section 2.1.3.2).  
 
Samples were placed in randomised order to negate batch effect, and appropriate standards and 
blanks run alongside. 60% of the samples were processed on one date for biomarker discovery, 
the remaining 40% were processed on a second date to be used as a validation set, to test any 
biomarker discoveries. 
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MALDI-MS spectra profiles 800-3500 m/z were acquired for each sample using the Bruker 
Ultraflex III. All spectra were reviewed visually alongside control samples before progressing 
to data analysis. 
 
3.2.2.2 Biomarker Panel Generation 
 
Data was exported from the Bruker software to Excel and an in-house designed artificial neural 
network (ANN) (as described in the section 2.2.2.5) algorithm was used to data mine it and 
generate set of peptide masses that can discriminate two groups. 
 
A stepwise analysis of 10 steps (repeats) was used.  
 
3.2.2.3 Identification of m/z Values in the Biomarker Panel  
 
At the time of defrosting for MALDI-MS profiling 2µL of each of the samples was taken to 
amass a pooled sample from each category. i.e. one “cancer pooled” and one “control pooled” 
sample that is made up of all of the other samples 
 
The two pooled serum samples were sent to the collaborative/sales contacts at Bruker (the 
supplier of the mass spectrometer) in Bremen, Germany to be analysed by the next generation 
of mass spectrometric technology. At Bruker, each pooled serum sample was deconvoluted via 
C18 liquid chromatography fractionation prior to tandem mass spectrometry (see section 2.1.3 
and 2.1.5). This was done in the same model of instrument (Bruker UltrafleXtreme) however 
using an automated program and different mode within Flex Control 3.3. Using this function 
an automated run acquires all the m/z values detected in each spot and compiles a list, following 
this the instrument switches to a more sensitive mode/reflection mode (see section 2.1.3) then 
returns to each spot and selectively isolates, fragments and measures each of the best intensity 
m/z values for each spot. In reflectron mode, the flight path of the ions is increased allowing for 
separation of the small, fragmented peptides (see 2.1.3.4). The fragment parent and fragment 
m/z values were searched at Bruker and the list of protein identities assigned to each was 
returned. 
 
The peptide m/z values from the biomarker panel generated above were cross-referenced to the 
parent m/z values of the file returned from LC-MALDI-TOF profiling. A very wide boundary 
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(1 Da) was applied to allow for machine-to-machine variation and the disconnected nature of 
this method. Additionally, with the knowledge that thousands of peptides share the same m/z 
value, these potential identities were used to not conclude a match but as a research clue/piece 
of evidence to guide future experiments. The potential error in identity matching is reduced 
slightly by this being the same model of instrument analysing the same samples. For this reason, 
more than one protein identity may be assigned to each peak. 
 
3.2.2.4 ELISA  
 
Two ELISA kits for were purchased and performed as per instructions in the kits. 
Genway Vitronectin ELISA KIT Catalog number 40-831-160002. 
Immunology Consultants Laboratory Inc Transferrin L11 0-3S1 
 
3.2.2.5 Additional Analyses 
The following additional analyses were conducted and not relevant or reported in this line of 
investigation. 
 Comparison of Transferrin and Vitronectin ELISA results against tumour stages and 
grades. 
 Box plots of peaks of interest against stages and grades. 
 CA125 and CEA levels supplied from clinical information were  
o Correlated with MS values of interest 
o Correlated against Transferrin and Vitronectin levels as assayed by ELISA 
o Included in a stepwise analysis 
 CK10Ab was purchased as there was not an ELISA KIT available. It was used for IHC 
and western blots and also SILAC work started with CK10. 
o IHC of Biomax ovarian cancer TMA 
o IHC of frozen tissue from same source as  
 The ANN analysis was repeated only containing the peptide masses that had matched 
identities. 
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3.3. Results 
 
3.3.1. Generation of Biomarker Panel from MALDI-TOF-MS Data 
 
Spectra of the test samples were acquired (as described in the methods section 3.2.2.1) and 
viewed in FlexAnalysis, any spectra deemed not to be of sufficient quality were removed from 
analysis at this stage. Intensity values of monoisotopic peak values for each sample were 
exported to MS Excel format using FlexAnalysis software. Statistica and in house developed 
software was used to compute the mass values that are differentially expressed between cancer 
and cancer-control groups. 
 
Table 7 (below) details the results of the stepwise analysis. The performance (Average Test 
Performance), and error (Average Test Error) of the model with the addition of each peak value 
(input ID) is seen. Optimal performance of the model is at loop 5, the m/z for ions 1647.8, 
1219.6, 3312.2, 1493.8 and 1820.0 produce a test performance of 91% and a test error of 9%.  
 
Table 7.Stepwise Analysis Generation of a Biomarker Panel. Summarises each step of the stepwise 
model. The performance and error of the model is detailed with the addition of each input ID/ peak label. 
LOOP 1 
Input ID 
(m/z) 
Average 
Train 
Perf 
Average 
Test Perf 
Average 
Valid. 
Perf 
Average 
Train 
Error 
Average 
Test 
Error 
Average 
Valid. 
Error 
Input 
Index 
1 1647.8 0.59 0.64 0.50 0.22 0.22 0.27 4240.00 
2 1219.6 0.76 0.73 0.75 0.18 0.18 0.18 2099.00 
3 3312.2 0.82 0.86 0.75 0.14 0.13 0.18 12562.00 
4 1493.8 0.85 0.91 0.83 0.12 0.12 0.15 3470.00 
5 1820.0 0.91 0.91 0.83 0.10 0.09 0.13 5101.00 
6 3293.8 0.91 0.91 0.83 0.08 0.07 0.15 12470.00 
7 2269.2 0.91 0.91 0.83 0.09 0.08 0.14 7347.00 
8 2541.4 0.88 0.91 0.83 0.09 0.08 0.13 8708.00 
9 1981 0.90 0.91 0.83 0.09 0.08 0.14 5906.00 
10 2202.6 0.88 0.91 0.83 0.09 0.08 0.14 7014.00 
 
The ANN model was remade in Statistica software using identical parameters with 60% of the 
samples, tested using 20% then validated on the final 20%. Then all of the cases were blindly 
classified using the Statistica ANN fifty times.  
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Figure 15 (below) is a population chart of the performance of the model in Statistica. Each 
sample is seen in the x-axis; the y-axis represents the amount of times that case was correctly 
or incorrectly classified. Three control cases were incorrectly classified as cancer and 7 cancer 
samples were classified as controls. 
 
 
Figure 15. Population Chart of the Performance of the Biomarker Panel Discriminating Cancer from 
Controls.  
All cases with a value above 75/the red line were classified as cancer, all cases below 75/the red line were 
classified as controls. Three false positives and 7 false negatives are seen.  
 
 3.3.2. Identification of the Peaks in the Biomarker Panel 
 
LC-MALDI-TOF-MS/MS was performed on a pool of the cancer and cancer control serum to 
produce a list of possible identities for each peptide mass identities in the biomarker panel. The 
possible identities were compared with current literature and Vitronectin and Transferrin were 
selected to be interesting candidates for validation using immunoassay.  
 
The peptide m/z values from the biomarker panel were cross-referenced to the parent m/z values 
of the file returned from LC-MALDI-TOF profiling. Table 8 below details the protein identities 
nearest to the m/z values of interest. This gave more than one possible identity for some of the 
m/z and none for one. A very wide boundary (1 Da) was applied to allow for machine-to-
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machine variation and the disconnected nature of this method. Additionally, with the knowledge 
that thousands of peptides share the same m/z value, these potential identities were used to not 
conclude a match but as a research clue/piece of evidence to guide future experiments. The 
potential error in identity matching was reduced slightly by this being the same model of 
instrument analysing the same samples. 
 
Table 8 Potential Identities of the m/z values of the biomarker panel. The m/z values generated from the 
cancer vs control panel (left column) are cross-referenced against the m/z values of the parent ions generated 
from tandem mass spectrometry of the same samples by Bruker in Bremen, Germany. Empty cells indicate no 
match. 
m/z 
from 
OvCa 
vs Con 
panel 
Pooled Cancer   
Run 1of1  
Pooled Cancer 
Run 2of1 
Pooled Control  
Run 1of1 
Identity  m/z  Identity  m/z  Identity  m/z  
1647.8 
Homo sapiens 
Vitronectin  
(sterile-Cell Culture 
Tested Attachment 
Factor)  
1646.8 
APOE_HUMAN 
Apolipoprotein E 
Homo sapiens  
1647.8 
APOE_HUMAN 
Apolipoprotein 
E OS=Homo 
sapiens APOE 
PE 
1647.8 
 -   -  
VTNC_HUMAN 
Vitronectin Homo 
sapiens  
1646.8 
VTNC_HUMAN 
Vitronectin 
Homo sapiens 
VTN  
1646.82 
1219.6  -   -  
LV102_HUMAN Ig 
lambda chain V-I 
region Homo 
sapiens  
1219.66  -   -  
3312.2 
Homo sapiens 
keratin 1 (KRT1)  
3312.3  -   -   -   -  
1493.8 
KRHU0 keratin 10, 
type I, cytoskeletal 
- human  
1493.7 
K1C10_HUMAN 
Keratin, type I 
cytoskeletal 10 
Homo sapiens 
1493.73 
TRFE_HUMAN 
Serotransferrin 
Homo sapiens 
TF 
1494.73 
 -   -  
TRFE_HUMAN 
Serotransferrin 
Homo sapiens TF 
1494.73  -   -  
1820  -   -   -   -   -   -  
 
Table 8 shows, when the samples were re-analysed with the same instrument with peptide 
matching functionality. The protein identities with the closest m/z values to 1647.8 were 
Apolipoprotein E and Vitronectin, 1219.6 to lambda chain V-I, 3312.2 to Keratin 1, 1493.8 to 
Serotransferrin and no parent m/z values were within 1 Da of 1820. 
 
Keratin 1 is a common contaminant in mass-spectrometric experiments and is generally 
discounted from results, leached from researcher’s skin and hair despite personal protective 
equipment can be hard to eliminate entirely, thus is a poor biomarker candidate for further 
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research. Apo lipoprotein is a highly abundant serum protein so without a quantitative 
application it would be hard to make a publishable novel contribution to current knowledge. 
 
The lists of potential identities were then compared with current literature and two identities 
were chosen for further investigation based on their relevance, reported link to ovarian cancer, 
and therefore their potential use as a prognostic biomarker. Transferrin has been reported to be 
expressed in serum at decreasing levels relating to increasing stage (Nosov et al., 2009). The 
role of Vitronectin in ovarian cancer progression has been inferred in a cell line study of the 
effects of its agonist on cell adhesion and motility/ metastatic potential (Beck et al., 2005) 
 
Keratin 10 and lambda chain V-I were chosen as secondary candidates to be investigated at a 
later stage. Namely CK10, from these results CK10 was chosen to immunohistochemically 
stain a tissue microarray of ovarian cancers by other researchers however the results are not 
available to this study. 
 
3.3.3. Validation of the Peaks in the Biomarker Panel 
 
The Figures below show the amount of inferred proteins as measured by immunoassay for each 
cancer and cancer-control case. The cancer control group show a wider range of Transferrin 
serum levels which is significantly (p-value = 0.0243) higher in the cancer control group. Figure 
17 (below) shows the amount of Vitronectin as measured by immunoassay for the cancer and 
cancer control group. No significant difference in expression between the two groups is noted 
(p-value = 0.258) 
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Figure 16. Boxplot of Transferrin Levels as Measured by ELISA.  
Transferrin levels of 30 cancer cases and 30 cancer control cases as measured by immunoassay. The average serum 
concentration of the cancer group is (2.56 mg/mL) is lower than that of the cancer-control group (3.25 mg/mL) 
with a p-value of 0.0243. 
 
 
Figure 17. Boxplot of Vitronectin Levels as Measured by ELISA.  
Vitronectin levels of 30 cancer cases and cancer control cases as measured by immunoassay. The average serum 
concentration of the cancer group is 85.8 µg/mL and the control group is 75.5 µg/mL.  
 
The peak intensities of a peak suggested to be Vitronectin were correlated against the immune 
assay values. Figure 18 (below) shows that no correlation was seen between the level of 
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Vitronectin as measured by immune assay and peak intensity of the peak suggested to have 
been Vitronectin. To better demonstrate the poor correlation all 200 serum samples analysed 
(cancer, cancer control, benign and benign control) are shown, zero values are seen in cases 
where either no Vitronectin was measured by ELISA (x axis), or, no m/z of 1647.8 was 
detected in the MALDI-TOF spectra (y axis). 
 
Figure 18. Vitronectin Levels as Measured by ELISA (µg/mL) and Peptide Peak m/z 1647.8 Intensity.  
Correlation of Vitronectin as measured by ELISA against the intensity value of the peptide peak with the suggested 
identity as Vitronectin. 
 
3.4. Discussion 
 
This chapter aimed to address the need for robust replacements for out-dated low-accuracy 
diagnostic clinical tools currently used. Despite its popularity, MALDI-MS profiling studies of 
ovarian cancer patient material have so far not produced any robust biomarker identities to 
further this field (Cadron et al., 2009, Hays et al., 2010, Timms et al., 2011) 
 
There are instances where the biomarker discovered by MALDI-MS data has been utilised 
(Yang et al., 2013) and (Timms et al., 2011). Most recently Timms et al., 2011, published a 
MALDI data profiling study with methodologies similar to those in this report. Combined with 
CA125 two chemokines improved the prognostic ability of serum analysis. Analysis of peptide 
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yielded peptides which when combined with CA125 improved sensitivity and specificity. Due 
to the nature of the data identity of the peptides were disputable. They used this identity as a 
suggestion, and combined with literature and made an inferred identify. Based on the calculated 
guess a separate platform was used to validate the differential expression of this which worked. 
 
In this study MALDI-MS profiles of serum from cancer patients were acquired and analysed 
using bioinformatics methodologies. It was demonstrated that a biomarker panel can be 
generated from MALD-MS data using ANN algorithms with a promising predictive power 
comparable to that of CA125.  
A MLP-ANN used in a stepwise manner was used to generate the biomarker panel. MLP-ANNs 
have been criticised for their closed, black-box nature, the ANN used to generate the panel was 
created in-house and conducted under the supervision of one of its creators to ensure its correct 
use (Lancashire et al., 2008) 
A biomarker panel of five peptide mass values discriminated cancer from age matched controls 
with a 91% sensitivity (Table 7). Possible protein identities were assigned to these peptide 
masses reanalysing a pool of the serum using LC-MALDI-MS/MS and online databases to 
calculate probable protein sequence information thus protein identities. Immunoassay was 
performed for the quantitation of Transferrin and Vitronectin, two potential identities of peptide 
peaks of interest (Figure 16 and Figure 17). 
 
In an ideal scenario, a biomarker panel would be repeated and validated on a different 
technological platform, and on a different cohort of serum samples from patients with ovarian 
cancer and age matched controls and the same changes in protein expression observed. 
 
The sensitivity and reproducibility achieved with the biomarker panel generated from the MS 
data was not reproduced for a series of reasons including 
 The heterogeneity of the sample set used 
 The lack of a second cohort serum of samples 
 The lack of identities of the peptide masses in the biomarker panel 
 The allocation of possible identities for a peptide based only on mass the same sample 
but on different machine or different analyses in the same machine.  
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3.4.1. Samples  
 
No other cohorts of serum from ovarian cancer patients with aged matched controls, collected 
in a standardised protocol were available to this group for validation of the biomarker panel 
produced. Blinding the data and presenting it to the trained ANN is the closest that could be 
attempted to ‘blind validation’ of the model. Presenting the same data to the ANN may arguably 
produce a higher performance. Though it should be noted the results of the validation seen in 
Table 7 are truly blinded 20%.  
 
Although all samples analysed were selected by a consultant gynaecological oncologist from a 
biobank collected over three years it was unavoidable to include a variety of stages, grades and 
histologies in the cancer group. See section 3.2.2.1 sample details. Treating this ‘mixed bag’ of 
cancer samples as one group will hinder the detection of biomarkers that that would categorise 
between the subcategories. 
 
3.4.2. Identification of the Biomarker Panel Proteins 
 
Not all peaks in the biomarker panel were matched to any potential identities. Thus, the full 
performance of the biomarker panel cannot even be attempted to be repeated using another 
technological platform. As in other biomarker detection studies using MALDI-MS data (Timms 
et al., 2011 and Yang et al., 2013), the data served mainly as a guidance, and where a story 
seemed to match the other literature this was investigated further.  
 
One of the potential identities of the peaks in the biomarker panel was Transferrin. Nosov et al., 
(2009) published their interest in this protein alongside Transthyretin, Apolipoprotein A-1 and 
CA125 based on their previous evidence and the hypothesis that all three of these play a role in 
oxidative stress which links to carcinogenesis (Nossov et al., 2008 and Nossov et al., 2009).  
 
The increased expression of Transferrin in the serum of cancer patients compared to controls 
produced in this study (Figure 16) did not reflect the trend noted in the literature; where serum 
Transferrin levels decreased with higher grade of tumour (Nosov et al., 2009). This discrepancy 
may be explained by the particular subset of samples, it was suggested by Nossov et al., (2008) 
that these markers were more sensitive to a mucinous histopathological subtype. 
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The approach of matching peptide mass values from MS MALDI data to LC-MALDI-MS/MS 
data for an identity was used as it was the best available option, however, is fundamentally 
flawed. 
 
The exact peptide mass values from the biomarker panel have 4 decimal places and is a result 
of what the Bruker FlexAnalysis software has recognised to be a monoisotopic peak value and 
used to export as the raw data. The mass values for the LC-MALDI-MS/MS ‘identity’ run were 
also generated using the Bruker software suite however on a different instrument in a different 
laboratory. Some inter and intra instrument variation is to be expected so a very wide window 
of 1 Da either side of the biomarker was used to generate the possible identities. 
 
Researchers at the time (early 2000s) see Table 3, were less concerned with the identity of 
biomarkers generated by SELDI and MALDI MS if they were clinically applicable this was all 
that mattered: “Although knowledge of the identity of a marker is not prerequisite to its utility” 
Jacobs et al. (2004) 
 
Further to this, it is possible that the peptides that were not matched to an identity are novel 
proteins coded by a cancerous mutation or novel single nucleotide polymorphism (SNP) 
therefore would not be found by conventional database searching. If a SNP or mutation was 
suspected the MALDI-TOF-MS/MS data could be searched against an in-silico database of 
hypothetical mutations however, this is not currently available. Moreover, is more likely that 
the peptides were either not detectable by or not detected on in the MALDI-TOF-MS/MS 
sample used for the matched identification.  
 
In summary, the inability to identify markers, and the ambiguity of the identities assigned to 
peptides of the biomarker panel, was a major limitation to this strategy for biomarker discovery. 
 
3.5. Conclusion 
 
In conclusion, the first null hypothesis (HO-i) can be rejected: Unique patterns in protein 
expression in the sera can be detected by MALD-TOF-MS and ANNs and used to distinguish 
cancer from control on a blinded validation set. 
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However insufficient data or evidence leads to the acceptance of the second null hypothesis 
(HO-ii): The masses of the peptide peaks expressed differentially in the tested serum cannot be 
identified by linking data from LC-MALDI-MS with the MS profiles. 
 
Consequently, the third null hypothesis cannot be addressed as the full set of peptides in the 
biomarker panel were not identified.  
 
Approaching the task with the next generation of technology, where all protein and sequence 
data is available from the same analysis the biomarker panel is generated from will result in a 
biomarker panel of peptides of a known identity.  
 
LC-MALDI-MS Profiling Strategy for Biomarker Discovery in Ovarian Cancer 
83 
 
4. Proteomic Evaluation of LC-MALDI-TOF-MS as a Profiling Strategy for 
Biomarker Discovery in Ovarian Cancer 
 
Chapter Abstract 
 
Spectral features alone, such as the biomarker panel of m/z values generated in chapter 3 have 
limited real world applicability, and are not able to be validated fully without further insight as 
to what they are. A confident assignment of a protein identity to each data/spectral feature was 
key to being competitive with current literature. 
 
The work described in this chapter aimed to test and evaluate the capabilities and reproducibility 
of the (now available) next generation of protein profiling instrumentation LC-MALDI-MS/MS, 
and upstream sample preparation and fractionation techniques, such as the OFFGEL 
fractionator and Millipore C18 Zip Tips. Several sample preparation protocols were planned to 
be compared with a view to apply the best performing to the cohort of clinical samples used in 
chapter 3, of which there were limited stocks. 
 
Multidimensional data was produced from ten replicates of four sample preparation techniques; 
due to time restrictions, this was not as many as initially outlined. The ten replicate experiments 
of each of the four methods were compared to assess the overall reproducibility of sample 
preparation and data acquisition. Of the tested sample preparation methods analysed to 
completion one was found to consistently yield a higher number of protein identities. 
Unfortunately, a deeper analysis of the data collected indicated that there was an overall 
relatively low/poor reproducibility in the data acquisition. This was demonstrated by a retention 
time shift of the chromatograph however the accuracy is also limited by the experimental design 
of LC MALDI spotting being an ‘offline’ analysis. It was concluded that, as the capability of 
the instrumentation had been measured and its limitations now known, a clinical cohort of 
samples could be analysed in this manner and the resulting data used with the caveat that there 
is a margin of error of a known size which must be taken into consideration on final analysis. 
However, this caveat may make it unappealing to apply to a rare sample set of which there is a 
limited stock. 
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4.1 Introduction 
 
4.1.1 Need for Identification and Reproducibility of Biomarkers. 
 
The results from chapter 3 as with many studies listed in Table 3 produced results that had 
potential, if validated, to improve the prognosis of ovarian cancer sufferers. However, these 
proved to be massively flawed by the lack of conclusive identification of peptide mass values 
that distinguished cancer from controls.  
 
Previously the identification of the peptide mass values of interest generated from MALDI-
TOF-MS data were matched to protein identities from a separate LC-MALDI-TOF data 
acquisition based on its mass alone (Section 3). LC-MALDI-MS/MS analysis of each test 
sample individually would provide a three-dimensional peptide map and matched protein 
identities of peptides present in the sample (as opposed to a two-dimensional MS spectrum with 
no sequence information), analysis of this data would provide the identity of any proteins found 
to be differentially expressed between groups. Reproducibility of data and validation of findings 
needed to be addressed to compete with criticisms in the current literature. Had the technology 
been available, the samples for biomarker discovery could have all been analysed via LC-
MALDI-TOF-MS/MS. The mass values that distinguished cancer from control with protein 
identities assigned to them could have been generated at this stage, thus more confidence in 
their identity, and likelihood of validation. When LC-MALDI-TOF technology became 
available to the project, the ovarian cancer cohort could be reanalysed. Due to limited sample, 
optimisation of the sample preparation protocols was needed to ensure the samples were 
analysed under the conditions that would produce the maximum protein identities. 
 
To maximise the information recorded from each test sample, experiments were conducted to 
test the capabilities of the available Bruker LC-MALDI-MS platform. 
 
Different sample preparation and data extraction methods were tested to uncover which 
produced the highest number of proteins identified with a high confidence. 
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4.1.2. Liquid Chromatography  
 
Liquid chromatography (LC) is used to fractionate molecules within a sample based on their 
affinity to bind to an analytical column (as described in section 2.1.5.). A complex sample is 
bound to an analytical column and eluted from it at increasing concentrations of a solvent; the 
mobile phase. For example, using LC, proteins within a serum sample can be bound to then 
separate from a C18 column based on their affinity to bind to C18 silica in the presence of the 
solvent acetonitrile. Periodical fractions of the eluent from the column can be collected and 
analysed at a greater detail than the original sample. LC systems are often coupled to an 
electrospray mass spectrometer for a continuous mass spectral analysis of the sample as it is 
eluted at an increasing concentration from the column. 
 
4.1.3. The need to Address Reproducibility to Progress with the Research in the Area. 
 
Publications based on MALDI data are heavily criticised on the reproducibility of the data and 
the lack of the identification of the peptide peaks of interest. 
It is also seen (Cadron et al., 2009) that the majority of the identities that have been implied are 
high abundant proteins, or already known acute phase reactants (Diamandis 2004). In theory, a 
serum protein released by or in response to a tumour would be found at concentrations orders 
of magnitude lower than these. 
 
4.1.4. Sample Fractionation Techniques. 
 
Removal of the highly abundant proteins, or separation of the proteome on a separate dimension, 
can be conducted to allow access to the lower abundant proteome (Margulies and Shevack 
1996). Additionally, fractionating the proteome on a third dimension and analyses of each 
separate fraction decreases the complexity of the sample and increases the chance of access to 
proteins of lower abundance. Two different examples of fractionation techniques include. 
 Immuno-depletion proteome (Margulies and Shevack 1996). Relevantly to serum 
proteomics is the Sigma ProteoPrep20 immuno-depletion column (Sigma-Aldrich 
2012); Sera to be analysed is run through a column containing antibodies to the 20 most 
highly abundant proteins in serum. The abundance proteins are captured and removed 
or analysed separately. This process removes 90-95% of the total protein from the 
sample (Sigma-Aldrich 2012). 
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 Isoelectric focusing. The OFFGEL fractionator 3100 (Agilent Technologies 2010) 
applies an electric current to the sample loaded. Proteins or peptides within the sample 
are fractioned into 12 or 24 portions based on their isoelectric point (pI).  
 
Analysed data acquired from each fraction can be compiled post-acquisition to piece together 
a proteome at an increased resolution than a non-fractionated sample. 
 
4.1.4.1. Millipore Zip Tips. 
 
A ZipTip, or solid phase extraction in a pipette tip (see section 2.1.5 for solid phase extraction), 
is one such method of sample purification; they are relatively cheap means for liquid 
chromatography used with an isocratic mobile phase. Millipore Zip Tips are a 10 µL pipette tip 
with a bed of chromatography media fixed at its end. Drawing in and aspirating a sample 
through a ZipTip will remove salts and detergents which, due to their charged nature, can hinder 
spectral quality by increasing signal to noise ratio: biomolecules in the sample bind to the 
immobilised absorbent resin inside each tip, damaging salts and detergents are washed away 
resulting in de-salted, purified and concentrated sample. C18 and C4 are two types of ZipTip that 
can be used depending on the nature of the analyte (Millipore Corporation 2005). 
 
4.1.4.2. Alkylation and Reduction. 
 
Proteins are commonly reduced and alkylated prior to analysis.  
 
Breaking disulphide bonds relaxes and linearises the 3D structure of a protein (Sechi and Chait 
1998, Hale et al., 2004 and Wedemeyer et al., 2000). Disulphide bonds between cysteine 
residues are key to the stability of tertiary structure of proteins (Wedemeyer et al., 2000). 
Reductive unfolding, is the loss of protein tertiary structure due to the chemical reduction of 
these bonds (Wedemeyer et al., 2000). The resulting exposed sulphydryl groups are highly 
reactive so an alkylating agent is often added to oxidise and stop unwanted reactions or 
refolding within the protein (Hale et al., 2004). In gel-based techniques such as in 1 or 2-
Dimensional Polyacrylamide Gel Electrophoresis (1 or 2D-PAGE) this standardises the 
movement of proteins through medium increasing the resolution of bands or spots (Sechi and 
Chait 1998). Additionally, the linearisation or the protein increases access of proteolytic 
enzymes to digestion cleavage sites prerequisite for protein identification from mass 
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spectrometric peptide mass fingerprinting. Improving digestion efficiency should result in more 
peptides cleaved per protein, and a cleaner mass spectrum with better resolved peaks for optimal 
protein identification through database matching (Hale et al., 2004). 
 
To be able to publish in the area, and more importantly for confidence in the reproducibility in 
the data, repeated measurements of the capabilities of the instrumentation, sample preparation, 
and methods used was a necessary step. 
 
To do this, a large stock of human serum used for regular quality control was analysed multiple 
times through different sample preparation workflows and data acquisition and extraction to 
discover the optimal rout for the future analysis of the serum from ovarian cancer patients with 
controls. 
 
Figure 19 (below) depicts 40 replicates of one sample being analysed via four protocols/ 
workflows (10 in each). Some requisite procedures are consistent across all 40 replicates i.e. 
thawing and dilution or tryptic digestion. Other potentially optional steps i.e. alkylation and 
reduction or pre-digestion C18 ZT are conducted on 10 replicates and 10 replicates of a control 
condition which was identical barring the optional procedure was shown next to it. 
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Figure 19. Multiple Analysis of one Serum Sample via Different Sample Preparation Workflows. 
One serum sample used for quality control seen on the top level was analysed 10 times four each of four 
workflows. Each line and circle represents one replicate. 
 
4.1.5. Aims and Hypotheses of the Chapter 
 
To assess the quantitative power of MALDI-TOF-MS data. 
H0-iv: There is no correlation between protein amount loaded for detection and the signal 
intensity of protein detected. 
H1–iv: The signal intensity values of a detected protein is relative to the amount of protein 
loaded. 
 
Optimise Sample preparation; identify a satisfactorily reproducible combination of sample 
fractionation and preparation techniques to maximise the number of meaningful protein 
identities from one serum sample using MALDI-TOF MS. 
H0-v: All tested sample preparation techniques prior to LC-MALDI-MS produce equal amounts 
of meaningful protein identities. 
H1–v: One sample preparation technique prior to LC-MALDI-MS will yield a greater amount 
of meaningful protein identities.  
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Method validation. Assess reproducibility and robustness of above protein mapping methods. 
 
To assess the validity of using LC-MALDI-MS data to find differences in protein expression in 
serum. 
H0–vi: There will be no significant difference between the LC-MALDI-MS profiles of serum 
samples prepared under identical conditions. 
H1–vi: Differences will be seen in the LC-MALDI profiles of serum samples prepared under 
identical conditions. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
 
4.2.1.1. Equipment used 
 
Table 9. Equipment Utilised for LC-MALDI-TOF-MSMS 
Equipment Supplier 
Bruker UltrafleXtreme Matrix Assisted 
Laser Desorption Ionisation-Time of Flight 
Mass Spectrometer (MALDI-TOF) 
Bruker Daltonics 
Nano-HPLC-Protineer fc-II Target Spotter Bruker Proteineer 
Desktop computers with use of SpecAlign, 
Excel, Statistica and Bruker Software 
which comprises of: FlexControl 3.3, 
FlexAnalysis 1.3, Profile Analysis 1.1, 
Biotools 3.2, ClinProTools 2.2 software 
controlled by WarpLC 1.2 as part of the 
Compass Series 1.3. 
Bruker Daltonics 
384 spot MALDI-TOF targets; Grounds 
Steel 384, Anchor Chip 384 and PAC 384 
Bruker Daltonics 
Automated pipetting machine FluidX 
Sonicator VWR Ultra Sonic Cleaner 
-80˚C freezer New Brunswick 
37˚C Incubator Heraeus 
Vortex mixer Scientific Industries 
10 μL Millipore ZipTips C18 pipette tips Millipore 
Polypropylene bottles for reagent storage Nalgene F.E.P. 
1.5 mL Eppendorfs Eppendorf 
1 mL pipette Gilson 
200 mL pipette Gilson 
2 mL pipette Gilson 
0.2-1 mL tips Gilson 
20-200 μL tips Gilson 
0.5-10 μL tips Gilson 
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4.2.1.2. Reagents used: 
 
Table 10. Reagents Utilised for LC-MALDI-TOF-MSMS 
Reagent Supplier Grade 
Acetone Sigma LC MS 
Acetonitrile (ACN) Sigma LC MS 
Alpha-Cyano-4-hydroxycinnamic acid (CHCA) Bruker Daltonics 
MALDI-TOF-
MS 
Ammonium bicarbonate Sigma Laboratory 
Distilled water 
Barnstead 
Diamond 
nano pure 
Methanol Sigma LC MS 
Peptide Calibrant II Bruker Bruker Daltonics MS  
Trifluoroacetic acid (TFA) Fisher Scientific HPLC  
Trypsin – Trypsin Gold, Mass Spectrometry Grade Promega MS  
Tryptic Digest of Bovine Serum Albumin  Bruker Daltonics MS  
 
4.2.1.3. Stock Solutions Made and Used 
 
Table 11. All stock solutions made and used for LC-MALDI-TOF-MSMS 
Reagent Composition 
0.1% TFA in H2O 
(50 mL) 
50 µL TFA 
49.95 mL – Distilled water 
0.1% TFA in Acetonitrile 
(50 mL) 
49.95 mL – Acetonitrile 
50 µL TFA 
80% ACN diluted with 0.1%TFA 
(50 mL) 
40 mL – ACN 
10 mL - 0.1% TFA solution 
Trypsin solution 0.5 mg/mL 
(200 uL) 
100 mg – Trypsin Gold, Mass Spectrometry Grade 
200 mL – 100 mM ammonium bicarbonate 
NH4HCO3 
Iodoacetamide 200 mM 
(1 mL) 
36 mg Iodoacetamide 
1 mL of 50 mM ammonium bicarbonate 
Dithiothreitol (DTT) 200 mM 
(1 mL) 
30 mg DTT 
1 mL 50 mM ammonium bicarbonate 
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4.2.2. Methods 
 
4.2.2.1. Production of the BSA Standard Curve. 
 
The following dilutions (Table 12) were made from an unused tube of Bruker Tryptic Digest of 
Bovine Serum Albumin (125 µL was added to the new vial containing 500 pMol to create a 4 
pMol/µL stock.) 
 
Table 12. Dilutions made for production of a BSA standard curve. 
Volume of 0.1%TFA (µL) Volume of BSA BSA (fMol/µL) 
10 0 0 
195 5uL of (4 pMol/µL) 100 
5 5 µL (100 fMol/µL) 50 
6 4 µL (100 fMol/µL) 40 
7 3 µL (100 fMol/µL) 30 
8 2 µL (100 fMol/µL) 20 
9 1 µL (100 fMol/µL) 10 
9.5 0.5 µL (100 fMol/µL) 5 
10 0 0 
 
0.5 µL of each dilution were manually spotted to a Bruker PAC target. One of each replicate 
were used for optimisation of the mass spectrometer parameters i.e. laser power and detector 
sensitivity then the remaining seven were fired on under identical parameters using an 
automated data acquisition function within the Bruker FlexControl software. Bruker 
FlexAnalysis software was used to export the intensities of the calculated monoisotopic peaks 
present in the sample. 
 
4.2.2.2. QC Serum Sample 
 
QC serum sample was collected in November 2008. Briefly; 50 mL of vein blood was taken 
from 4 volunteers; 2 female and 2 male fully informed and consenting volunteers. The blood 
was left to clot for between 30 min and one hour at room temperature until clotted then 
processed under contamination level 2 conditions. Firstly, the bloods were centrifuged at 22°C 
for 15 min and at 2000 x rcf, then the serum supernatants were collected with Pasteur pipettes 
and pooled into one sterile container and gently agitated at 4°C while aliquots were made. Three 
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thousand 30 µL aliquots were made into sterile 0.5 mL micro tubes. Aliquots were stored at -
80°C for future use. 
 
Following standard practice for serum samples in the John van Geest Cancer Research Centre 
proteomics lab, serum samples are used for no more than three freeze thaw cycles before they 
are discarded.  
 
Later protein assay revealed the QC serum concentration to be 70 mg/mL; (1.061 µL contains 
1 mg of protein). 
 
4.2.2.3. Multiple Workflows Tested for Optimisation 
 
Although more workflows were originally planned and would have been insightful, data was 
collected for 10 replicates of each of four workflows. As depicted in Figure 19 above and Table 
13 below, multiple replicates of one test serum sample were tested under each condition.  
 
Table 13. Summary of the Workflows Applied to Replicates of one Test Sample.  
  
Sample 
Preparation 
Condition 1: 
Pre-digestion 
ZipTip 
Controls run 
in Parallel to 
Condition 1 
Sample 
Preparation 
Condition 2: 
Alkylation 
and 
Reduction 
Controls run 
in Parallel to 
Condition 2 
Sample Number n=10 n=10 n=10 n=10 
Samples were digested 
prior to digestion 
Yes No No No 
Samples Reduced and 
Alkylated 
No No Yes No 
 
See sections 4.2.2.5 and 4.2.2.6 below for the protocols used in each condition. 
 
4.2.2.5 Alkylation and Reduction of Sera 
 
The following protocol was adapted from an online source (http://www.ocbn.ca/insolution.htm 
2012). Urea was omitted for compatibility with MALDI-TOF-MS. 
 
5 µL of DTT was added to 1.06 µL of QC serum (containing 1 mg total protein) diluted in 100 
µL 50 mM ammonium bicarbonate and the sample thoroughly vortexed. The sample was 
wrapped in foil to protect from light and incubated at 37°C. After one hour precisely, 20 µL of 
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200 mM iodoacetamide was added and the sample was again vortexed. 20 µL of 200 mM DTT 
added and the sample vortexed and left at room temperature for one hour. 10 µL Trypsin (0.5 
mg/mL in 100 mM ammonium bicarbonate) was added then the sample incubated at 37°C 
overnight (18 h). Following the digestion, digests were refined using Millipore C18 ZipTips: 
(see3.1.4). Elutes were diluted in 20 µL 0.1%TFA and chromatographically separated and 
spotted to Bruker MALDI-TOF targets using the Bruker nLC. Data was acquired using the 
Bruker UltrafleXtreme 
 
See Table 13 and Figure 20. Flow chart of alkylation and reduction of QC sera and controls.  
 
4.2.2.5.1 Controls for Alkylation and Reduction Protocol 
 
1.06 µL QC serum (containing 1 mg total protein) was diluted in 21.2 µL 0.1% TFA timed to 
match dilution time of the paired test sample (section 4.2.2.5). The sample was vortexed and 
kept at 4°C for the duration of the additional steps for alyklation and reduction in section 4.2.2.5. 
10ul Trypsin (0.5 mg/mL in 100 mM ammonium bicarbonate) added at the same time as the 
paired test sample (section 4.2.2.5) and incubated at 37°C overnight (18 h). Digests were refined 
using Millipore C18 ZipTips: see 3.1.4. Elutes were diluted in 20 µL 0.1%TFA and 
chromatographically separated and spotted to Bruker MALDI-TOF targets using the Bruker 
nLC. Data was acquired using the Bruker UltrafleXtreme in as close as possible time to the 
paired test sample (section 4.2.2.5) 
 
See Table 13 and Figure 20. Flow chart of alkylation and reduction of QC sera and controls. 
 
4.2.2.6 Pre-digestion C18 ZipTip of Sera 
 
2 µL QC serum diluted in 38 µL 0.1%TFA and vortexed. 10 µL was removed and used for 
control (see 3.1.6.2), the remaining 30 µL was refined using Millipore C18 ZipTip: See 3.1.4 
producing 4 µL of refined proteins in 4 µL of 80% ACN in 0.1% TFA.  
The following reagents were added to the 4 µL eluate: 7.6 µL HPLC grade water, 16.6 µL 100 
mM ammonium bicarbonate and 1 µL of 0.5 mg/mL Promega trypsin gold in 100 mM 
ammonium bicarbonate and the sample vortexed. Samples were incubated overnight at 37°C. 
Following this the digests were refined using Millipore C18 ZipTips: (see .4.1.4).  
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The resulting elutes were diluted in 20 µL 0.1%TFA and chromatographically separated and 
spotted to Bruker MALDI-TOF PAC targets using the Bruker nLC and data was acquired using 
the Bruker UltrafleXtreme. 
 
See Table 13 and  Figure 21. Flow chart of pre-digestion ZipTip of sera versus controls 
 
4.2.2.6.1 Controls Pre-digestion C18 ZipTip 
 
Firstly 10 µL of a one in 20 dilution of QC serum was prepared; see 3.1.6. After the paired test 
sample (3.1.6) had been ZipTipped, 7.6 µL HPLC grade water, 16.6 µL 100 mM ammonium 
bicarbonate and 1 µL of 0.5 mg/mL Promega trypsin gold in 100 mM ammonium bicarbonate 
were added and the sample vortexed. Samples were incubated overnight at 37°C. The digests 
were refined using Millipore C18 ZipTips (see 4.1.4). The resulting elutes were diluted in 20 µL 
0.1%TFA and chromatographically separated and spotted to Bruker MALDI-TOF PAC targets 
using the Bruker nLC and data was acquired using the Bruker UltrafleXtreme in as close as 
possible time to the paired test sample. 
 
See Table 13 Figure 21. Flow chart of pre-digestion of sera versus controls 
 
4.2.2.7. Paired Comparisons  
 
To produce LC-MALDI-MS/MS data up to four samples could be analysed each day, this 
averaged at two per day. To avoid day-to-day variations such as lab temperature affecting the 
results, each of the 10 replicate test samples were processed in tandem with a control. See Figure 
20 and Figure 21 below. 
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Figure 20. Flow Chart of Alkylation and Reduction of QC Sera and Control Workflow.  
Control and test condition 2 serum samples defrosted, processed and analysed together to minimise external 
variation. 
 
Each pair were run alternately to negate batch effect i.e. one test sample, one control one test, 
one control. 
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Figure 21. Flow Chart of Pre-digestion Zip-tip QC Sera and Control Workflow.  
Control and test condition 1 serum samples defrosted, processed and analysed together to minimise external 
variation.  
 
4.2.2.8. A Model for use on Clinical Cohort of Samples 
 
To assess the applicability of the experimental and data-processing set-up ready for application 
to a clinical cohort of samples, the data from the 10 alkylated and reduced samples with the 10 
controls run in parallel were exported from the software and compared. Differences between 
the groups were investigated in two ways 
 Comparison of the protein lists acquired – a qualitative assessment. 
 Comparison using Bruker software (see 4.2.2.8.2) – a semi quantitative assessment 
 
4.2.2.8.1 Comparison of the Protein Lists Acquired 
 
The full lists for each of the 20 samples (10 alkylated and reduced and 10 controls) calculated 
peptide sequences and protein identities were exported from the Bruker WARP-LC and Protein 
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Viewer software to Excel. Basic Excel functions such as Sort, IF and PiVot-Tables were used 
to compare the presence or absence of proteins across and between replicates. This is a 
qualitative analysis as no values are assigned to the protein identities only their presence or 
absence counted. 
 
4.2.2.8.2. Comparison using Bruker Software 
 
Bruker Profile Analysis software was used to semi-quantitatively compare the data of the ten 
alkylated and reduced replicates with the 10 controls run in parallel as a model for use on sample 
with clinical disease and controls. 
 
Profile Analysis software aligns, collates and compares the retention times and mass values to 
produce bins of data which, to the best of its ability, aims to separate out each peptide peak 
based on the two dimensions; mass and retention time. Full description of the method of this 
calculation can be found in (Bruker Profile Analysis User Manual 2.0.). 
 
The Scheduled Precursor List (SPL) is an account of peptide peaks detected and their alignment 
to a retention time. The bins, referred to as ‘buckets’ are of varied size depending on what it has 
calculated to be one peak/peptide. It is calculated within the Bruker software and contains the 
values from the bucket list and the values of error tolerances and the size of the windows and 
boundaries of the calculated ‘buckets’. The intensity values of the buckets are compared using 
an MS-T-test within the software to list the buckets in order of the difference in intensity 
between the two groups. 
 
With great difficulty, the SPL list, the bucket table, and the MS T-test were exported from the 
software into Excel using Adobe Acrobat Reader and manually checked in word and Excel for 
further analysis. 
 
The peak m/z values from buckets whose intensity values were found through T-test to be 
significantly differentially expressed between the two groups (p-value of >0.05 and >= 2-fold 
change) were searched against the peptide sequence/ protein identity tables to match protein 
identity information. 
 
The SPL list was searched to find the time shift tolerance calculated by the Bruker software. 
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PiVot Tables in Excel were used to further investigate the occurrence of proteins identified by 
T-test to be differentially expressed between the two groups. These and the identities of the 
significant buckets were compared with that of the qualitative analysis as described in section 
4.2.2.8.1. 
 
4.3. Results  
 
4.3.1. Semi-quantitative Nature of MALDI-TOF-MS 
 
As a proof-of-principal, to asses if MALDI-TOF data can be treated as semi-quantitative a 
standard sample of BSA digest was diluted at several concentrations, spotted to a MALDI-TOF 
target plate and data acquired. Flex Analysis software was used to view spectra (Figure 22) and 
export the numerical monoisotopic peak values to Excel to plot a standard curve (Figure 23). 
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Figure 22. Increase of Peak Intensity with Increase in Concentration of Sample Loaded from a BSA digest.  
20a) A monoisotopic distribution of a peptide mass 2044.9 is exported from FlexAnalysis software; mass (m/z 
ratio on the x axis) is plotted against the intensity (arbitrary units on the y axis). The trace in red depicts a sample 
loaded at 100 fMol/µL; orange 50 fMol/µL, yellow 40 fMol/µL, green 30 fMol/µL, light blue 20 fMol/µL, indigo 
10 fMol/µL, grey 5 fMol/µL and black 0 fMol/µL. A stacked view of the same spectra are seen in 8b in visual 
range of neighbouring peaks.  
 
A standard curve of BSA concentration was plotted against the intensity of one BSA peptide 
peak measured in the spectra. Linear line of best fit has a R2 of 0.9567. 
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Figure 23. BSA Standard Curve from Peak Intensity. 
 BSA Concentration (fMol/µL) of the sample loaded on the x axis is plotted against the signal intensity (arbitrary 
units) detected from the m/z value 2044.9 a known BSA digest peak as measured by MALDI-TOF-MS on the y 
axis. The linear regression curve fitted has a R2 value of 0.9567. 
 
4.3.2. Reproducibility of the Third Dimension; Retention Time of the Analytical Column 
 
To measure the shift variability of the retention time, the total number of peptides that had eluted 
from the analytical column were plotted against retention time for all 10 replicates or each 
workflow. The time at which 50% of the total compounds had eluted was used to assess the 
variability of retention time. As an example Figure 24 (below) includes the 10 replicates of the 
controls run in tandem with the alkylated and reduced samples. 
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Figure 24. Retention Time Reproducibility. 
Total number of eluted peptides from the column is plotted against retention time/fraction (spot over a 384-spotted 
target plate) for 10 replicates of controls run in parallel with the alkylated and reduced workflow (condition 2 
controls, Table 13). Percent of the total compounds eluted is on the y axis plotted against retention time on the x 
axis Retention time is represented in fractions 10 seconds apart. The retention time/fraction at which 50% of the 
peptides had been eluted from the column were compared. 
 
For the 10 replicates from the control samples run in parallel with the alkylated and reduced 
samples (seen in Figure 24). The time/fraction at which 50% of the sample loaded had been 
eluted had a range of 500 s from 2080 s to 2580 s with a mean average of 2221 s, median and 
mode of 2160 s and a standard deviation of 159.5 s. 
 
See section 4.3.5.1. for Bruker Software calculations of retention time shift. In summary, 
retention time windows calculated to correspond to each peptide peak ranged from 0 to 1333 s 
(22.13 min) with an average of 421 s (7.01 min) preceding the peak and 534 s (8.54 min) 
following the peak. 
 
4.3.3. Reproducibility of Identities Acquired using LC-MALDI-TOF-MS/MS  
 
The full list of peptides identified from each run for all replicates were exported to Excel using 
Bruker WARP-LC and ProteinViewer software. For an explanation of the power model the 
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results from the 10 alkylated and reduced replicates are presented in a histogram below; Figure 
25; wherein the occurrences of the accession codes across each replicate were examined. A 
larger proportion of the identities only occurred in one replicate. Based on the distribution noted 
a power model was used. If a peptide identity occurred in 80% or more replicates it was 
considered true (Figure 25 solid colour bars). Identities occurring in 70% or less replicates were 
not considered reproducible and excluded from further analysis (Figure 25 faded bars). 
 
 
Figure 25. Histogram of Protein Identity Occurrence. 
The number of times a protein identity occurred out of the 10 replicates of the alkylated and reduced workflow 
(condition 2, Table 13) is represented. The largest proportions of identities only occur in one of the replicate. 
Identities that occurred in 7 or less replicates were regarded as non-reproducible and not included in further 
analysis (faded bars). The identities that occurred in 8 or more replicates (bold bars) were regarded as reproducible 
and included in further analysis.  
 
The power model exemplified here on the alkylated and reduced samples was applied to all four 
workflows, cross-reference and displayed in Venn diagrams below. The application of the 
power model can be observed within the concentric circles of each workflow. Protein identities 
not meeting the 80% power model criteria are represented by the seven faded bars above are in 
the outer seven grey circles. Protein identified considered reproducible represented in the three 
non-faded bars above are in the central three coloured circles below. 
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The power model as described above was applied to the test samples. 
 
The 10 replicates from the alkylation and reduction workflow detailed in methods section 
4.2.2.5 resulted in 38 reproducible identities; the control replicates run in parallel with the pre-
digestion ZipTip samples described in section 4.2.2.6. produced 74 reproducible identities 
(Figure 26). Four identities were only reproducibly identified in the samples that were alkylated 
and reduced, 40 were reproducibly identified in only the control group and 34 identities were 
reproducibly identified from both workflows. 
 
 
 
Figure 26. Venn Diagram Comparing the Lists Protein Identities Acquired from the Alkylation and 
Reduction Sample Preparation Workflow and Control.  
The 10 replicates that were alkylated and reduced before digestion produced 217 protein identities; 38 of which 
occurred in 80% or more replicates and considered reproducible (blue), the remaining 179 occurred in 70% or less 
replicates and were disregarded from further analysis (grey). For the control samples run in parallel with the pre-
digested alkylated and reduced workflow 339 protein identities were acquired; 74 occurred in 80% or more of the 
replicates (red), the remaining 265 only occurred in 70% or less of the replicates and were removed from further 
analysis (grey). When the reproducible identities acquired from alkylated and reduced group were cross compared 
with the controls run in parallel. 4 identities are unique to the alkylated and reduced group, 40 are unique to the 
controls and 34 are reproducibly found in both. 
 
The 10 replicates from the pre-digestion ZipTip work flow detailed in methods section 4.2.2.6 
resulted in 36 reproducible identities; the control replicates run in parallel with the pre-digestion 
ZipTip samples described in section 4.2.2.6.1. produced 58 reproducible identities (Figure 27). 
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Four were unique to the pre-digestion ZipTip group, 26 were uniquely found in the control 
group and 32 were reproducibly identified from both sample preparation workflows.  
 
 
Figure 27. Venn Diagram Comparing the Lists of Protein Identities Acquired from the Pre-digestion 
ZipTip Sample Preparation Workflow and Control.  
The 10 replicates that were ZipTipped before digestion produced 265 protein identities; 36 of which occurred in 
80% or more replicates and considered reproducible (green), the remaining 229 occurred in 70% or less replicates 
and were disregarded from further analysis (grey). For the control samples run in parallel with the pre-digested 
ZipTip workflow 722 protein identities were acquired; 58 occurred in 80% or more of the replicates (red), the 
remaining 664 only occurred in 70% or less of the replicates and were removed from further analysis (grey). When 
the reproducible identities acquired from pre-digest ZipTip group were cross compared with the controls run in 
parallel. 4 identities are unique to their-digestion ZipTip group, 26 are unique to the controls and 32 are 
reproducibly found in both. 
 
The identities of the 74 proteins considered to be reproducibly identified from the best 
performing workflow above; the controls run alongside the alkylated and reduced samples are:  
 
A1AG1, A1AG2, A1AT, A1BG, A2MG, AACT, ALBU, 
ANT3, APOA1, APOA4, APOB, APOC1, APOC3, APOE, 
C1QB, C4BPA, CERU, CFAH, CLUS, FETUA, FINC, 
GELS, HBA, HBB, HEMO, HEP2, HPT, HPTR, 
HRG, HV304, HV305, IC1, IGHA1, IGHG1, IGHG2, 
IGHG3, IGHG4, IGHM, IGKC, ITIH1, ITIH2, ITIH4, 
KNG1, KV119, KV402, LAC2, LV403, PLMN, PON1, 
THRB, TRFE, TTHY, VTDB, VTNC, CBG, CFAB, 
CO3, KV105, LV302, SC6A2, ZA2G, A2AP, AB12B, 
AFAM, ANGT, C1R, CO4B, ITSN1, KV114, KV121, 
LUM, PZP, TANC1, and  ZCH18   
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Highly abundant serum proteins are highlighted in bold. Albumin (ALBU), Apolipoprotein A1 
(APOA1), Transferrin (TRFE) Alpha 1 Acid Glycoprotein (A1AG1), Complement C1q 
(C1QB), Fibronectin (FINC) and a2-Macroglobulin (A2M2). 
 
4.3.5. A Model for use on Valuable Clinical Samples 
 
To assess the applicability, data exportability, ease of use and computer processing time of this 
experimental and data processing set up with an aim to apply it to a to a more valuable clinical 
cohort of samples, the data from the 10 alkylated and reduced replicates and their 10 controls 
run in parallel were analysed using Bruker Profile Analysis Software. To re-iterate in this 
context the comparison of the alkylated and reduced verses control is less relevant, the point of 
this was to assess the reliability of the available software to process, extract features (i.e. 
recognise spectral peaks accurately) from the multiple replicates of the multidimensional data 
and make a comparison.  
 
The software collated and aligned the retention times and mass values to produce a list of 
peptide peaks that are differentially expressed between the two groups (see section 4.2.2.8.2). 
 
The bucket table consisted of 4458 buckets. The MS T-test within the Profile Analysis software 
found 553 buckets to have a p-value of <0.05 and a fold changer greater than 2. That is to say 
the intensity values of 553 areas of spectra aligned by retention time and mass significantly 
differed between the two groups. 
 
4.3.5.1. Measured Error. 
 
On exporting the SPL list the margin of error of the retention time shift and mass shift calculated 
by the software are as follows: Retention time windows ranged from 0 to 22.13 min with an 
average of 7.01 min preceding the peak value and 8.54 min following the peak value. The shift 
in mass value of peaks calculated to be the same compound ranged from 0 to 0.23 Da with an 
average of 0.08 Da preceding the peak value and 0.06 Da proceeding the peak value. 
 
4.3.5.2. Investigation of Peaks Calculated to be Significantly Differentially Expressed Between 
the two Groups. 
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The mass and retention time values of the ‘buckets’ found to be significantly differentially 
expressed between the two groups were cross compared with the peptide sequence lists 
exported from each of the sample runs. The window sizes and boundaries of error for the 
buckets from the SPL list were used to do this. 
 
Within the 10 alkylated and reduced replicates and the 10 controls run in parallel, there were 
30 incidences where one ‘bucket’ value corresponded to more than one peptide identity. That is 
to say two or more peptide of different sequence identity were shown to have the same mass 
and retention time within the boundaries/tolerances of the SPL list. 
 
It should also be noted that multiple ‘bucket’ values correspond to one protein identity. From a 
list of 533 values corresponding to location in spectra aligned by retention time and mass 136 
protein identities in total were linked to these values.  
 
Using the SPL list, the peptide sequence and protein identity table for all 20 samples were 
filtered to only include peptides within a ‘bucket’ values. A consistency confidence of 80% was 
applied to these peptide lists, in that an identity had to appear in 8 out of the 10 replicates to be 
included. Sixty-seven identities were matched in the 10 replicates of the alkylated and reduced 
samples; 6 peptides occur in 80% or more replicates, 61 occurred in 70% or less replicates and 
are not considered reproducible. One hundred and twenty-two peptide s from the control group 
remained after filtering with the bucket boundaries 30 peptides occurred in 80% or more of the 
replicates, 92 occurred in 70% or less. When the reproducible peptides are cross compared 24 
were unique to the control group, 6 were found in both and none were unique to the alkylated 
and reduced samples.  
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Figure 28. Venn Diagram Comparing the Lists of Protein Identities from Peptide IDs Matched from MS-
T-test. 
The data from the alkylated and reduced replicates and 10 controls run in parallel were filtered to only include 
values in the SPL list. Sixty-seven identities were matched in the 10 replicates of the alkylated and reduced 
samples, 6 of which occur in 80% or more replicates (yellow), 61 occurred in 70% or less replicates (grey). One 
hundred and twenty-two peptides from the control group remained after filtering with the bucket boundaries 30 
peptides occurred in 80% or more of the replicates (red), 92 occurred in 70% or less (grey). When the 
reproducible peptides are cross-compared 24 were unique to the control group, 6 were found in both and none 
were unique to the alkylated and reduced samples (yellow). 
 
This provides evidence of 24 proteins detectable in the controls that are not in the alkylated and 
reduced samples, and 6 proteins that are present at significantly different levels between the 
two groups. 
 
4.4. Discussion 
 
This chapter aimed to assess the applicability of LC-MALDI-TOF to serum biomarker 
discovery in ovarian cancer. The Bruker software has no inbuilt feature to corroborate, collate 
or compare technical replicates, so this was performed where possible using the Bruker Flex 
software package and for a wider comparison the data was exported and transferred into Excel 
for analysis. 
 
4.4.1. Semi-quantitative Nature of MALDI-TOF MS 
 
As a proof-of-principal, to asses if MALDI-TOF-MS data can be treated as semi-quantitative a 
standard sample of BSA digest was diluted at several concentrations, spotted to a MALDI-TOF 
target, data acquired, exported then reviewed (Figure 22 and Figure 23).  
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On visual analysis (Figure 22), a clear trend of increased signal intensity with increase in 
concentration of sample loaded is seen. When the spectra are exported numerically and plotted 
on a graph (Figure 23) the trend has a R2 value of 0.9567 
 
Data provided is sufficient to reject the null hypothesis (H0-iv) and accept the alternate 
hypothesis: Intensity values of detected proteins is relative to the amount of protein loaded. 
 
4.4.2. Chromatographic Reproducibility 
 
The reproducibility of the chromatography of the C18 column in the LC system was assessed. 
This was done firstly by comparing the amount of the total protein eluted at each fraction time 
point from 10 replicates (section 4.3.2. and Figure 24). The time at which 50% of the total 
protein eluted from the column in 10 replicates had a 500s range. As the samples are spotted 
into 384 10s fractions (3840s), the 500s range represents a 13.02% of the run time in total.  
 
A more accurate representation of the retention time shifts was found in the Bruker SPL list, 
where each individual peptide peak shift time is being calculated (see section 4.3.5.1.). These 
had a large range; 1333s, 34% of the total run time. But when averaged they show a slightly 
smaller range in retention time shift; 421s which represents 10% of the total run time.  
 
In both calculations, the retention time variability compares poorly, is 10 times larger, in 
comparison to recent literature (Benk and Roesli 2012, Neubert et al., 2008). However, this 
data was produced on different instrumentation with smaller time intervals between fractions 
and a lower number of replicates, in Neubert et al., 2008 retention time shift calculations were 
assessed on 6 peak values. Retention time and area under peaks can be attributed to column 
packing, column age, contamination, temperature and gradient instability (Hsieh et al., 2014).  
 
When the peptide identity lists were filtered to only include the values in the SPL list there were 
numerous occurrences of multiple identities being linked to one bucket value. It is possible that 
numerous peptides have the same m/z values and chromatographic properties on a C18 column. 
It is also possible that there is room for error in the bucket window size and boundary calculation 
and two or more peaks are held within the bucket. The mathematics/algorithms behind the SPL 
list generation are encrypted in the Bruker program; not known. 
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Precise assessment of the chromatography of this workflow cannot be conducted with the 
instrumentation available as the chromatographic unit has no online detection system. Column 
elute can only be viewed in 10 second fragments. If time allowed the addition of a retention 
time standard, spiked into a sample before processing could be evaluated. This would address 
retention time shift problems but is an additional processing step and may suppress signal 
sample signal of proteins in very low concentration s with similar affinity to the C18 column. 
 
Unfortunately, due to the fractionated and uncoupled nature of the LC separation to the 
MALDI-TOF-MS data acquisition, a thorough investigation of retention time was not possible. 
Moreover, online monitoring and ad hoc adjustments were not able to be made during data 
acquisition. Although some of the assessments were made based on the identification of a 
peptide or bucket table calculation, which holds a potential yet limited possibility of error, it 
was satisfactory to indicate the size of the retention time variation. 
 
As described in Escher et al., (2012), in LC-MS setups that are directly coupled to a detector, 
standards of a stable and reproducible retention time can be included or run alongside samples 
and the variation in their elution time is used to calibrate retention times of sample data as it is 
being collected. 
Bruker software used does not easily accommodate retention time alignment so would have to 
be done post data acquisition in the data analysis. Although retention time standards were 
available for purchase, to apply a retention time calibration using them would need to be 
developed thus would not be simple. 
 
4.4.3. Reproducibility of Identities Acquired Using LC-MALDI-TOF-MS/MS  
 
For a qualitative assessment of protein identities, the full lists of peptides identified from each 
run for all of the workflows replicates were exported to Excel using Bruker WARP-LC and 
Protein Viewer software. The occurrences of the accession codes across each set of replicates 
were observed. Figure 25 is a histogram that displays the typical distribution of protein identity 
occurrence across 10 replicates.  
 
A large number of protein identities occur only in one replicate. This pattern reflects that shown 
in similar research where 3 LC-MALDI-MS workflows were compared (Hattan et al., 2005). 
These are likely to be an error produced from the combination of the size of tolerance in mass 
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shift, algorithms with in Mascot and the probabilities involved with matching when peptides 
with similar sequences occur. It should be noted that other search databases other than Mascot 
are available and could be made compatible with the Bruker software output. Mascot is an 
industry standard and accepted utility in peer research, it has merits and pitfalls, Mascot is not 
able to incorporate the mass accuracy of the fragment ions when searching, future iterations of 
the software may do so however on this occasion a measurement made with potential to increase 
validity of a protein identity match that was not able to be incorporated. Searching the MS data 
against another database would most likely produce similar, but not identical lists of protein 
identities for each sample. Although it is possible this may have marginally increased/improved 
any result adding this extra parameter to explore was not considered relevant expansion of the 
analysis. The variation of the measured m/z values is constant despite the choice of database to 
deduce protein identities. 
 
When a power model of 80% was applied, in all four workflows the number of protein identities 
considered ‘reproducible’ drops dramatically: Of the 10 alkylated and reduced replicates, just 
17.5% of total identities were found reproducible; 21.8% in that of the controls run in parallel 
(Figure 26). Of the 10 replicates that were ZipTipped before digestion, 13.6% of the total 
proteins identified were found to be reproducible and just 8% for the controls run in parallel 
(Figure 27). 
 
The purpose of this work was to evaluate sample preparation and data acquisition workflows 
with a view to apply the best to a cohort of clinical samples. This data demonstrates the 
importance of running test samples in replicate. However, it would be impracticable/ a drain on 
sample volume and instrument time to run each of a cohort of test samples in duplicate (10 
times). The difference in number of protein identities that occur in three or more replicates 
warrant running a test sample in as least triplicate. 
 
4.4.4. Comparison of the Proteins Identified from each Workflow 
 
When using the power model of 80% in both sample work flows tested the control group 
produced more reproducible identities.  
Thirty-eight proteins were reproducibly identified in the 10 alkylated and reduced replicates 
compared to 74 for that of the controls run in parallel (Figure 26). Thirty-six proteins were 
LC-MALDI-MS Profiling Strategy for Biomarker Discovery in Ovarian Cancer 
112 
 
reproducibly identified from the 10 replicates that were ZipTipped before tryptic digestion, 
compared to 58 for that of the controls (Figure 27). 
 
Contrary to published work stressing the importance of alkylating and reducing samples prior 
to aid digestion and therefore identification (Sechi and Chait 1998, Hale et al., 2004 and 
Wedemeyer et al., 2000), the evidence from this work (Figure 26) shows a marked reduction of 
proteins identified from serum samples reduced and alkylated prior to digestion. 
 
A C18 ZipTip purification prior to digestion was performed to reduce the amount of noise and 
signal suppression from salt and large, overabundant proteins such as albumin. However, data 
from this work showed that performing that C18 ZipTip step prior to digestion decreases the 
number of achievable reproducible protein identities (Figure 27) 
  
The protocols selected were tried and tested (Vafadar-Isfahani et al., 2010, Ontario Cancer 
Biomarker Network 2012). However, if time allowed it would be worth investigating the ZipTip, 
alkylation and reduction procedure further to assure they were successful before disregarding 
literature and concluding they do not increase the number of proteins identified. It is possible 
that the alkylation and reduction procedure used did in fact reduce and alkylate the samples, 
however confirmation the protocols were successful would support the findings from this work. 
 
Evidence is provided to reject the null hypothesis (H0-v) and accept the hypothesis that: One 
sample preparation technique will produce greater amount of meaningful protein identities. This 
was the method for the controls for the alkylated and reduced samples (section 4.2.2.5.1) 
 
4.4.5. A Model for use on Valuable Clinical Samples 
 
To assess the ease of use, applicability and computer processing time of the experimental/data 
processing setup ready for use on a more valuable cohort of clinical samples, the data from the 
10 alkylated and reduced replicates and their 10 controls run in parallel were compared using 
Bruker Profile Analysis Software. A function within the Bruker software package, which 
appropriately handles and performs semi-quantitative comparison of the multidimensional data 
generated. 
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This was conducted to confirm the reliability and ability of the software to recognise and extract 
spectral features (i.e. consistently recognise spectral peaks accurately) from the multi-replicate 
multidimensional data, and, to investigate the exportability of any data generated. To confirm, 
in this context the comparison of alkylated and reduced versus control is less relevant, this was 
conducted on these data, as this was the only data set with multiple replicates generated so far. 
 
Data provided in section 4.3.4. and 4.3.5. provides evidence to reject the null hypothesis (H0--
vi) and accept the hypothesis that: Differences will be seen in the LC-MALDI profiles of serum 
samples processed through different sample preparation conditions. However, the 
reproducibility of this difference is questionable. Two different sets of proteins were found to 
be significantly different between the two groups when the data was exported and analysed in 
two different ways; qualitatively (section 4.4.4. above), and semi quantitatively (section 
4.2.2.8.2.) 
 
When the power model of 80% confidence (see section 4.4.3) was applied to the potential 
peptide identities from the semi quantitative comparison (Figure 28); 24 proteins were shown 
to be significantly expressed in the controls and not the alkylated and reduced samples, 6 were 
found to be expressed at different levels, and none were found to be expressed in the test 
samples and not the controls. This is contrary to the qualitative comparison (section 4.3.4); 
where 4 proteins were demonstrated to be expressed more in the alkylated and reduced 
replicates compared to the controls.  
 
This investigation has shown that the data from samples run in LC-MALDI-TOF–MS/MS has 
low reproducibility and can easily be interpreted in multiple ways to draw contradicting 
conclusions.  
Furthermore, the final number of protein identities accepted with 80% confidence is low. In 
comparison to hypothesised size of the serum proteome (see section 2.1.2.) it is miniscule 
evidencing this to be an insufficient model to represent the system and thus a questionable 
platform for biomarker discovery.  
 
4.4.6. Limitations of the Methods Tested 
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The comparison was made to firstly corroborate or refute any differences already seen using 
each method. Secondly, to rehearse a method and unearth any difficulties that may arise when 
applied to valuable clinical samples. 
 
To match the areas of spectra aligned by mass value and retention time found to be significantly 
different between the two groups to a peptide identity with the software resources available the 
data needed to be exported and matched to the peptide identity lists manually; outside of the 
Bruker software. This in its self is a source to introduce error. The difficulty of exporting the 
processed data in the form of a SPL list was noted (section 4.2.2.8.2.) The Bruker software 
prohibits direct export of the numerical values. The values of the table were exported as an 
image and converted into text using Adobe reader. The values of the exported table were 
checked for errors against the original manually. The size of the table leaves large opportunity 
for human error. This increases the time involved in analysis, decreases the validity of any 
findings and therefore reduces the utility of this method to biomarker discovery on a cohort of 
valuable clinical samples.  
 
There were 30 incidences of one ‘bucket value’ corresponding to more than one identity (section 
4.3.5.2.). Separating the protein identities from the peptide mass on a third dimension (retention 
time) was introduced to reduce the ambiguity that has previously been problematic in Chapter 
3. As ambiguity in identity still exists the sample preparation workflows and advance in 
technology tested adds little to the potential of previous work (Chapter 3). 
 
Limitations found with the workflows tested are linked mostly to the flexibility of software 
provided with the instrumentation, the necessity to export data for use in another, or, the 
unknown parameters embedded in the software’s coding such as the Bruker ‘bucket’ boundary 
generation or those within Mascot matching masses to sequences. This view is shared in a recent 
review, Benk and Roesli 2012 state the capabilities of LC-MALDI-MS have not been realised 
due to the lack of suitable computer programs. The difficulty in using LC-MALDI-MS data is 
aligning the data with confidence on both dimensions and normalisation before it is analysed, 
the way this is conducted has a massive influence on any results (Van den Berg et al., 2006, 
Podwojski et al., 2009). The purpose of adding the LC separation is to add another value to a 
peptide of one m/z so it can be differentiated. The Bruker software does not take this value into 
consideration when calculating sequence identity based on probability. This leaves the users of 
the technology responsible to add in this extra value to the data. Researchers must choose 
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between using the software provided which contains unknown parameters of feature selection 
which are a possible source of error, or, developing bioinformatic analyses tailored to the nature 
of the data, samples and study design, which though achievable (Tong et al., 2012, Timms et 
al., 2011, Shin et al., 2008) in itself is overly demanding on time and a questionable devotion 
of time and resources compared to overarching goals of research; cancer biomarker detection. 
 
Additionally, due to the high number of possible amino acid combinations making any 
particular pre-cursor ion (m/z value), this methodology is fundamentally challenged. The lack 
of resolution by chromatographic separation means that multiple peptides with the same mass 
to charge ratio will likely overlay in a MS spectrum so multiple identities can be inferred from, 
leaving the question: Which is the correct protein identity? As highlighted in Figure 4, the 
limited number of separable data points in each spectrum verses the number of proteins or 
peptides expected to be present in each sample, thus making it impossible to represent this data 
in the space of a single mass spectrum. 
 
Peak area is a widely-accepted measurement in mass spectrometry and arguably better 
represents the ion measurements quantity compared to overall intensity as used above. 
Unfortunately, within the Bruker Flex software package ‘peak area’ data was available but not 
clearly defined or readily accessible, so, deducts from this methods ability to be intemperate as 
semi-quantitative measurement. 
 
It is also noted in section 4.3.4 that a number of the proteins significantly consistently identified 
from all workflows were common, high abundant serum proteins. The utility of these proteins 
expression in serum is already doubted to have value in disease detection and have been shown 
to supress the detection of differential expression of lower abundant proteins believed to be of 
more importance as biomarkers (section 2.1.5). 
 
4.5. Conclusion 
 
To conclude, all null hypotheses listed in section 4.1.5. H0-iv,v,vi can be rejected in favour of their 
alternate hypotheses. 
 Intensity values of MALDI-TOF-MS data can be used to indicate the relative protein 
quantity within a sample, however it was noted the accuracy of this is low. 
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 One sample preparation technique produced more reproducible peptide identities than 
others. 
 Difference in the LC-MALDI profiles of serum samples produced under different 
conditions was shown to be different using a qualitative and semi-quantitative method. 
 
Evidence is also provided to suggest 
 Both sample processing workflows tested reduced the number of reproducible 
identities attained from samples. 
 Clinical samples should be run in at least triplicate to reduce the number of false 
identities attained 
 Of the two methods of data export and analysis conducted, different conclusions can 
be drawn from the raw data collected.  
 
4.6 Review of Findings and Future Direction for Onco-proteomics in MS 
 
During the time of this study, advances of instrumentation improved considerably allowing a 
more reliable output of larger numbers of protein identities and more accurate quantitation. At 
the time of this study it was not possible to generate accurate quantitative data which subsequent 
generations of mass spectrometer were capable of doing. The precious ovarian cohort of 
samples was therefore not analysed using the workflows investigated in chapter 4. Considering 
the rarity and diminished volume of the clinical cohort of ovarian cancer patient serum, the lack 
of confidence in the potential yield of the LC-MALDI-MS approach and the likelihood that a 
more accurate way of conducting serum protein biomarker discovery by MS existed (Marx 
2013), and would soon be available, these samples would be saved for when they can be 
employed in a more meaningful way. Meanwhile, the now-evaluated LC-MALDI workflow 
could be applied to more appropriate cohorts with more abundant sample volumes, the 
measured error in retention time and protein identity used as a caveat to include upon analysis 
of results. Other sources can be mined for ovarian cancer biomarkers, namely gene array 
databases available online. 
 
In the below chapter, an alternative source of data is explored. Gene microarray data sets 
available through online repositories, are freely available, offer larger sample numbers, and 
higher accuracy in the measurement of gene targets that lead to protein production. 
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A repository of gene expression data sets was searched as an alternative source to discover 
relevant biomarkers. The line of questioning aimed to interrogate data acquired from the cohort 
of serum samples collected for use in chapter 3 could not necessarily be continued due to the 
availability of clinical information. Available variables for the cohort of serum samples in 
chapter 3 categorise the patients by cancer or control, supporting only categorical comparisons 
designed to detect serum biomarkers differentially expressed between the two groups. The best 
data sets available in the online repository were derived from genetic material of grade 3 
tumours with gene expression and survival time available, both continuous variables. Therefore, 
a study design to compare gene expression with patient survival time was put in place. 
 
4.6.1. Future of Protein Mass Spectrometric Biomarker Discovery 
 
Shotgun proteomics; is a metaphorical description of a close-range wide-target approach to 
analyse the entire proteome. As much proteomic information as possible is catalogued from 
samples then conclusions or further hypotheses are drawn from these. This strategy was used 
in chapter 3 and 4 of this document and a large portion of mass spectrometry protein biomarker 
discovery research since the early 2000’s (Table 3). 
The results suggest that this approach is flawed for the following reasons: 
 Identification of the peptides/proteins present are generated from matching masses of 
hypothetical sequence calculated from genomic information on online databases (i.e. 
Mascot) to the MS/MS measurements collected from the mass spectrometer.  
o The MS/MS measurements are dependent on the type of mass spectrometer 
itself, some peptides ionise better under different conditions; i.e. ESI or MALDI 
(Benk and Roseli 2012), thus not all will be catalogued from one mass 
spectrometer and generate identity. 
o  The tolerances and margins of error in the matching algorithms of the mass 
spectrometer software and the database itself. 
 Data dependent acquisition. The MS/MS data acquisition procedure within the Bruker 
UltrafleXtreme is similar to other mass spectrometers of its generation and now can be 
termed Data Dependent Acquisition (DDA) (Law et al., 2013). When data is acquired 
in this manner the list of peptides which are selected for fragmentation for identification 
acquisition is dynamic as it is dependent on the detection of the peptide. There are 
numerous reasons a peptide would not be detected consistently including sample 
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preparation, its intensity sitting on the threshold of detection or in the case of MALDI 
inconsistent distribution of the peptide across the matrix crystals of the dried spot. In 
the Bruker UFX detailed above, the instrument would take an MS scan from each of the 
384 fractions, pause while compiling a list of peptides present and assign each peptide 
to the fraction in which it is expressed the highest, then move on to MS/MS each of the 
peptides in its assigned fraction. Which m/z are selected for MS/MS data acquisition 
from each run are selected based on the consistency of their ability to ionise within the 
mass spectrometer, and, algorithms within the mass spectrometer software recognising 
their consistency (Picotti et al., 2013). In the Bruker software detailed in chapter 4 the 
peptide precursor list is dependent on what is recognised to be one peptide value based 
on its retention time to a C18 column and its m/z values. The lists were shown not to 
separate out peptides individually, and were shown to have irreproducible variations 
between samples.  
The generations of mass spectrometers produced after the Bruker UltrafleXtreme 
address this inconsistency by changing the order the sample is fragmented and detected 
within the mass spectrometer, termed Data Independent Acquisition (DIA) (Law et al., 
2013, Chapman et al., 2014). Using DIA quantitative measurements are independent of 
the detection of the precursor (see Figure 9 and Figure 10 for parent and fragment ion 
information). DIA approaches fragment the entire sample prior to detection. The 
detected fragment quantitative measurements are summated and matched to their parent 
ion using databases or a separate run of MS data. DIA approaches are preferable as they 
offer increased sensitivity as less sample within a run is lost to the MS scan, improved 
reproducibility as the detection of fragments are more consistent over replicate samples 
and have the potential to detect theoretical proteins with use of theoretical ion databases. 
DIA approach for analysing complex protein mixtures include; Waters© instrumentation 
which separate the fragments in another dimension, drift time, using the Synapt 
(Distiller et al., 2014), Thermo who combined existing quadrupole and Orbitrap 
constituents in the Q-star Exactive (Hao et al., 2012), and ABSciex SWATH (Gillet et 
al., 2012) which again uses existing technology but detects the sample in a different 
order (Griffiths et al., 2014, Ziqi et al., 2014). Currently SWATH is an emerging popular 
and increasingly referenced DIA approach (Biognosis 2014). 
 With hindsight, MALDI-MS offers a fast, instantaneous measurement of the protein 
content of a sample, which is an attractive concept for biomarker research, however 
speed of analysis is of limited effect for discovery and may only be relevant at the 
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clinical implementation stage. As a discovery platform although speed of acquiring data 
increases the amount of samples that can be analysed in the same time frame as each 
other however the difference between instant or minutes to an hour when coupled to and 
LC does not impact results of a typical discovery cohort of 50-100 samples. In fact, for 
this reason desorption ionisation is popular in developing mass spectrometric techniques 
emerging for precision medicine/clinical proteomics such as FAIMS and DESI (ELRIG 
2016, Takáts et al., 2014, Balog et al., 2013). 
 It is still not currently possible to catalogue the entire serum proteome although 
proteomic discovery technology has experienced extraordinary technological advances 
in recent years. The exponentially increasing sensitivity and specificity of novel 
technologies and data processing algorithms, together with the ever-increasing 
capabilities and solutions in computing, provide a promising future for not only 
characterising the proteome but combining data and technology platforms creating a 
holistic aim to study ‘omics’ (Gil et al., 2015). This conceptually also holds promise to 
confront additional challenges posed in proteomics which add to the dynamicity of the 
proteome, including the measurement/quantification of global phosphorylations, 
glycosylations, or any post translational modifications. However, this is not currently 
the case. 
 This sentiment is echoed by Anderson (2010). Who, in commentary on general protein 
biomarker discovery (not only cancer biomarkers) identifies a similar futility in protein 
biomarker discovery using the currently (in 2010) available technological platforms. 
They also site the difficulty in obtaining access to high quality sample sets, the absence 
of an organised development pipeline and a lack of a “useful theory of biomarkers”. 
 
To refer to the shotgun analogy, so far technology available allowed researchers to undertake 
studies using in the correct range to hit a portion of a large target, with little aim to reproduce 
the result. The new fashionable term is Targeted Proteomics; crowned method of the year 2012 
by Nature Methods (Nature Editorial 2013), focuses on how technology available is best suited 
to quantifying a smaller subset of proteins/peptides of interest based on an hypothesis, rather 
than profiling the whole proteome in all of its complexity repeatedly and in more depth every 
time new technology is available (Marx 2013).  
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A quantitative mass spectrometer capable of targeting multiple ions is all that is needed to apply 
a ‘targeted’ tactic. So far this has typically been a triple quadrupole (Marx 2013). Multiple 
Reaction Monitoring (MRM), also called Selected Reaction Monitoring (SRM) (Hoffman 
1996) is the isolation and quantification of fragments of a peptide based on their characteristics 
of mass, flight and behaviour in a collision cell. MRM data can provide ‘absolute quantitation’ 
of protein content, it is reproducible, selective and robust. MRM has been referred to as the 
mass spectrometrists ELISA (Picotti et al., 2013) and has been professed to supersede immuno-
based protein detection solutions. Quantitative mass spectrometry data of a number of proteins 
fragments could potentially one day be used in place of a multiplex of ELISA of other immune-
technique (Picotti et al., 2013).  
 
However, in the case of ovarian cancer, which protein fragments need to be quantified, remain 
to be found. The targeted approach has since been applied to early detection of ovarian cancer 
Tang et al., (2013), however is not a discovery platform which is still needed in this field. 
Some suppliers have incorporated bioinformatics/ software-solutions to process MRM-type 
measurements with the potential to be used for quantitative biomarker verification, for example 
ABSciex SWATH analysis (Gillet et al., 2012, Marx 2013). 
 
4.6.2. Future for Biomarkers for Ovarian Cancer 
 
Despite a wealth of data and information being produced from ovarian cancer patient material 
little has changed in the diagnostic, prognostic or treatment care for patients with ovarian 
cancers (Hays et al., 2010, Siegel et al., 2013 Vaughan et al., 2012). This represents an unmet 
need in patient management. 
 
Detection of ovarian cancer disease in its early stages is accepted to be the ideal route to 
improved survival. A biomarker from a non-invasive screening test is the awaited discovery. 
However, firstly; the ideal sample is not available, secondly; if it were there is no confirmed 
technological analysis platform available with a proven reproducible sensitivity to detect the 
subtle differences (if any) expected. This view is supported by Jacobs et al., 2004, who 
acknowledges the majority of cohorts are flawed as they are from late stage disease. A 
biomarker of late stage disease may be of use to detect recurrences and response to therapy yet 
may be completely different to early stage. It is possible that metabolic and molecular events 
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are completely different in early or premalignant disease and that an accurate marker of this 
could have decreased specificity or sensitivity at detecting later stage disease (Jacobs et al., 
2004).There are very limited samples from preclinical/pre-diagnosed patients in existence 
(Jacobs et al., 2004), the samples from UKCTOCs screening trial is one of a handful worldwide.  
 
The majority of samples collected from patients volunteering for research are of those already 
admitted to hospital and already on a treatment pathway. The only biological samples currently 
available for study are from the late stage disease. The tissue samples donated by patients of 
later stage disease can be used with their clinical information to stratify subgroups within them 
then used to predict future patients’ likely response outcome and response to treatment: the 
concept of precision or personalised medicine.  
 
Ovarian cancer is most commonly diagnosed in Stage 3. For which the prevailing treatment is 
cyto-reductive surgery proceeded by platinum based chemotherapy. Although 70% of patients 
respond at first, a majority will develop a resistance to platinum based therapy (Miller et al., 
2009). The ability so segregate the patients who are likely to develop resistance may aid 
treatment. 
 
For the current body of work represented in this document evidence has been produced to 
suggest that pursuit of the goal of an early stage biomarker is currently not an effective use of 
funds and samples. Using a “targeted approach” and the next generation of mass spectrometry 
technology such as those listed in Marx (2013), which offer significant confidence of protein 
identities shown quantifiably to be differentially expressed between two samples. If proven to 
yield reproducible results when extensively tested on more freely available human samples 
would then provide further information. 
 
The human genome is far better characterised than the proteome, thus making its analysis more 
likely to produce results with lower ambiguity and higher reproducibility. In the following 
section an alternative approach to biomarker discovery is taken, using genomic array data from 
in-silica sources online, and literature already available.  
 
This change in tactic offers the project the opportunity to move from evaluation of technological 
capabilities and methodologies to an evaluation of biological measurements acquired from a 
pear reviewed source relevant to the hypothesis allowing the clinical question to be addressed.  
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Figure 29 taken from (Braem et al., 2011) was generated from an extensive investigation and 
review of potential biomarkers associated with ovarian cancer. The figure highlights the 
absence of validation or refuting of potential biomarkers published to date rather than 
generating new. Also mentioned by (Vaughan et al., 2012). 
 
 
Figure 29. Number of Investigated Genes in Ovarian Cancer. 
Remade from Braem et al., (2011) lays out numbers accounting for the high number of investigated ovarian 
cancer genetic markers (>1000), no attempt has been made to replicate a large number of them (865) the rest 
have been replicated to differing extents. 
 
In a recent collaborative report (Vaughan et al., 2012), strategising effective research on ovarian 
cancer, it was accepted that the sharing of data, results, methods and samples is crucial to 
narrowing down common active cellular mechanisms in what is a relatively rare yet 
genotypically diverse disease. Thus, reinvestigating published genes and data is a worthy 
endeavour. 
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5. Transcriptomics: Gene Expression Array Analysis as a Strategy for 
Biomarker Discovery in Ovarian Cancer 
 
Chapter Abstract 
 
Stratification of patients with the demonstrably heterogeneous disease ovarian cancer, based on 
evident active molecular pathways, would aid a targeted treatment and improve prognosis. 
Hundreds of genes have been significantly associated with ovarian cancer, although few have 
yet been fully verified by peer reviewed research, or clinical trials. 
A meta-analysis approach was applied to two carefully selected gene expression microarray 
data sets (E-GEOD-13876 and E-GEOD-26712) downloaded from ArrayExpress, a freely 
available repository of microarray experimental data. In both cases the data was collected from 
full genome arrays applied to Stage 3 serous ovarian carcinoma and tumour samples collected 
and processed under regulated conditions. Artificial Neural Networks, Cox Univariate Survival 
analyses and T-tests were used to filter genes whose expression were consistently significantly 
associated with patient survival times.  
A list of 56 genes were distilled from a potential 37000 gene probes to be taken forward for 
validation. The rigour of combining a meta-analysis approach with multiple testing using a 
variety of statistical procedures, increases power and confidence in the relevance of genes found 
to be of interest. Encouragingly, a number of the 54 are already reported to have an association 
with ovarian cancer survival. Further investigation and validation of the genes that are not yet 
reported to associate with survival may be clinical of interest and have potential to predict a 
patient’s response to treatment or be used as a novel target for therapy. 
 
5.1 Introduction 
 
RNA Microarray experiments, allow determination of the expression of entire genomes from 
nucleic acid extracted from biological samples (see Figure 12). To obtain the data in the current 
study RNA acquired from ovarian tumours was hybridised against microarray gene chips 
designed to detect expression levels of the entire human genome, multiple probes corresponding 
to different sequences within each gene are measured. These large, multidimensional data could 
be interpreted using endless analytical strategies to draw different conclusions. The debate and 
discussion of which is the appropriate statistical analysis for different types of data sets is open 
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(Allison et al., 2006) and the huge numbers of genes reported to have an association to ovarian 
cancer that have not yet been replicated, warrant reanalysis of data where available (Braem et 
al., 2011, Vaughan et al., 2012). Array Express is an online repository of microarray data which 
facilitates researches to share raw data for scrutiny and validation. 
 
In this chapter, two cohorts of data, publicly available on ArrayExress were selected, 
downloaded and analysed using a different strategy to that in their accompanying original 
publications; Crijns et al., 2009 and Bonome et al., 2008.  
 Crijns et al., 2009 used a continuous prediction algorithm to publish a panel of 86 genes 
that were shown to be strong predictors of survival in women with late stage ovarian 
cancer. Within the paper some of these, but not all, were validated on other data sets.  
 Bonome et al., 2008 differed from Crijns et al., 2009 by first categorising their patients 
based on their assigned debulking status, then used a Cox regression analysis published 
a prognostic gene expression signature of 57 probes which they validated on a separate 
blinded data set.  
The content focus is different in the two papers, in that Bonome et al., 2008 includes patient 
dependent variables and risk factors in analysis where Crijns et al., 2009 centre around survival 
time and gene expression. However for these purposes they both generated data from tumours 
from late stage ovarian cancer patients who then followed a similar treatment pathway of 
debulking surgery and platinum based chemotherapy (where appropriate) so were considered 
comparable. 
 
The statistical strategies used to meta-analyse the two cohorts of data consist of Cox univariate 
survival analysis, MLP-ANNs and T-tests (see section 2.2.2.).  
 
Parts of the work reported in the following chapters were published in (Coveney et al., 2015) 
see Appendix A. 
 
5.1.1. Known Influences on Survival time from Ovarian Cancer 
 
5.1.1.1 Platinum Resistance 
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Platinum based chemotherapies are used to treat a wide range of cancers with varying effect 
(Martin et al., 2008, Eckstein 2011). Their mechanism of action is to bind covalently to both 
strands of the DNA helix thus preventing the separation of the two strands prerequisite for 
translation and cell division. Platinum resistance and evasion of this damage depends on the 
tumour cells ability to recognise this as DNA damage and repair it or adapt in another way. 
Different cancer cell lines have been shown to both have this ability inherently, and to acquire 
it (Marchini et al., 2013). It is still to be proven whether resistant the cells are present in smaller 
subpopulations within the cancer prior to platinum therapy or whether they are a consequence 
of it (Marchini et al., 2013). 
 
Clear cell ovarian carcinomas, which are identifiable by histology, are already known to be a 
more aggressive phenotype of ovarian cancer that are less likely to respond to platinum therapy 
(Matsuzaki et al., 2015).  
 
Two of the five known DNA repair mechanisms have been reportedly linked to platinum 
resistance. These are: 
 Nucleotide Excision Repair (NER), where abnormalities in the helical structure of the 
DNA are recognised and enzymatically excised (Chang et al., 1999). 
 Mismatch Repair (MMR) in which unmatched, mismatched, inserted deleted base 
pairs are recognised then enzymatically excised (Kelland 2000). 
 
For a full review of DNA repair and platinum resistance in ovarian cancer and more the reader 
is referred to Martin et al. (2008) 
 
5.1.1.2 Epithelial to Mesenchymal Transition (EMT) 
 
Cell line studies have also implicated the phenomenon of epithelial to mesenchymal transition 
(EMT) in platinum based drug resistance in epithelial ovarian cancer (Rosanò et al., 2011). 
However, the exact mechanisms by which this happens are unconfirmed, in fact conflicting 
results have been reported from both in vivo and in vitro studies (Miow et al., 2014). The 
presence of markers of EMT such as SNAIL and E-cadherin have been linked with ovarian 
cancer invasiveness (Rosanò et al., 2011 ) and the activation of anti-apoptotic pathways such 
as NF-kB have been observed in cisplatin resistant cell lines (Miow et al., 2104). 
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Contrary to prior evidence, Miow et al., (2014) found that cisplatin had a higher efficacy on 
ovarian cell lines with mesenchymal status than those with an epithelial one. 
 
Interestingly, EMT may be inherent or acquired, different chemoresistant phenotypes have been 
described between cells that have naturally undergone EMT-like changes and those that have 
undergone EMT-like changes after exposure to a platinum based drug therapy (Miow et al., 
2014). The clarification between inherent and acquired EMT is relevant to unearthing molecular 
pathways involved in chemoresistance, however it is not always discussed when reporting 
results linking to EMT. 
 
Though there is a lot of research into the mechanisms of platinum resistance (Martin et al., 
2008), nothing has yet aided treatment in the clinic. Pathways directing clonal diversity, tumour 
adaptation and acquisition of resistance need to be verified. 
 
There are a number of geno- and phenotypes documented to correlate survival times from 
ovarian cancer including: 
 Mutations in the PI3K subunit, ARID1A and PIK3CA are linked to clear cell and 
endometreoide cancers (Jones et al., 2011, Kuo et al., 2009). 
 CyclinE1 (CCNE) associated with poor outcome (Farley et al., 2003). 
 There is an increased statistical likelihood of survival via clonal selection due to the 
large number of smaller peritoneal metastatic ‘seed’s’ recognised to be the metastatic 
pattern of ovarian cancer (Vaughan et al., 2012). 
 
There are numerous other factors affecting a patient’s survival time that are not specific to 
ovarian cancer, but would be a consequence of a specific onco-phonotype or characteristic of a 
type of cancer micro-environment the reader is referred to (introduction) and Hanahan and 
Weinberg (2011). 
 
In this chapter biomarker investigations were undertaken using mining of gene expression 
microarray data and is in contrast to the analysis of the previous chapter’s protein serum 
biomarker investigation in that the analyte measured is biologically “upstream”. The reader is 
referred to Figure 4 and Figure 11 in the introduction. Hypothetically the RNA measured here 
may well code for proteins that could be measured by mass spectrometry and the two results 
could be used to provide complementary evidence of one system. However, by necessity the 
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cohort of patients observed in the two chapters is different. Interestingly in theory gene 
expression microarrays should be provide a smaller number of variables to compare as the 
genome is smaller than the estimated proteome (Anderson and Anderson 2002 and Harrow et 
al., 2012), however, due to the technical challenges of analysing serum protein described above, 
far more variables are measured in gene expression microarrays. 
 
It is reiterated here the purpose of this change is to tailor the analysis to best suit the available 
samples, so the data is interrogated with the most relevant scientific question. 
 
5.1.2. Aims and Hypothesis of the Chapter 
 
This chapter aims to characterise genomic differences between tumours from patients with 
Stage 3 ovarian cancer that responded well to therapy and those which did not, based on the 
patient’s survival times.  
 
H0 vii: None of the gene expression measurements from the two cohorts will be found to be 
consistently associated with survival times from ovarian cancer when tested with a complement 
of statistical strategies. 
 
H1 vii. Genes will be found to be consistently significantly associated with survival time when 
a complement of statistical strategies are applied in a meta-analysis approach to two separate 
cohorts of patients measured with two different microarray platforms 
 
5.2 Materials and Methods 
 
5.2.1. Selection of Data Sets 
 
5.2.1.1. Array-Express Search Parameters for Sample Cohort Selection 
 
Factors that were considered when selecting data cohorts included:  
 The number of patient samples within the data set, this needed to be as large as possible 
to best represent the population of cancer cases studied. The larger a cohort is the higher 
confidence can be assigned to any results or conclusions drawn, in this context a sample 
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size of 44 versus 44 is the minimum for statistical significance (Abdel-fatah et al., 
2016). 
 The sample source. Only studies using patient tumour samples were considered, studies 
using cell lines were rejected. 
 The completeness of the data. In particular the Sample and Data Relationship Format 
(SDRF) file, those which did not contain clear data for all files available were not 
considered. 
 The focus of the study. A ‘fair’ meta-analysis needs utilise as similar sample cohorts as 
is possible. For example, a cohort of data generated from a trial of a novel drug/therapy 
cannot be fairly compared alongside cohort with patients on a standard/different 
treatment pathway. 
 The depth and detail of the data available. To take a meta-analysis approach, the same 
variable needs to be available for all data sets included. For example, time to relapse 
was measured in one data set is not comparable to survival time in anther data set.  
 The Array Design File (ADF) files needed to be cross-referenceable, one element of 
the adf table i.e. gene code needs to be in all data sets for a meta-analysis. The available 
data sets are generated from different gene chip platforms i.e. Affymetrix, Illumina, 
Agilent, each with their own probe design and number to represent a genome. Though 
possible, it is not practical to search and annotate this manually.  
 Full genomic representation. Only data generated from gene microarrays representing 
the full genome were considered. Those including only a subset or set of mutations 
were discounted.  
 
Survival time was the only dependent variable available in both the study cohorts selected for 
the analysis. Patients in both studies selected were subject to the same general treatment strategy 
of a possible debulking surgery, followed by platinum based chemotherapy where necessary. 
 
5.2.1.2. Two Data sets used for Meta-analysis 
 
In this context the term meta-analysis is used to describe a comparison looking for concordance 
across more than one data set, using more than one statistical analysis. 
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Gene array data was downloaded from Array Express, the data set was derived from analysed 
tissue from patients with ovarian cancer who have been treated with the same care pathway. 
Full data and information is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-
GEOD-13876/ and http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-26712/ 
(ArrayExpress accessed 2011).  
 
From the variables and data available this data could be mined for more genes that are expressed 
with significance in relation to survival time from Stage 3 serous ovarian cancer, and, to validate 
or refute any genes recently reported to be linked to ovarian cancer but not fully validated. 
 
Cohort 1: 
 
Full data and information is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-
GEOD-13876/ (ArrayExpress 2011) 
Array: A-GEOD-7759 - Operon human v3 ~35K 70-mer two-color oligonucleotide 
microarrays. 
Sample information: 157 consecutive patients with advanced stage (3, 4) disease donated 
tumour from cyto-reductive surgery prior to platinum based chemotherapy treated at University 
Medical Center Groningen (UMCG, Groningen, The Netherlands) in the period 1990–2003. 
Accompanying Publication: Crijns et al., (2009). 
 
Cohort 2: 
 
Full data and information is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-
GEOD-26712/ (ArrayExpress 2011) 
Array: A-AFFY-33 - Affymetrix GeneChip Human Genome HG-U133A [HG-U133A] 
Sample information: 185 late-stage (3, 4) high-grade (2, 3) ovarian cancer tumours donated 
from previously untreated patients at Memorial Sloan-Kettering Cancer Center between 1990 
and 2003. 
Accompanying Publication: Bonome et al., (2008). 
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5.2.2. Pre-analysis Data Evaluation and Processing  
 
Firstly, the survival distributions of the population of the two data sets were observed, the 
survival times ranged from 1 to 234 months and 0.7 to 130.4 months with a mean range of 25 
and 39 months in GEOD13876 and GEOD26712 respectively. The survival distribution was 
observed to be left skewed and similar between the data sets (See Figure 30).  
 
The MLP-ANN algorithm utilised requires a categorical variable, a cut off defining a short and 
long term survival group needed to be defined on survival (which, is a continuous variable). To 
minimise bias introduced from fitting a cut off to a continuous variable, the process was 
repeated at three possible time points. These were; above and below 16, 23 and 30 months (See 
Table 14 and Figure 30). 
 
The cut off points were fitted as closely to median, upper and lower quartiles survival time as 
possible without unbalancing the sample populations more than a ratio of 1:3.  
 
Table 14. Numbers of Cases in Short and Long or Short Term Survival Groups. Group sizes 
when of short and long term cut off are applied 
Survival cut-off 
No. of patients 
E-GEOD- 13876 
No. of patients 
E-GEOD-26712 
Cut off 1 (16 months) 
Lower 58 32 
Upper 55 97 
Cut off 2 (23 months) 
Lower 75 48 
Upper 38 81 
Cut off 3 (30 months) 
Lower 84 62 
Upper 29 67 
Total samples  113 129 
Minimum cohort size  29 32 
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Figure 30. Histogram of Distribution of Survival Times of Two Cohorts of Patients with Ovarian Cancer 
To enable a categorical analysis artificial cut-off points defining long and short term survivors were made. This 
was done at three different time points; Cut-off 1, 2 and 3 these were made at 16, 23 and 30 months. 
 
5.2.3. Analyses Applied 
 
5.2.3.1. ANN of Short versus Long Term Survival 
 
The ANN analysis does not accommodate censored variables i.e. those categorised as “death 
not from ovarian cancer” or “alive with disease”, so were excluded from this analysis.  
 
An in-house designed, multilayer, back propagation ANN algorithm (Lancashire et al., 2009, 
Lancashire et al., 2010 Kafetzopoulou et al., 2013), with an architecture of 1-2-1 was utilised. 
Within this a Monte Carlo Cross Validation (MCCV) was applied; the population is randomly 
divided into training, test and validation cohort with a ratio of 3-1-1 (60, 20 and 20%).  
 
For each gene probe, the gene expression values for a randomly selected 60% of the patient 
population are used to train the model, 20% to test, then 20% are applied as a blind validation 
This cycle is repeated 50 times and a report of the averaged predictive performance created; 
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this includes training, test and validation performance and error. This loop is repeated ten times 
for each gene probe. At the end, the ten reports for each gene probe were compiled in Excel and 
a mean average of the ten reports calculated. The average performance over the ten was 
calculated. All the gene probes were then sorted by the Test Error.  
 
Using the three-time point cut-offs ANNs was conducted on the two data sets. Each ANN was 
used to rank the gene probes in order of the predictive performance to distinguish short and 
long term survival on the blind validation subset. Two ANNs were conducted for each time 
point for each data set, a total of twelve analyses. Within each of the twelve analyses the gene 
probes were ranked by their predictive performance on an internal blind validation step and 
gene probes ranking below 0.05% were disregarded. The gene codes of these shortlisted gene 
probes were cross-referenced across the six ANNs from each time point in each data set. 
Multiple cross comparison systems were explored. Gene codes were weighted based on the 
frequency of their presence in the twelve ANNS. 
 
The list of weighted gene codes with a consistent predictive performance between long and 
short term survival were taken forward to the meta-analysis. 
 
5.2.3.2. Cross Validation with Cox Univariate Survival Analysis 
 
Cox proportional hazard model has the capacity to compute both censored and non-censored 
cases (Singh and Mukhopadhyay 2011) so “death not from ovarian cancer” or “alive with 
disease” were included increasing the sample numbers. 
A Cox univariate survival analysis was conducted on every gene probe in each data set 
individually to determine if the is expression significantly correlated with survival. To do this 
a macro (see Digital Appendix A) was created within Statistica 8 software that cycled round 
each of the thousands of gene probes within each data set and produced a report for each one. 
The reports were exported to Word, transferred to Excel and a macro function used to compile 
the results. Gene probes were ranked by their p-value and any below 0.05 were disregarded.  
 
The gene codes of the gene probes with a p-value of ≤0.05 were taken forward for the meta-
analysis.  
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5.2.3.3. Cross-comparison of Significant Genes 
 
The PiVot table function within Excel was used to cross-compare the gene codes that performed 
well as predictors in the MLP-ANNs and had a significant p-value in the Cox univariate survival 
analysis. Gene probes that did not occur in all four categories were disregarded. 
 
5.2.3.4. T-tests 
Two tailed type two Student’s T-tests were conducted in Excel applying the same time point 
cut-offs described above (Table 14 and Figure 30) to find a categorical analysis to a continuous 
variable. Genes that did not have a significant T-test p-value for one or more probe in both data 
sets were disregarded. Finally the averages of each were compared. Genes whose expression 
trends when correlated with survival differed between the data sets were disregarded.  
 
5.2.3.5 STRING Analysis 
 
The final list of 56 genes were searched in STRING 9.0 (2013) (see section 2.2.3.) to uncover 
any already published knowledge of association or interactions between them. 
 
5.3. Results 
 
A meta-analysis approach was applied to two carefully selected gene expression microarray 
data sets (E-GEOD-13876 and E-GEOD-26712) downloaded from ArrayExpress. In both cases 
the data was collected from full genome arrays applied to Stage 3 serous ovarian carcinoma and 
tumour samples collected and processed under regulated conditions. 
 
5.3.1. ANN of Short and Long Term Survival 
 
As described above the only available variable for analysis was survival time, a continuous 
variable. The ANN algorithm used requires a categorical variable. For this reason a cut off had 
to be made separating short from long survival. As described in section 5.2.2 multiple ANNs 
were conducted to best accommodate a categorical analysis around a continuous variable. 
 
Using the three time point cut-offs ANNs were conducted on the two data sets to generate six 
sets of gene codes of interest. Within each of the 6 ANNs analysis the gene probes were ranked 
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by their predictive performance on an internal blind validation step and gene probes ranking 
below 0.05% were disregarded. See Digital Appendix B for the ranking of each probe from 
both data sets ranked by their performance (Average Test Error) at all three cut-off points tested.  
 
5.3.2. Cox Univariate Survival Analysis  
 
Cox univariate survival analyses was conducted on every gene probe individually to determine 
if its expression significantly correlated with survival. See Digital Appendix B for the full 
listings of p-values of each Cox Univariate Analysis. 
 
5.3.3. Cross-comparison of Significant Genes 
 
When the gene codes of the gene probes found to be statistically significant from the ANN 
analysis and the Cox univariate survival analysis from the two data sets were cross compared 
there was an overlap of 126 gene codes, see Figure 31. These were:  
AASS, ACHE, ACOXL, ANGPTL2, ANKMY1, ARHGAP26, ATG4B, 
ATP2A3, BACH1, BACH2, BLMH, BMP4, BNC2, C19orf42, 
CACNA1E, CACNB2, CDC25B, CEP152, CLIP3, COL13A1, COLEC12, 
CSDC2, CTBP2, DCN, DCTD, DECR2, DHPS, DNAJC4, 
DOM3Z, EDNRA, EFNB3, EIF1AY, EPS8L1, EXOSC7, FAM32A, 
FAM60A, FGFR1, FHOD3, FKBP14, FYN, FZD7, GJB1, 
GLP1R, GLT8D2, GULP1, H2AFV, HBD, HIST1H3C, HNRPDL, 
HSD17B14, IDE, IGF2, IGFBP3, IGFBP6, IL17B, INTS5, 
KCNC2, KCNJ15, KIAA0528, KLHL23, LDB2, LIMA1, LRRC17, 
MAP4K4, MATK, MFAP4, M ME, MORC2, MPG, MTERF, 
MYCN, MYH6, MYO7A, NAV3, NCOR1, NDN, NEBL, 
NFX1, NOL11, NSUN6, NTRK3, OLFM1, OLFML3, PCDH17, 
PDZRN3, PHIP, PJA2, PKD2, POGZ, POLL, PPFIBP1, 
PPP3CA, PTK2, PTPRE, RABGAP1, RARRES2, RBM17, RBM6, 
RPL10, SCAMP1, SCN2B, SEMA3C, SERPINE1, SFRP4, SLC11A2, 
SMARCA4, SMARCD3, SMC3, SMG5, SPAG9, SPCS3, TMEM45A, 
TNFAIP6, TNFRSF14, TPM2, TPPP, TRO, TRPM4, TUSC2, 
WDR59, WTAP, WWC1, ZFHX4, ZMYM5, ZNF133, ZNF45. 
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Figure 31. Overview of Gene Microarray Meta-analysis Methodology.  
Two data sets (Cohort 1 containing 157 cases and 37632 gene probes, Cohort 2 containing 153 cases and 22283 
gene probes) were mined for gene expression values significantly associating with ovarian cancer survival using 
two statistical approaches. Method 1: a set of three ANNs using differing time point cut offs to define short and 
long term survival, Method 2; a Cox univariate survival analysis performed on every gene. Upon cross comparison 
of statistically interesting genes 126 gene probes were selected from a potential 37632 for further analysis. 
 
The list of GOIs was cross reference with the lists reported to be of interest by the initial 
investigators who generated the data GEOD 13876 (Crijins et al., 2009) and GEOD 26712 
(Bonome et al., 2008). Four genes were found to overlap; these are GULP from Bonome et al., 
(2008) and LRRC17, TMEM45A and TRO from Crijins et al., (2009). 
 
Gene codes were weighted based on the consistency of their performance to predict survival 
times of a blind validation set in the twelve ANNS performed at the three time point cut offs on 
two data sets see section 5.2.3.1. This is visualised in Figure 32, genes that occurred multiple 
times carry a higher weighting thus positioned higher in a pyramid of interest.  
 
When compiling the data for each quadrant of the overall meta-analysis depicted above, the 
lists from each set of three ANN analyses (depicted as method 1 above) could be combined/sub-
cross-compared at increasing levels of stringencies. For example if a gene occurs in the highest-
ranking portion if any of the three survival time cut offs are applied, or if it had to occur in two 
or more (more restive), or if it had to occur in all three (most restrictive). The overarching 
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stringency in this meta-analysis is attained from testing using multiple, different methods. For 
this reason, the least stringent combination was applied to maximise the genes taken forward 
for analysis by a different method. However the as the analysis had been conducted using all 
levels this information was compiled to rank the genes in order of occurrence across the 
increasingly stringent repeats. This may serve as an approximate rank in confidence. 
 
 
Figure 32. A Graphical Representation of the Order of Significance of the Genes of Interest. 
The 126 genes of interest were weighted based on the frequence of occurrence in the twelve ANNs. Genes at the 
top of the pyramid were seen more frequently than those at the bottom (see See Digital Appendix B for full gene 
rankings). 
 
All of the genes in the triangle were found to be of significant interest via meta-analysis from 
two data sets by both univariate cox regression survival analysis and ANN. The gene codes at 
the top of the triangle re-occur in multiple, and higher stringency options for combining lists 
prior to meta-analysis. The gene probe for GLT8D2 was the most consistent and high-ranking 
probe thus is positioned at the top of the pyramid; gene codes toward the bottom of the pyramid 
may have only appeared in the least stringent compilation of the pre-meta-analysis ANN lists 
however do meet all the criteria for the final analysis.  
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5.3.4. T-tests 
 
Using excel the data for all 126 genes listed above underwent T-tests using the same cut offs to 
define short and long term survival as described in section 5.2.2. Genes that did not have a 
significant p-value for one or more probe in both data sets were removed from the list. 
 
After the T-test elimination a data trend comparison (described in section 5.2.3.4.) was 
conducted. The purpose of this was to remove genes whose significant differential expression 
disagreed between the two data sets. Genes that were removed at this stage include ACHE, 
ATP2A3, COL13A1, EIF1AY, EPS8L1, FGFR1, KCNC2, KIAA0528, KLHL23, MATK, MYO7A, 
NEBL, NFX1, PTK2, RABGAP1, RPL10, SCN2B, SMARCA4, TPPP, TRO, and WWC1 which 
were all discounted because the significant differential expression between long and short term 
survival was observed to be opposed between the two data sets. For example, ACHE was in 
this comparison observed to be expressed at a significantly higher level in the tissue of short 
term survivors in data set GEOD13876, however a significantly lower expression observed in 
the tissue of short term survivors in data set GEOD26712. 
Genes whose expression trends were not consistent between the two data sets were removed, 
reducing the list of 126 genes of interest were refined to 56. These were: 
 
BACH1, BACH2, BMP4, CDC25B, CLIP3, COLEC12, CTBP2, 
DCN, DCTD, EDNRA, EFNB3, FHOD3, FKBP14, FYN, 
FZD7, GJB1, GLT8D2, GULP1, H2AFV, HBD, HIST1H3C, 
HNRPDL, IGF2, IGFBP3, IGFBP6, INTS5, LDB2, LRRC17, 
MAP4K4, MFAP4, NAV3, NCOR1, NDN, OLFML3, PCDH17, 
PDZRN3, PJA2, PKD2, PPFIBP1, PPP3CA, PTPRE, RARRES2, 
SCAMP1, SEMA3C, SFRP4, SLC11A2, SMC3, SPCS3, TMEM45A, 
TNFAIP6, TNFRSF14, TPM2, WTAP, ZFHX4, ZNF45.  
 
A superficial observation, even without deep research, it was apparent at this stage that several 
of the remaining genes were already associated with cancer by name; Tumour Necrosis Factor, 
Alpha-Induced Protein 6 (TNFAIP6), Tumour Necrosis Factor Receptor Superfamily, Member 
14 (TNFRSF14), Wilms Tumour Associated Protein (WTAP). Additionally apparent pathway 
associates in Insulin Growth Factor Binding Protein 1 (IGFBP3) and Insulin Growth Factor Binding 
Protein 6 (IGFBP6) and Insulin Growth Factor 2 (IGF2). 
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More relevantly, a brief  exploration of literature found NAV3, SPAG9, SMC, IGFBP6 and 
more have been described/ implicated in cancer studies (Carlsson et al., 2012, Garg et al., 
2008, Ghiselli 2006, Fu et al., 2007). The most pertinent are IGF2 and BMP4, which have 
been reported with relevance to ovarian cancer survival time (Sayer et al., 2005, Shepherd et 
al., 2008 and Thériault et al., 2007). 
 
5.3.5. STRING Analysis 
 
For observation purposes only, the final list of 56 genes were searched in STRING 9.05 (see 
section 2.2.3.) to uncover any obvious or already published association or interactions between 
them. This version of string was current between March 3rd, 2013 and December 27th, 2013, it 
lists 5,214,234 proteins from 1133 organisms (although only human was searched) and holds 
information of 336,561,678 interactions and is still available through archived databases within 
the website. Fourteen of the genes are reported to be linked by co-mention in literature and five 
by co-expression see Figure 33. 
 
 
Figure 33. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) Output Displaying 
known Associations between the Genes of Interest. 
56 gene codes found to be significantly relevant to ovarian cancer survival were entered into STRING. Any 
relations are represented as a colour coded connection between genes represented by a ball. Fourteen of the genes 
are reported to be linked by co-mention in literature (yellow lines) and five by co-expression (black lines). 
 
These links can act as leads to the publications linking creating the link.  
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5.3.6. Interaction Intact Analysis 
 
To follow up on the links observed using STRING, Reactome (Reactome 2013) and IntAct 
(IntAct 2013) were explored to find interactions or pathways for any demonstrated physical 
links between the 56 genes. These databases are both manually curated hence this is a more 
rigours search, only the gene codes for which there is published evidence relating to proteins 
with confirmed physical interaction should be listed. Using IntAct, evidence was found of 
translational interaction between IGF2 and Decorin. In that, the translated protein Decorin may 
act as a stimulatory competitive ligand to IGF2 (Morcavallo et al., 2014). 
 
5.4. Discussion 
 
This chapter aimed to characterise genomic differences between tumours from patients with 
Stage 3 ovarian cancer that responded well to therapy and those which did not.  
 
Using survival time as a measure of response to therapy based on the patient’s survival times a 
list of 56 genes were distilled from a potential 37000 gene probes to be consistently significantly 
expressed in relation to survival times from ovarian cancer measured from two separate 
populations of patients, on two microarray platforms measured in two laboratories.  
 
The rigour of combining a meta-analysis approach with multiple testing using a variety of 
statistical approaches, increases power and confidence in the relevance of genes found to be of 
interest. Encouragingly, a number of the 56 were immediately recognised as having known 
association with ovarian cancer survival (IGF2 and BMP4 and more). Further investigation and 
validation of the genes that are not yet reported to associate with survival may have clinical 
relevance and have potential to predict a patient’s response to treatment or be used as a novel 
target for therapy. These results warrant genomic and or proteomic validation, for example, 
using immunohistochemistry on tissue micro array. Moreover using the genes in combination 
with each other as a biomarker panel and clarifying the nature of these commonalities using 
more, freely available online resources such as STRING (Figure 33), KEGG, Reactome, 
BioGrid, Panther and HeTop. This could begin to unearth molecular pathways with potential to 
characterise and categorise the nature of an individual tumour and enable more tailored 
treatment.  
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The most ‘robust’ biomarkers remained. 
 
5.4.1. Comparison of Results with the Data Source Publications  
 
Based on a continuous prediction analysis the owners of the data have published a list of 86 
genes they calculated expression to correlate with time of survival (Crijns et al., 2009), some 
of which had not previously been linked to ovarian cancer. Crijns et al., 2009 used a continuous 
prediction analysis to list 86 genes whose expression was strongly correlated with survival time. 
They were able to find and use data sets containing 57 of these genes for validation of their 
findings. 
 
To validate the finding of any biomarker study the results must be reproduced with a different 
sample set or on a different technological platform. Crijns et al., (2009) were unable to attempt 
to reproduce 31 of 88 genes found to be significantly associated with ovarian cancer survival 
times as the validation data sets though having twin experimental design produced data using a 
different microarray technology which did not contain probes corresponding to these genes. 
Equivalently the 56 gene of interest listed above are biased to those genes whose probes on both 
Operon and Affymetrix platform, the nature of the meta-analysis will have filtered out genes 
only present on one.  
 
When compared to the accompanying publications of the data sets there were four gene overlaps; 
three from GEOD 13876 (Crijns et al., 2009) , and one with GEOD 26712 (Bonome et al., 2008) 
These are LRRC17, TMEM45A and TRO from Crijns et al., (2009) and GULP1 from Bonome 
et al., (2008). Their appearance in this meta-analysis acts as a second or third step of validation 
for each marker from the point of view of each paper. However the lack of crossover is more 
poignant. The lack of association of the other 83 genes listed to be of interest by Crijns et al., 
(2009) with survival, and 54 by Bonome et al., (2008) exemplifies the point made by Braem et 
al., (2011) and Devlin et al., (2003) that the need for reanalysis and meta-analysis of existing 
data and how different data processing and analysis applied to the same data can yield different 
results. Completely different gene sets and numbers of genes can be shown to be significantly 
differentially expressed between two data sets depending on the data mining methods applied 
to the same data (Devlin et al., 2003). 
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Interestingly commonalities with other larger meta-analyses were discovered (Ganzfried et al., 
2013 or Yang et al., 2014), the results of which were published after the initiation and majority 
of the work described above (Chapter 5).  
 
Ganzfried et al., (2013) used the R statistical package to compile data from 2973 cases from 23 
manually selected gene array data set. The emphasis of their study was to curate the larger 
resource, as it was not focused on biomarker discovery only reported the identification of one 
single marker (CXCL12) as an independent predictor of survival time.  
 
The analysis above (Chapter 5) based on two data sets contributes as well as any comparable 
study, (Ganzfried et al., 2013, Yang et al., 2014, Crijns et al., 2009 and Bonome et al., 2008) 
and contributes to knowledge with novelty by its unique combination of samples and analytical 
methods. Meta-analyses utilising a larger number of sub-cohorts to increase sample number, 
such as Ganzfried et al., (2013) n=2973, will experience detrimental effects consequent from 
extraneous variables introduced when combining cohorts from different sources such as, sample 
collection procedure, microarray platform or majority ethnicity. The base studies generating the 
data (such as Crijns et al., 2009 and Bonome et al., 2008) contain smaller, yet notably sized 
sample numbers inherently avoid such problematic extraneous variable influencing findings. 
The analysis in Chapter 5 falls between these two extremes. A larger sample number n=310 was 
achieved by the use of two data sets (157 + 153) which were carefully, manually selected. Genes 
of Interest (GOI) were ranked based on their performance in each cohort in parallel 
/discretely/simultaneously and the highest ranking taken forward for the comparison. Any GOIs 
that concord with similar studies findings will add a level of validity to an existing body of 
evidence implicating that genes role. Any discrepancy, are candidates for further investigation. 
If it were possible, a deeper investigation of each sample, data processing and analysis method 
used to draw each conclusion may in itself lead to identifying reveal new knowledge (e.g. if 
one cohort had a higher number of one ethnicity – ethnicity could be investigated as a potential 
effector variable) however lack of wider sharing and availability of raw data and software used 
to generate results prohibits this. 
 
As discussed above the same data can be re-analysed to draw different conclusions depending 
on the analysis applied (Allison et al., 2006). As Ganzfried et al., (2013) combined numerous 
data sets generated from different microarray platforms a global normalisation would have been 
applied. Normalisation of data can itself influence downstream results depending on the method 
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applied (Zyprych-Walczak et al., 2015). It may be insight full to analyse the performance of 
each gene in each constituent cohort, to its performance across the combined, normalised data 
set as a whole. 
 
5.4.2. Interpretation and Implications of Results  
 
This chapter’s analysis infers that the variation of survival times is a consequence of different 
genes activations acting to either make the tumour more aggressive or able to evade platinum 
based chemotherapy. Though there are numerous non-recorded uncontrollable extraneous 
variables that could also determine patient survival times, this assumption must be made in 
order to hypothesise and derive possible meaning from the results. 
 
A key observation was that the IGF2 gene, already accepted to be implicated in ovarian cancer 
was identified to be present in higher amounts in the short term survivors, together with a 
stimulatory ligand (Morcavallo et al., 2014). This strongly implicates activation of the growth 
pathway downstream of IFG2 in the cancers from the short term survivors.  
 
5.4.2.1. Known Mechanisms of Resistance to Platinum Based Chemotherapy 
 
Proteins that are reported to play a role in platinum chemoresistance include Excision Repair 
Cross-Complementation group 1 (ERCC1), xeroderma pigmentosum complementation group 
F of the NER pathway; increased in acquired chemo resistance, and Mut and Mut associated 
proteins of the MMR pathway as reviewed in (Martin et al., 2008). See section 5.1.1. 
 
At a superficial level ERCC1, though representative probes were on both of the arrays was not 
found to be amongst the top ranking gene probes associated with survival times in the meta-
analysis of two patient cohorts using these the above described analysis. This suggests that 
different/other cell signalling or/chemoresistance pathways are responsible for this particular 
difference in survival times observed in the above meta-analysis. 
 
On closer examination, ERCC1 was found to be in the significant portion (p=0.03744) of 
highest ranking genes from the Cox univariate analyses of the GEOD 13876 data set if censored 
cases are removed. This could be taken to suggest that in this patient subset the ERCC1 
mechanism of DNA repair was responsible for their shorter survival, however as recurrence 
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data is not available no conclusion could be drawn. Or, it is possible that there is a subgroup 
within or outlier within the GEOD 13876 cohort influencing this. This was just a preliminary 
comparison, as discussed below a deeper investigation into all the genes associated with the 
ERCC1, Mut and any other known pathways of mechanisms of chemoresistance would be 
insightful, however is a separate top-down/reductionist/targeted type of data analysis entirely. 
To be done properly is beyond the scope and resources of the current study. Fishing for one 
gene of interest is not the appropriate use for this analysis data. 
 
However, any conclusions or indications derived from comparison with current knowledge can 
be considered to be restricted. The main limitation being the majority of current ovarian cancer 
chemo resistance knowledge is based from studies of cell lines with acquired resistance 
(Marchini et al, 2013). Though insightful to delve into specific mechanisms, cell line models 
do not incorporate the heterogeneous character of tumours and the tumour microenvironment 
as variables, which are accepted to be a significant component of ovarian tumours. Many cell 
line studies fail to investigate the histopathological origins of the cell they are drawing 
conclusions from (Vaughan et al., 2012). 
 
The genes found to significantly associate with survival times in the above chapter were are 
linked to mechanisms of chemo resistance, for example EMT pathways; EDNRA (Rosanò et 
al., 2011)  
 
5.4.3. Support of the Methods Used 
 
Incorporating false discovery testing to an analysis increases the confidence of any deductions, 
thus, yields results with a higher validity (Devlin et al., 2003). False discovery refers to the 
phenomena that over any number of observed measurements a proportion of them will have 
been discovered by random chance. Strategies such as multiple testing, meta-analysis, or adding 
in decoy data mitigate false discovery, or by its measurement allows researchers to crop result 
to only include those with minimal probability of having occurred by chance. Gene array studies 
finding differential expression of a handful of interested genes have been criticised for 
insufficient hypothesis testing and rejecting the null hypothesis too readily (Devlin et al., 2003). 
Encouragingly, the approach used in this study has been adopted by other researchers. Marchini 
et al., (2013) used a similar filtering approach; a series of statistical analyses of different types 
to gradually refine a list of differentially expressed genes to investigate further. 
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Using more than one analytical method increased the rigor of a test, in this chapter we have 
used three different approaches to filter genes based on their association with survival time from 
ovarian cancer. The differing characteristics of each compile a stringent filter and enhance the 
meticulousness of the analysis/ made a really stringent shortlist.  
 
Cox proportional hazard analysis was applied to determine if the continuous independent 
variable of each genes expression levels associated with survival time (see section .2.) The Cox 
univariate analysis added the capacity to include censored cases/incomplete data, which neither 
ANN nor T-tests have. ANNs are a form of machine learning applied to non-linear data to assess 
the predictive power of each variable. Thus adding a predictive element to the finalised list. 
(See section 2.2.2 for details of each). The T-test is a widely accepted test to assign a 
significance to the difference between two populations this process coupled with a trend 
analysis added an extra, fundamental/widely accepted level of confidence in the finalised genes. 
 
Two of the approaches, ANN and T-tests are best suited to data with categorical variables where 
here they are applied to a continuous independent variable: survival time. Performing these 
analyses thrice at each of three definitions of what is long or short term survival (Figure 30) 
tailored these analysis for this purpose. 
 
The observation that a number of the condensed list of 56 GOI contains genes and proteins 
already associated with cancer is encouraging: TNFAIP6, TNFRSF14 and WTAP are implicated 
with tumours by name, NAV3, SPAG9, SMC, IGFBP6 and more have all been reported or 
specifically implicated in cancer studies (Carlsson et al., 2012, Garg et al., 2008, Ghiselli 2006, 
Fu et al., 2007), and some associate with ovarian cancer survival, namely, IGF2 (Sayer et al., 
2005) and BMP4 (Shepherd et al., 2008, Thériault et al., 2007 ) 
 
5.4.4. Criticisms of the methods used 
 
Multicentre studies increase the opportunity for operator bias, even from sample collection. The 
meta-analysis in this this thesis limited sample numbers to only include samples that could be 
defended to be described as comparable, however, are they? From the documented evidence 
available, the samples considered for this analysis were comparable, however, if the full sample 
collection and patient information were scrutinised in depth there is likely a parameter that 
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would separate them. Due to the nature of experimental design at the different centres there will 
always be some fundamental differences. 
 
5.4.4.1. The Availability of Additional Information 
 
Non-controlled, non-recorded extraneous or confounding variables that may have also 
influenced the patient’s survival time from ovarian cancer. Namely overall health, smoking 
status or family cancer history. Despite having more than the MIAME requirements, limited 
information about the samples used, processing of samples and data acquisition was available. 
None of the known risk factors associated with ovarian cancer are available such as: BRCA1 
and 2 status, oral contraceptive use, parity and menopausal status (though this could be deduced 
by age). 
 
Other factors that affect survival time that may differ between patients in the above data sets 
and patients in data sets used for validation, include the experience and expertise of the care 
givers of the patients in the two centres (Erickson et al., 2014).  
 
This data is only based on patients who were entered into a treatment pathway. Though based 
on a different population, a recent US report found that nearly half of patients diagnosed with 
ovarian cancer did not receive the ‘standard’ NCNN endorsed treatment pathway (Erickson et 
al., 2014). Reasons for this included the overall severity of the condition combined with the 
average age of patient at diagnosis and co-morbidities. Thus, nearly half of the patients that this 
data appears to be drawn from are not genomically represented in the above analysis. 
 
5.4.4.2. Challenges in Studying Ovarian Cancer 
 
Survival time is a common measurement applied to assess treatment efficacy or subcategorise 
patient groups in clinical study. It is used as it is an accessible measure, however, can not include 
any number of extraneous factors effecting each patient’s vitality, neither does it incorporate 
the quality of the life measured. There is still a need to address the way success in treatment is 
evaluated. As with this body of work, researchers are limited to the samples and variables 
recorded. Time of survival is a common measure, however, an increase in life span is still 
normally less than 5 years and not a solution or cure to the disease, the quality of life of a patient 
undergoing drastic treatment is not considered. A recent collaborative focus group (Vaughan et 
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al., 2012) called for the inclusion of quality of life and symptom benefit analysis to be included 
as a measure of success or parameter/ variable in such research. 
 
According to Machin, Cheung and Parmar (2006), survival analysis has a predetermined ideal 
sample size which should ideally be determined prior to data collection. As this was a 
retrospective analysis of data this was not possible however the minimum ideal sample number, 
based on a log rank power model to achieve a power of 0.8 and a p-value of 0.05 is 65. Using 
the selection criteria of Stage 3 serous the data utilised in this analysis is nearly double the 
minimum. However, due to the relative rarity incidence of samples cohorts of such a size are 
rare. A cohort of comparable size consisting of only Stage 1 tumour would be of great scientific 
value but near impossible to acquire. 
 
Ovarian tumours are known for their wide ranging reported cellular histology compared to other 
cancers. This may be due to the tumour microenvironment accounting for a larger proportion 
of the tumour burden, although this is not quantified (Vaughan et al., 2012). 
 
The data analysed above is from gene arrays are based on lysates of ovarian tissue, Crijns et al., 
2009 details the strict requirement for tumour tissue included in the study, however, even within 
the tumour microenvironment multiple cell types with different activated gene pathways are 
present. Even with these inclusion criteria in place, the genetic information available represents 
the entire tumour microenvironment, not just tumour cells, this includes the host reaction to 
tumour cells. Not all data sets available on ArrayExpress detail their inclusion criteria for tissue, 
comparing samples with an unknown mixture of both within them is not a fair comparison, and 
will increase the probability of creating irreproducible results. Laser capture micro-dissection 
prior to microarray analysis to extract tumour cells from the surrounding stoma cells increases 
the accuracy of the measurement to represent the genome of the cancer would to some extent 
mitigate this , as performed in Sayer et al., 2005. However, is not always practicable, the yield 
from micro-dissected sections are comparatively small and the addition of an extra sample 
handling protocol may add variation.  
 
5.4.4.3. The Array and Data Analysis Methodology 
 
The data used was selected on criteria that it represented genes from the whole known human 
genome. However they do not contain probes to all known genes, additionally as the two were 
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from different gene chip platforms a small proportion of genes were not represented on the 
other chip. 
 
One challenge in meta-analysis of gene microarray data, also disapprovingly reported by 
Ganzfried et al., (2013), is the disambiguation of in syntax, semantics abbreviations used to 
annotate variables in both the sample information files and the microarray platform annotation. 
For example the gene TNFAIP6 has eleven possible aliases in the format of gene codes alone. 
On a smaller scale using a search and match function in Excel “IGF2” will not be matched to 
“IGF-2”. Curated databases may have basic formats for information to be in before publishing 
however are not completely standardised. 
 
It is commonly accepted that, database and clinical annotations formats need to be standardised 
to maximise their utility to meta-analyses (Array Express 2010, Wu et al., 2014 and Carey et 
al., 2008 in Ganzfried at al., 2013). However they are each tailored to their own purpose and 
still may make using multiple resources a challenge.  
 
In this chapter, a concordance strategy was applied to across multiple analyses to mitigate false 
discovery. This strategy was reasoned to be more appropriate than other adjustments for false 
discovery such as the Benjamini-Hochberg or Bonferroni corrections where the p-value 
threshold of significance is adjusted based on the number of variables and or sample size. Yang 
et al., (2013) in a study of common cancers used p-values of ≤0.05 and did not correct for false 
discovery.  
 
5.4.4.4. Downstream Analyses 
 
STRING and all protein text mining interaction databases are inherently bias to well-studied 
entities/genes. As acknowledged by Yang et al., (2013). The encouraging web of association 
observed in Figure 33 needs to be considered in context of the colour coding between each 
point and how it was generated within STRING. Yellow lines represent associations drawn from 
algorithm text mining, black and pink represent co-expression and experimental evidence. It is 
possible that all the genes represented as linked with yellow lines are not co-expressed/ have 
no relation to one and other. Additionally, it is possible that all the genes represented as separate 
are connected or part of a pathway/family but there is as yet no evidence. STRING analysis is 
not a result as such, more a tool to direct further investigation. 
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In summary, 56 genes were found to have a consistent significance throughout the meta-
analyses. The chances of having focused on these genes by chance was is minimal due to the 
number of, and differing statistical filtration steps applied. The inclusion of some genes already 
implicated in ovarian cancer adds to the confidence in the strategy applied however the study 
is limited due to the data sets and information available. There are still multiple ways the 
existing data could be re-examined to add even more rigor to the existing analysis, or, derive 
different information. 
 
5.4.5. Future work 
 
Re-analysis of the data available 
 All the gene probes could be collapsed into one per gene. This would reduce the 
influence of each probe.  
 An interaction analysis could be performed so observe the influence of each genes of 
interest on all others in the data set. Findings would be interesting to compare to (Yang 
et al., 2014), who in a similar study, found that the genes with the most prognostic power 
tended not to hub i.e. be influential of the expression of large numbers of other genes.  
 Hypothesis lead data mining. Prior analyses could give evidence that the genes found 
to be of interest share a common characteristic. All gene probes could then be separated 
and grouped by an ontological annotation i.e. cellular location, function, or pathway 
involvement, then then each category could be given an overall significance score based 
what proportion of the genes of interest are has a significant T-test, Cox univariate 
survival or high predictive performance. In particular; if pathway annotations for both 
sets of gene probes were available for example, it would be possible to deduce a really 
informative conclusion. Which ontological category is overrepresented in the set of 
genes that significantly associate with survival times? For example: DNA repair / 
angiogenesis pathway contained x% probes that significantly associated with survival, 
whereas housekeeping pathway had none. However, though possible there is no short 
way to annotate the gene probes from the two platforms (Affymetrix and Operon) with 
common pathway search terms. Also see Table 2 for discussion on interaction and 
pathway databases. Marchini et al., (2013) exemplifies hypothesis lead gene data 
mining whilst investigating chemo-resistance in ovarian cancer; analysis of quantitative 
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PCR and microarray analysis of a test set of tumour tissue generated a list of 
significantly relevant genes. A hypothesis was derived from this list that EMT /MET 
signalling pathways were significantly associated with chemo resistance in ovarian 
cancer. Following this, signalling pathway category annotations were assigned to their 
gene interest list using Reactome and KEGG to assess which pathways are 
overrepresented in each listed pathway. This approach can be criticised as being bias, 
commonly reported and investigated genes will be better documented an more likely to 
come up in a pathway analyses than their newly discovered counterparts. Constant re-
use and basing conclusions from databases of existing pathway records such as KEGG 
may drown out newly discovered interaction and pathways.  
 Evaluation of existing evidence. Namely Transferrin, Vitronectin and ApolipoproteinA1 
as published by Nosov et al., (2009), though these markers are for early detection of the 
disease there role in survival. Their lower expression was shown to negatively correlate 
with early disease detection. Are their increased expression associated with improved 
survival? (though not replicated by this study). 
 Re-divide the full genome to pathways and see which have the highest proportion as 
significant to survival time however this is currently not feasible due to no ready/ fast 
way of assigning pathway to each gene probe and ensuring it is officially correct. 
 Molecular pathways involved in angiogenesis are increasingly well characterised and 
implicated in survival from and incidence of ovarian cancer (Zhang et al., 2003), a 
deeper analysis of the genes in these pathways expressions relation to survival time 
could make an interesting contribution to this body of research. 
 When using online databases of information, great care must be taken to ensure they are 
being used both to their full potential and appropriately so not to misunderstand the 
information displayed in them. In the example of STRING there is little room for error 
conducting a search however the interpretation of the results must be done with the 
known caveats that, well reported genes will display more connectivity, the database is 
based on algorithms literature searching the internet i.e. not curated by specialists. 
Connections between proteins categorised “databases” or “text mining” is vague and 
may have little scientific meaning. Additionally understanding who has sponsored or 
curated a search engine or database may influence the interpretation of results. This is 
often the explanation as to the reasons behind differing findings from different databases.  
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 A current barrier to the progress of the work is the lack of factual, accepted circuitry 
diagrams of heterotypic inter and intra cellular interactions, identified by Hanahan and 
Weinburg (2011) to be an obstacle to current research, but they also predict these 
circuitry diagrams to develop exponentially over the next decade. Some progress is 
already noted and discussed (chapter 5 and 6.1) and however not yet truly centralised. 
Although until these exist in a 100% validated format development of these database 
are a reductionist approaches that do not truly represent biology. Current existing 
versions such as KEGG are based from multiple sources of evidence, it could be argued 
that it is over simplistic impossible to accurately to knit together information separate 
research sources into something as intricate and individual and variable as a cellular 
molecular pathway. Obviously, these resources need to be developed somehow but it is 
up to the scrutiny of a researcher to understand the strength/foundation of these 
resources whilst under construction. 
In the above chapter a number of calculations, interpretations and analyses of the of two 
microarray data sets are made. These could still be reanalysed using any combination of known 
or novel data mining strategies. Evidence from other sources could confirm or refute such 
observations. 
 
5.5. Conclusion  
 
Within the listed boundaries of what was available for analyses, 56 genes were found to 
significantly and, consistently associate with survival from ovarian cancer. The meta-analysis 
tactic means these findings are less likely to be biased by sample cohort, collection centre, gene 
array platform or statistical analysis computation and the risk of false discovery is reduced. The 
RNA expression micro array platform by nature limited this discovery to a known gene to which 
a predesigned oligonucleotide probe existed on both arrays used, so a novel onco-sequence was 
never a potential discovery despite being likely occurrence. Additionally, although expression 
of mRNA implies translation into protein expression would occur this is not guaranteed, and if 
it does then any number of post translational modifications could take effect between this 
measurement and an onco-phenotype. None the less, these findings need to be confirmed on 
other patient samples and technological platforms. 
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6. Validation Strategies  
 
Chapter Abstract 
 
A meta-analysis in chapter 5 ranked probes from genome wide microarrays by their relevance 
to survival time from ovarian cancer. A potential list of 37632 genes were whittled down using 
increasing levels of stringency into a list of 56 with an encouraging body of evidence indicating 
they are expressed at different levels between samples from patients with short and long 
survival times.  
In this chapter, after reintroducing and defining validation and verification, the list is further 
refined based on additional evidence of their differential expression. Firstly each of the genes 
of interest generated in chapter 5 were individually verified on a larger sample set of gene 
microarray data using Kaplan Meier Plotter, a freely available online resource which accesses  
a range of additional microarray data sets. This verification step reduced the list of 56 to 7 genes 
with observations corroborating the findings of the meta-analysis in chapter 5. Verification of 
the translated proteins of these 7 genes could give insight into their role at a cellular level within 
the tumour environment. One of the candidates EDNRA was selected to be the first for 
verification at a protein level by immunohistochemistry on a tissue microarray of ovarian tissue. 
Significant trends association the expression of EDNRA with cancer stage, grade and histology 
are observed. The merits, limitations and direction for further research are discussed. 
 
6.1. Introduction  
 
As eluded to in the introductory chapters (section 1.1.3.1.) for any potential biomarker (defined 
as “a naturally occurring molecule, gene or characteristic by which a particular pathological or 
physiological process, disease, etc. can be identified” Oxford Dictionaries, 2015) to progress 
from a discovery stage to a clinical setting it must first undergo challenging and rigorous stages 
of peer review, verification, validation before clinical trials to satisfy firstly the scientific 
community regarding discovery methodology, then the clinical community for the safety of is 
application in testing the general public (de Gramont et al., 2014, Henry et al., 2012 and 
Goossens et al., 2015), for this reason there are few new fully approved biomarkers. 
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The word “validation” has been used with different meaning between clinical or research 
settings (Suresh et al., 2011, Halling at el., 2012). It is therefore poignant to clarify where the 
results from chapter 4 and 5 fall in this continuum. The verb “validate” means to confirm or 
substantiate: in a research laboratory setting, a discovery generated from one methodological 
platform are reported as validated when reproduced on another, however from a wider 
perspective reproducing results on a second platform is actually “verification” of a finding, in 
that is not conclusive but supportive evidence warranting further research. Full “clinical 
validation” requires the rigor of multistage clinical trials including thousands of samples and 
multiple methodological platforms.  
 
Figure 34 (below) adapted from the National Cancer Institute (NCI 2016) portrays biomarker 
discovery as a continuum roughly divided into three stages. This encompasses both the clinical 
and academic/research perspective of either a stage 1 approach for discovery or a stage 2 
approach for clinical validation. By definition to verify is “to make sure of” or “demonstrate an 
accuracy or truth” in practicality verification step biomarker discovery is an analytical 
validation.  
 
Like Braem et al., (2011) The Office of Cancer Clinical Proteomics also recognise the 
imbalance in the past decade of thousands of reported biomarker discoveries compared to the 
handful of those that are clinically validated for any cancer, not just ovarian. As discussed in 
section 3.6 they also imply the reason for this to be due to the current status/model of research 
at the moment. Although larger multicentre cohorts or meta-analyses exist, the majority of the 
1000s of biomarker discoveries derive from independent research groups operating 
independently across the globe with seemingly large but in-fact insufficient sample numbers 
which are the maximum resources available to them.  
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Figure 34. The Biomarker Discovery to Validation Pipeline. 
Adapted from NCI, 2016). Stage 1 discovery stage data is commonly generated in a research lab from a non-
targeted bottom-up approach of thousands of potential variables on low sample numbers. Stage 2 Verification 
experiments entail hundreds of samples on a more targeted platform able to measure 10 – 100s of variables. Finally 
if evidence to substantiate a clinical trial results, the potential individual or sometimes panels of biomarkers are 
clinically validated via the standard four phase clinical trials, on thousands of prospectively collected patient 
samples. 
 
Figure 34 above summarises the biomarker discovery to validation pipeline as outlined by the 
NCI (NCI 2016). Stage 1 discovery stage research is commonly generated in a research lab 
from a non-targeted bottom-up approach of thousands of potential variables on low sample 
numbers such as; gene chip microarrays, mass spectrometry, 2D-PAGE perhaps on cell lines, 
or animal models. Variables indicating signatures with potential diagnostic value are taken 
forward to scale-up experiments to verify findings. Stage 2 verification experiments entail 
hundreds of samples often sourced from clinical patients conducted in a research laboratory on 
a more targeted platform able to measure 10-100s of analytes more accurately for example 
ELISA, Western blot, targeted mass spectrometry, PCR. Finally, if evidence to substantiate a 
clinical trial results the potential biomarkers may undergo full four phase clinical validation on 
prospectively collected clinical samples as part of a four phase clinical trial. 
 
It is at this point and in this context worth highlighting the rarity and value of the large cohort 
of samples collected prospectively for the UKCTOCs ovarian cancer screening study (Jacobs 
et al., 2004, Menon et al., 2014, Jacobs et al., 2015), this is a rare example of wide scale 
standardised sample collection. So far, these samples have been used for their primary purpose; 
the clinical validation of the Risk of Ovarian Cancer Algorithm (Jacobs et al., 
2015).Additionally, banked surplus samples have been utilised for the discovery and 
verification of more ovarian biomarkers (Russell et al., 2016). Successful completion of such a 
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collaboration of this scale in this context is rare (NCI 2016), the value of these specimens should 
be highlighted as specimens are suitable for all 3 stages of the biomarker discovery pipeline 
above, the samples and any data acquired from them should be utilised to its maximum potential. 
 
The analyses described herein (chapter 6), progress the Stage 1 potential biomarkers discovered 
in chapter 5, through Stage 2 analytical validation alternatively termed biomarker verification 
and their clinical implication investigated. Firstly the biomarkers discovered in chapter 5 are 
filtered for accuracy by validation on the same technological platform they were discovered: 
gene microarray expanded to a considerably larger sample cohort, the consequent/ filtered 
verified GIOs are investigated at a protein level using immunohistochemistry.  
 
Encouragingly, the 56 genes of interest generated from Chapter 5 include both known and novel 
candidates associating with ovarian cancer survival. Notably, overexpression of IGF2 in ovarian, 
and many cancers in general, is well documented. IGF2 and BMP4 are both independent 
predictors of survival in ovarian cancer (Sayer et al., 2005, Laatio et al., 2011). Increased IFG2 
ligand binding/activation is seen in ovarian cystic fluid (Kanety et al., 1996), which eventuates 
inactivation of molecular pathways key to cell invasion (Lee et al., 2005). IGFBP6 and IGFBP3 
are part of these pathways and the latter is downstream of a p53 cascade, TP53 being described 
as a “near-invariant” feature in ovarian cancer (Bowtell et al., 2015). BMP4 is a recognised 
mediator of ovarian metastasis and cell invasion (Thériault et al., 2007), overexpression 
indicative of poor prognosis, and, has been implicated in cisplatin Chemoresistance (Laatio et 
al., 2011). Others, namely NAV3, WTAP and MAPK, have been discovered in or implicated in 
cancers of other organs, but less so for ovarian (Carlsson et al., 2012, Little et al., 2000 and 
Wagner et al., 2009). In a large scale system-level meta-analysis of genomic data from The 
Cancer Genome Atlas (TGCA) TNFAIP6 and NAV3 amongst a panel of 15 other genes were 
implicated in ovarian cancer survival and possibly other cancers namely glioblastoma breast 
and kidney cancer in the context of their signalling pathways (Yang et al., 2013). 
  
Validation Strategies 
155 
 
6.2 Validation of Genes of Interest using Gene microarrays  
 
6.2.1. KM Plotter Introduction 
 
The Kaplan Meier Plotter (KM plotter) is a free meta-analyses web tool which allows 
researchers to assess the performance of their biomarkers in silica on a manually curated data 
bank of multiple cohorts of micro-array data (Gyorffy et al., 2103 and KM Plotter 2014).  
The curators source their databank from published micro array data and created a simple web 
interface, researchers enter the gene of interest and selected relevant parameters to tailor the 
sample subset to their needs. The service is available for breast (n=4142), lung (n=1464) and 
ovarian cancer (n=1715), although the final sample number is dependent on the parameters 
selected. 
 
Hypothesis 
 
H1-viii. Genes of interest will be verified to significantly associate with ovarian cancer survival 
time when investigated on a wider sample cohort. 
 
H0-viii. None of the genes of interest found to significantly associate with ovarian cancer 
survival time will be verified to do so when investigated on a larger sample cohort. 
 
6.2.2. Kaplan-Meier Methods / Utilisation Strategy 
 
A broad perspective was taken with regards to sample selection. The largest number of available 
samples were included in this analysis. This is primarily; due to the lack of ability to manipulate 
and select cases within the separate samples sets in the KM plotter.  
 
The gene code of each of the genes of interest was entered into the web-tool. For the first layer 
of analysis (round of elimination) the default search parameters were used. These were; to 
produce a report for all available gene probes, to auto-select the best cut off to separate short 
and long term survivors and to measure the output in progression free survival. No restrictions 
were made based on stage, histology, grade, CA125 levels, debulking status or 
chemotherapy/treatment pathway. The latest version of the web tool (version 2013) was used. 
One thousand one hundred and seventy one samples were available using these parameters. 
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A report was generated for every available gene probe, some probe gene codes only had one 
available probe set. The output was available and saved as a .pdf of the Kaplan Meier plot and 
a .txt file of what is reportedly the raw plot data. 
 
KM plotter gives a score for the reliability of the gene probes in the array that represent that 
gene, this is based on their criteria; probes are ranked as excellent, medium or poor. For clarity 
and to minimise any ambiguity in this analysis any probes ranked by KM plotter as “poor” were 
recorded by default however discounted for the purpose of evaluating each genes validator 
performance. 
Genes of interest were ranked by how many probes separated short and long term survival that 
matched the pattern observed in the analyses in chapter 5, i.e. higher expression associated with 
shorter term survival. The number of probes available for each gene of interest were considered. 
Those which were represented by more than one probe were given extra weight when choosing 
which were the best candidates for protein validation. 
See Appendix (Digital Appendix B) for evaluation of each gene and Table 15 for the summary 
of this evaluation.  
 
As a second round of analysis the exact process was repeated however with the patient group 
split cut-off set at median. This is a more stringent evaluation of the performance of the gene. 
A report generated from a gene represented by multiple gene probes may have all been 
significant predictors of survival using different time point cut offs. However if they are also 
all significant using the same cut-off this is a better representation of the whole gene.  
See Table 15 for a summary report of the performance of each of the genes of interest from 
chapter 5 ability to predict progression free survival in the KM plotter assembled cohort 
described above.  
KM plotter does not optimise the cut point based on p-value, at best it can find the best of five 
(lower quartile, lower tertile, median, upper tertile, upper quartile).  For this reason the p-value 
presented may not represent the optimal p-value for each probe. Given these uncertainties, and 
other caveats discussed above and below a p-value of 0.05 was used as the criteria to label a 
result “of interest”. A Bonferroni correction was considered (resulting in a p-value of 0.00089) 
of which most probes still pass; however some may be falsely excluded. More weight was 
placed on the qualitative aspects of the comparisons; number of probes, trends matching 
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hypothesis and probe quality. The results presented here are as is without correction or further 
exclusion. 
 
As a third round of analysis the above process was repeated with filters applied. These were 
selected to best fit the two data sets in chapter 5. Overall survival with a follow up threshold of 
5 years, Stage 3 and 4, serous with possible platin therapy. 
 
The sample cohorts utilised in KM plotter are; GSE14764 (n=80), GSE15622 (n=35), 
GSE18520 (n=63), GSE19829 (n=28), GSE23554 (n=28), GSE26712 (n=195), GSE30161 
(n=58), GSE3149 (n=116), GSE9891 (n=285), TCGA (n=565). 
 
6.2.3. Results and Discussion of KM Plotter Reports 
 
The first, low stringency, round of analysis removed genes whose probes expression did not 
match the trend observed in the data from chapter 5 and did not distinctly separate short and 
long term survivors using any group cut off point. A lenient p-value of <0.05 was used to 
maximise the number of genes that could remain in the analysis, given the caveats of using KM 
plotter, which are discussed below, the hierarchy of qualitative considerations were deemed to 
be of more value to evaluate a genes performance. Using the auto-select best cut off function, 
KM plotter does not reveal which group cut off was used for each individual probe leaving the 
possibility that they may be different from each other. Hence, information from this round may 
not appropriately represent, and is of limited use to assess, the performance of genes represented 
by multiple probes. For genes who had multiple probes strongly separating short and long term 
survival groups using an undisclosed group cut off the process was repeated using the median 
as a set group cut off for all probes. It is possible that the genes that were discounted at this 
level probes best performing cut off points were all the same but not the median, but this was 
not investigated further at this stage. The genes whose median expression used as a cut-off point 
to group patients support the findings of chapter 5 are DCN, EDNRA, IGF3, NAV3, TNFAIP6, 
WTAP and PPFIBP1. Genes that strongly supported trends in chapter 5 yet were only 
represented by one probe are BMP4, COLEC12, GJB1, GLT8D2, LDB2, MFAP4, OLFML3, 
PDZRN3, PJA2, RARRES2, TMEM45A, TNFRSF14, ZFHX4. 
 
Using the high stringency approach MAP4K4 was the only gene represented by multiple probes, 
and GJB1, GLT8D2, LDB2, MFAP4, OLFML3, PDZRN3, PJA2, RARRES2, TMEM45A, 
TNFRSF14, ZFHX4 by single probes.  
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Table 15. Summary of KM Plotter Analysis. The performance of each gene of interest (rows) in KM plotter is noted against 
increasingly stringent criteria (columns), a tick marks the criteria has been met.  
Comment 
[Gene 
Symbol] 
Is there more 
than one probe 
set available? 
Is the same trend in correlation 
with short or long term survival 
observed in all "reliable" probe 
sets for the gene? 
AND 
Does the trend match that 
observed in the meta-analysis? 
Is there a strong p-value for 
all available "reliable" 
probes? 
 
Using any cut-off 
Is there a strong p-value for all 
available "reliable" probes? 
 
Using median cut-off 
Score 
      
DCN ✓ ✓ ✓ ✓ 4 
EDNRA ✓ ✓ ✓ ✓ 4 
IGF2 ✓ ✓ ✓ ✓ 4 
NAV3 ✓ ✓ ✓ ✓ 4 
TNFAIP6 ✓ ✓ ✓ ✓ 4 
WTAP ✓ ✓ ✓ ✓ 4 
PPFIBP1 ✓ ✓ ✓ ✓ 4 
GJB1   ✓ ✓ ✓ 3 
LDB2  ✓ ✓ ✓ 3 
OLFML3   ✓ ✓ ✓ 3 
PDZRN3  ✓ ✓ ✓ 3 
PJA2   ✓ ✓ ✓ 3 
TMEM45A  ✓ ✓ ✓ 3 
GULP ✓ ✓ ✓   3 
IGFBP3 ✓ ✓ ✓  3 
INTS5 ✓ ✓ ✓   3 
SMC3 ✓ ✓ ✓  3 
FYN ✓ ✓     2 
HNRPDL ✓ ✓   2 
MAP4K4 ✓ ✓     2 
PPP3CA ✓ ✓   2 
SEMA3C ✓ ✓     2 
SPAG9 ✓ ✓   2 
TPM2 ✓ ✓     2 
ZNF45 ✓ ✓   2 
BMP4   ✓ ✓   2 
COLEC12  ✓ ✓  2 
GLT8D2   ✓ ✓   2 
MFAP4  ✓ ✓  2 
RARRES2   ✓ ✓   2 
TNFRSF14  ✓ ✓  2 
ZFHX4   ✓ ✓   2 
BACH1 ✓    1 
CTBP2 ✓       1 
DCTD ✓    1 
EFNB3 ✓       1 
FZD7 ✓    1 
H2AFV ✓       1 
HBD ✓    1 
NCOR1 ✓       1 
PKD2 ✓    1 
SCAMP1 ✓       1 
SFRP4 ✓    1 
SLC11A2 ✓       1 
SPCS3 ✓    1 
BACH2         0 
CDC25B     0 
CLIP3         0 
FHOD3     0 
FKBP14         0 
HIST1H3C     0 
IGFBP6         0 
LRRC17     0 
NDN         0 
PCDH17     0 
PTPRE         0 
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Table 15 above lays out how GOIS were ranked based on the consistency of the significance in 
their performance under increasingly stringent criteria.  
 
Genes were eliminated or progressed based on; the number of probes available to represent 
their identity, the reliability of these probes (as evaluated by KM plotter), if the trend of 
expression difference observation noted matches all the probes for each gene from the KM 
plotter cohort, and that of the data generated in Chapter 5.  
 
This evaluation was performed in two rounds, firstly using the “find best cut-off” option, 
meaning different probes may have been found to be of interest  based on different survival 
time cut-offs. This was considered and although not specified by the software can be deduced 
based on the number of cases assigned to each group, which is shown. The second round was 
repeated using the median cut-off only. This narrowed this list to a manageable number to take 
forward to the next round of validation/verification.  
 
Figure 35 displays the Kaplan Meier plots exported from KM plotter for each of the finalised 
genes. These were produced at the final elimination round where the median cut-off was applied 
to all. 
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Figure 35. Kaplan Meier Plots of the Highest Ranking Genes of Interest.  
IGF2 
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WTAP 
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EDNRA  
Probe 3. 204463 
EDNRA  
Probe 1. 204464 
NAV3 
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TNFAIP6 
Probe 1. 206025 
TNFAIP6 
206026  
DCN 
Probe 2. 211813  
DCN 
Probe 3. 211896 
PPFIBP1 
Probe 1. 214374 
EDNRA  
Probe 2. 216235 
DCN 
Probe 1.  (209335) 
WTAP 
Probe 2. 210285 
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From the KM plotter validation all using a median cut off. Only high quality probes were considered. Strong 
differential expression between long and short term survivors was seen probes for the following genes DCN p= 
0.0022, p=0.0000045, p=0.00059, EDNRA p=0.0011, p=0.014, p=0.0084, Two for TNFAIP6 p=0.018 and 0.026, 
WTAP p= 0.033 and 0.0099, IGF p=0.014, NAV3 p=0.015 and PPFIBP1 p=0.00023 
 
Figure 35 above visualises the significance of the difference in survival time of patients 
categorised by the expression of the GOIs in their tumours.  
 
6.2.3.1. Cautions and Caveats Considered when Interpreting KM Plotter Data 
 
KM plotter is a powerful tool however has limited functionality and its calculations are closed, 
that is, researchers input a question based on limited selection variable parameter selection and 
a statistical output is given. The rigidity of the analysis meant that several cautions and caveats 
were considered alongside the data generated from KM plotter. 
 
An important point to consider was if the microarray data of the multiple cohorts accessed by 
KM plotter was truly representative of the target population. Here, a broad perspective was 
taken with regards to sample selection. This means the samples used are not as tightly controlled 
as in chapter 5, where a thorough search of available data sets on Array express was performed 
and the two data set with the most comparable data patients selected. All available samples were 
included in this analysis, this is not ideal as different cancer stages, grades, histologies and 
treatment pathways are inadvertently/involuntarily included. The effect of this was limited by 
the decision to measure the output as progression free survival and not overall survival as this 
would have exacerbated the effect of effective/successful treatment pathways. This is primarily 
due to the lack of ability to manipulate and select within the separate samples sets. Certainly, 
the next step to fully validate these findings would be to download and explore all the data sets 
that are included in KM plotter however the data sets are sourced from various repositories, not 
all are freely available, and the scale of this is beyond the remit of this project. A specific 
example of the scale of the task is the KM plotter has the option to search each sample cohort 
separately, however, each gene code (of which there are often multiple aliases) must be 
manually entered and searched separately. This is very time consuming and may be a more 
worthwhile exercise in an investigation with a different, more specific, hypothesis for example 
an investigation of a cell-signalling pathway exploring how a gene is orchestrating a response. 
A limited number of genes could be manually tested in each selected data cohort ant the 
concordance of their performance observed. 
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This analysis is bias towards the genes represented by multiple gene probes within the arrays. 
For the current purpose of selecting a gene for protein validation, the simplest standard of 
multiple probes yielding the same trend was used to best indicate up or down-regulation of the 
gene. Future experiments could bring insight into genes only represented by one gene probe, or 
for genes with probes yielding highly significant yet conflicting trends, it is possible that these 
represent mutations or single nucleotide polymorphisms, however, verification of the 
suggestion of mutation is outside the remit of this project. Genes represented by one gene probe 
may be highly biologically meaningful however did not have the potential to perform well in 
the high stringency analysis. This shows how one probe is not best to represent the gene and 
would need to be addressed by a different array design, or, next generation sequencing (section 
2.2.1.2). 
 
This verification could be considered subtly bias as GEO26712 was not able to be removed 
from the sample set, however, although exactly how many overlapping cases is unknown and 
not able to be found out, the potential problematic subset can only account for a small portion 
of the total number n=1171. Evidence also strongly indicates that when the filters to stage were 
applied the GEO26712 samples were removed. Curiously, this raises concern as to why the 
curators of the database interpreted the data differently, as this information is clearly stated in 
the publication this data set was generated from (Bonome et al., 2008). This may suggest the 
database curators had access to more sample information than what was available to this study, 
or interpreted the given information in a different way. An unexpected benefit of discovering 
this was that it makes a cohort of n=808 that does not include GEO26712, a selection process 
the web tool was not able to do deliberately. From this observation and testing, MAP4K4 was 
the only gene with multiple probes that strongly separated short and long term survivors when 
the median cut off was applied. This could suggest that MAP4K4 is an indicator of poor overall 
survival in this particular sample subset: stage 3 and 4 serous ovarian cancers treated with 
platins. If more time was available repeating this on all the iterations of sample subsets may 
add to building a profile of its relevance to each category available i.e. gene stage, grade or 
treatment pathway.  
 
Five categories of group cut off are available. The web tool does not indicate which samples 
are allocated to each category when each cut of is applied. An “auto select best cut off” option 
is available and was utilised here, however it is possible that the best performing place, or most 
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appropriate place to divide the cohort is in between one of these 5. A desirable future feature 
for the web tool may include more iterations of cut off values, or even a sliding scale.  
 
It is also worth noting that at least one of the data sets available in KM plotter cohorts met the 
stringent criteria and were considered for the meta-analysis in chapter 5, however, rejected on 
the basis of lack of availability of sample information. The major shortcoming in using KM 
plotter to verify the findings of chapter 5 is that no considerations and adjustments to sample 
data are traceable/visible. 
 
Nonetheless, KM plotter provided a platform to perform a powerful analysis to begin the 
verification of observations generated in the meta-analysis of Chapter 5. Data has been 
compiled to evaluate and refine the list of GOIs to a manageable number for the next available 
method of verification.  
 
6.2.3.2. Indications for Further Research 
 
Encouragingly, the finalised genes include those whose expression are already reported to 
associate with ovarian cancer survival, such as IGF2 (Sayer et al., 2005, Kanety et al., 1996, 
Lee et al., 2005) NAV3 and TNFAIP6. Strong association of the expression of NAV3 and 
TNFAIP6 and survival time supports findings of Yang et al., (2013) who in a systems level 
analysis found these genes amongst 13 others to be prognostically significant in the context 
pathways involved in multicellular organisational development. 
 
From this data mining EDNRA and DCN gathered the strongest evidence to take forward for 
further validation; although their probes did not have the highest significance values, they were 
both represented by multiple probes graded as high quality, the measured expression of all of 
these show a consistent and strong difference for all to separate long and short term survivors. 
The next best performing GOIs; TNFAIP6; WTAP; IGF2; NAV3; PPFIBP1 were represented by 
fewer (two or one) probes. 
 
6.3. Translational Validation Strategy using Immunohistochemistry 
 
Rationalisation for selection of one GOI for Immunohistochemical validation. 
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The interest list was reduced from 56 using a larger cohort of gene array data (Chapter 6.2.). 
The members of the short list could vary depending on the choices of stringencies applied used 
however put succinctly, IGF2, WTAP, TNFAIP6, NAV3, DCN, PPFIBP1 and EDNRA were of 
interest as their expression was verified to correlate with survival time from ovarian cancer in 
an larger, independent sample. Progressing from these genomic findings, evidence of translated 
protein in ovarian tissue were considered. 
 
Two tissue microarrays of ovarian cancer were available to this project. One sourced from a 
clinical collaborator, an additional TMA was also sourced from Biomax. The former had 
survival data that would make comparable analysis of protein expression to the analysis of gene 
microarray data in chapter 5, the latter was the largest commercially available TMA containing 
ovarian cancer and accompanying information about cancer stage and grade, however lacked 
patient survival data. The clinical TMA would provide a better validation strategy however 
delays were encountered using this TMA inhibiting its use in this project. 
 
Although the visualisation of protein expression matching all finalised genes of interest would 
provide an informative, comprehensive/ holistic validation of the finding so far and insight for 
further work. It was unfortunately only feasible to investigate one marker further at first. 
 
A report was compiled for each of the seven finalised GOI. Various data sources were mined 
for more information namely GeneCards (GeneCards 2013) and The Human Protein Atlas 
(Pontén et al., 2008, Uhlen et al., 2010, Human Protein Atlas., 2014). GeneCards (2013) was 
particularly useful for this purpose, its comprehensive compilation of all aliases decreased the 
chance of overlooking important information related to each gene due to incomplete 
nomenclature information. Additionally the summarised representation of numerous other 
databases allowed insight into associated genes and proteins, genetics, domains, function, 
cellular location, ontology, known pathways, pharmacology of associated drugs, othologs, 
paralogs, variants, associated disorders and publications. A thorough review of all of these was 
outside the remit of this project and again many may have been overlooked entirely if it were 
not for the continual growth of this resource. The holistic view of information allowed 
hypothesising and insight of the genes of interest in a wider setting than the ovary or cancer 
tissue.  
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Table 16 below, lists each of the finalised seven GOI pseudonyms and briefly outlines how 
different nomenclature can hinder a thorough literature search and how information could be 
overlooked if it were in not for attempts to catalogue and centralise information. There are at 
least 11 aliases for each of the seven genes of interest, the number of search terms increases 
from 7 to over 77. 
 
Table 16. Aliases of the Finalised Seven Genes of Interest. (GeneCards 2015) 
Gene Code Full Name Aliases  
DCN Decorin 
Decorin Proteoglycan, Bone Proteoglycan II , SLRR1B, PG-S2 , CSCD, 
PG40, Dermatan Sulphate Proteoglycans II, Small Leucine-Rich Protein 1B, 
Proteoglycan Core Protein, DSPG2, PGII, PGS2. 
WTAP 
Wilms tumour 1 
associated protein 
Wilms Tumour 1 Associated Protein, Wilms Tumour 1-Associating Protein, 
Female-Lethal(2)D Homolog, WT1-Associated Protein, HFL(2)D, Putative 
Pre-MRNA Splicing Regulator Female-Lethal(2D, Wilms Tumour 1-
Associating Protein, Pre-MRNA-Splicing Regulator WTAP, PNAS-132, 
KIAA0105, MUM2. 
IGF2 
Insulin-like 
growth factor 2 
Insulin-Like Growth Factor, T3M-11-Derived Growth Factor, IGF-II, Insulin-
Like Growth Factor 2 (Somatomedin A), Chromosome 11 Open Reading 
Frame 43, Insulin-Like Growth Factor Type 2, Insulin-Like Growth Factor II, 
Somatomedin A, Somatomedin-A, C11orf43, PP9974. 
TNFAIP6 
Tumour Necrosis 
Factor, Alpha-
Induced Protein 6 
Tumour Necrosis Factor, Alpha-Induced Protein 6, TNF-Stimulated Gene 6 
Protein , Hyaluronate-Binding Protein, TNF Alpha-Induced Protein 6, TSG-6, 
TSG6, Tumor Necrosis Factor Alpha-Inducible Protein 6, Tumour Necrosis 
Factor-Stimulated Gene-6 Protein, Tumour Necrosis Factor-Inducible Gene 6 
Protein, Tumour Necrosis Factor Alpha-Induces Protein 6. 
NAV3 
Neuron Navigator 
3 
Neuron Navigator, POMFIL1, Pore Membrane And/Or Filament Interacting 
Like Protein, Unc-53 Homolog, STEERIN3 , KIAA0938 , Unc53H3, Pore 
Membrane And/Or Filament-Interacting-Like Protein 1, Steerin 3, Steerin-3. 
PPFIB1 
PTPRF interacting 
protein, binding 
protein 1 (liprin 
beta 1) 
PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1), Protein 
Tyrosine Phosphatase Receptor Type F Polypeptide-Interacting Protein-
Binding Protein 1, PTPRF-Interacting Protein-Binding Protein 1, HSGT2 , 
Protein-Tyrosine Phosphatase Receptor-Type F Polypeptide-Interacting 
Protein-Binding Protein 1, Liprin Related Protein-1, Liprin-Beta 1, Liprin-
Beta-1, KIAA1230, HSgt2p, SGT2, L2,  
EDNRA 
Endothelin 
receptor type A 
Endothelin Receptor Type A , HET-AR, ETA-R, ET-A, ETRA, ETA , 
Endothelin-1 Specific Receptor, Endothelin Receptor Subtype A, G Protein-
Coupled Receptor, Endothelin-1 Receptor, Endothelin A Receptor, ETAR, 
 
Insulin growth factor 2 (IGF2) is a growth factor from the insulin family, has already been 
reported in colon lung and breast cancer (Sayer et al., 2005, Kanety., et al., 1996). Higher gene 
expression of IGF2 has already been shown to be a poor predictor of survival in ovarian cancer 
(Sayer et al., 2005). 
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Sayer et al., (2005) lists four possible mechanisms which lead to higher levels being seen in 
short term survivors of ovarian cancer. These are; alteration of downstream binding proteins, 
loss of transitional suppression or increased transcriptional activation and loss of imprinting. 
IGF2’s synergistic interactions with endothelin’s and the endothelin axis which themselves 
have been characterised in the growth and neovascularisation of a number of cancers namely 
ovarian (Nelson et al., 2003). 
 
IGF2 overexpression has been shown in relation to the cancer progression (Sayer et al., 2005), 
thus it is less likely to be a good biomarker of the early stage disease and current investigations 
are underway investigating its potential to guide treatment by predicting poor responders who 
develop a resistance to platinum therapy. Evidence from cell line studies have shown IGF2 as 
a possible therapeutic target (Sayer et al., 2005). 
 
Endothelin receptor type A (EDNRA) is the primary receptor for endothelin-1. Activation of 
EDNRA initiates G protein coupled receptor (GPCR) mediated activation of 
phosophatidylinositol-calcium second messenger system. In animal studies it has been shown 
to be involved in, but not dependent on ovulation via its activation of Endothelin-2 (EDN2) 
(Bridges et al., 2010). Endothelin 1 is reported to be involved in long lasting vasoconstriction, 
polymorphisms in EDNRA are believed to be linked to migraines and scarlet fever (GeneCards 
2014). More relevantly, expression of EDNRA is reported to be associated with poor survival 
from ovarian cancer, cell line studies have directly implicated activation of EDNRA with EMT 
in ovarian cancer cell lines. Rosanò et al., (2011) detail endothilin-1 activation of EDNRA as 
having anti-apoptotic results via downstream activation of the PI3K Akt pathway. In an earlier 
study the group report the receptor agonist endothelin-1 to be present in high concentrations in 
ascites (Rosanò, et al., 2003). Both in vivo and in vitro inhibition of EDNRA increased 
sensitivity to platinum chemotherapies (Rosanò et al., 2011) making it a potential drug target. 
Antagonists of EDNRA have been shown in vitro and in vivo to increase tumour cell apoptosis 
(Rosanò, et al., 2003 and 2006) and inhibits mutagenic effect (Rosanò, et al., 2003), however, 
has not emerged from clinical trial. 
 
Decorin. There are multiple known splice variant transcripts for the DCN gene. The protein 
coded for is a small peptidoglycan found intracellularly and as part of the extracellular matrix. 
Decorin is involved in normal cellular matrix assembly binding to collagen fibrils. Decorin has 
been shown to be expressed in healthy human ovarian stroma and granulosa cells around 
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ovulation and in increased amounts in the corpus luteum at the time of mensuration and the 
levels detected were dependent on hormone signalling (Adam et al., 2012) Despite being listed 
as having growth suppressor activity on tumour cell lines (GenCards 2014, Nash et al., 1999) 
a recent review has compiled evidence from several sources/studies implying that Decorin is 
actually a tumour promoting factor itself, or by interaction with members of pathways involved 
in cell survival, cell growth, metastasis, and neovascularisation/angiogenesis (Bi and Yang 
2013). This juxtaposition/conflict of evidence may be explained by Bi and Yang (2013) being 
a collaboration of a wider body of information, whereas Nash et al., (1999) evidence is based 
solely on two cell lines. In another cell line study, Sherman-Baust et al., (2003) isolated cisplatin 
resistant ovarian cancer cell lines and explored collagen IVs role in chemoresistance, decorin 
alongside other genes were found to be contributing factors. More recently in a functional 
genomic study investigating myofibroblast from gastric cancer, increased amounts of DCN, 
alongside other proteins, were found to be consequent after stimulation by growth factors, one 
of which was IFG2, and that loss of ability to regulate secretion of these were associated with 
advanced cancer (Waugh et al., 2015). Similarly, the direct interaction of Decorin as a ligand to 
IGF2 has been demonstrated (Morcavallo et al., 2014). Most relevantly, in a quantitative 
proteomic analysis of ovarian cancer specimens sourced from primary debulking surgery, listed 
decorin, alongside 44 other proteins, to have significantly higher expression in the cases that 
would go on to develop chemo resistance (Pan et al., 2009) this evidence is most 
complementary to the findings above where increased expression of gene DCN significantly 
associate with a poorer prognosis from ovarian cancer. This evidence could also be used to 
support the suggestion that the shorter survival observed in chapter 5 and 6.2 is indeed due to 
chemo resistance. Further to this some of the additional co-expressing proteins of interest listed 
by Pan et al., (2009) were found to be significant in the meta-analysis of chapter 5 however 
eliminated in a round of increasing statistical stringency when refining to the genes with the 
strongest association with survival, namely IGFBP2. 
 
NAV3. The protein coded for by the Neuron Navigator 3 (NAV3) gene is expressed 
pronominally in cells of the nervous system. The NAV proteins as a group are involved in 
cytoskeletal dynamics (Carlsson et al., 2012) the C.elegans equivalent of human NAV3 is 
responsible for axon guidance during neuronal growth. Several point mutations in the NAV3 
gene have been identified which are missense and lead to increased or decreased activity. 
Maliniemi et al., (2011) demonstrate its silencing in keratinocytes events in upregulation of up 
to 20 genes involved in inflammation cell signalling and associates mutations in NAV3 to Basal 
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and Squamous cell carcinomas. Deletion of the NAV3 gene correlated with increased tumour 
metastasis (Carlsson et al., 2012). Bleeker et al, (2009) narrate NAV3 amongst a wider list of 
genes found to have mutated variants in melanoma and pancreatic carcinoma but not 
glioblastoma. Carlsson et al., (2012) demonstrate two mechanisms decreased NAV3 expression 
could promote colorectal tumour growth; firstly, colorectal cancer cells became less susceptible 
to growth control mechanisms and secondly became more sensitive to cell growth signals from 
inflammatory signals. Though this is at odds with the trend observed in the current data (derived 
from ovarian cancers) which shows increased expression of normal NAV3 associating with poor 
survival, is likely attributed to, thus not worth commenting on, the different tumour origins 
colorectal and ovarian.  
 
PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) (PPFIBP1) gene codes for a 
protein which is a member of the LAR protein-tyrosine phosphatase-interacting protein (liprin) 
family. This family of proteins are known to interact with transmembrane protein tyrosine 
phosphatases who are involved in mammary gland development and axon guidance. PPFIBP1 
has been shown to bind to and inhibit a calcium binding protein implicated in tumour 
invasiveness and metastasis (GeneCards 2014, NCBI 2015) and binds 14-3-3 a known onco-
protein (Benzinger et al., 2005). Most relevantly PPFIBP1 was listed amongst over 100 genes 
to be significantly differentially expressed between 19 serous papillary ovarian tumours and 15 
controls as measured by microarray (Bignottii et al., 2006). However this particular link was 
not followed up in any subsequent publication. 
 
Tumour Necrosis Factor, Alpha-Induced Protein 6 (TNFAIP6) gene codes for a protein of 
the same name, a member of the hyalouron-binding protein family. This domain is involved in 
cell migration and extracellular matrix stability. TNFAIP6 expression is induced by tumour 
necrosis factor alpha and interlukin-1, pro-inflammatory cytokines, and makes its inflammatory 
effects via its interaction with inter-alpha-inhibitor (GeneCards 2014, NCBI 2015). Despite its 
name it is involved in the normal function of the ovary in the expansion and fertility of the 
oocyte (Irving-Rodgers and Rogers 2006). TNFAIP6, alongside NAV 3 and 13 other genes, was 
included in Yang et al. (2013) in a list of genes with high centrality gene expression network 
analysis in a wide reaching study of glioblastoma, breast, kidney and ovarian cancer. Zhang et 
al., (2011) finds a strong correlation between the expression of TNFAIP6 and YAP which was 
demonstrated to confer the characteristics of chemo-resistance in ovarian cell lines although its 
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association was not statistically significant on its own after correcting for multiple testing this 
observation was still noteworthy.  
 
Wilms tumour suppressor gene (WTAP) codes for the protein Wilms tumour suppressor 
associated protein expressed across the nucleoplasm, implication in transcription and post-
transcriptional regulation of other cellular genes via mRNA splicing regulator (GeneCards 
2014). WTAP specifically interacts with Wilms Tumour suppressor gene (WT1), Wilms 
tumours are a rare paediatric condition in which nephroblastomas occur as a consequence gene 
mutation causing abnormal development of the kidney or genitourinary system (Little et al., 
2000). Jin et al., (2012) identify WTAP to be overexpressed in glioblastomas as well as 
demonstrating via knockdown experimentation its regulatory role in cell migration and invasion. 
WTAP has been included in a panel of genes representing stem cell characteristics in a study 
aiming to isolate subpopulations of breast cancers (Christgen et al., 2007). Helleman et al., 
(2006) listed WTAP as of interest in a study investigating genes responsible for chemo-
resistance in ovarian cancer, however was not shortlisted it for further investigation. 
 
For an ortho- and ontologic summary, each of the short listed GOIs were searched using the 
KEGG web tool (see section 2.2.3) the results of which are summarised in Table 17. Of the 7 
GOIs three (DCN, EDNRA and IGF2) were included in at least one functional pathway. 
Pathways relating to cancer were adapted and included below: 
 
Table 17. KEGG Pathways found to be Associated with the Shortlisted Genes of Interest. Bold text 
indicates any which include cancer and are adapted below. Genes are in alphabetical order. 
Gene Code 
KEGG Orology 
Code 
KEGG 
Pathway Code Participant Pathways 
DCN K04660 
ko04350 
ko05205 
TGF-beta signalling pathway 
Proteoglycans in cancer 
EDNRA K04197 
ko04020 
ko04022 
ko04024 
ko04080 
ko04270 
ko04924 
ko05200 
Calcium signalling pathway 
cGMP-PKG signalling pathway 
cAMP signalling pathway 
Neuroactive ligand-receptor interaction 
Vascular smooth muscle contraction 
Renin secretion 
Pathways in cancer 
IGF2 K13769 ko05205 Proteoglycans in cancer 
NAV3 89795 None found No KEGG pathways listed 
PPFIB1 None found n/a  
TNFAIP6 K19018 None found No KEGG pathways listed 
WTAP None found n/a No KEGG othologs listed 
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Both DCN and IGF2 pathways were categorised as Proteoglycans in Cancer: DCNs pathway 
code Ko05205 is subcategorised as Chondroitin sulphate/ Dernatab sulphate proteoglycan 
(GSPG/DSPG) (Figure 36), IGF2 orthologue code ko05205 is subcategorised as of Heparan 
sulphate proteoglycans (HSPGs) (Figure 36). EDNRA pathway code is ko05200 under the 
category Pathways in Cancer.  
 
The following figures have been adapted from the KEGG web tool (KEGG 2015), the 
limitations of which have been mentioned above - that the reductionist view to construct such 
diagrams from currently available data cannot yet accurately represent biology. Never the less, 
putting the genes of interest into context of current knowledge known pathways holds some 
insight: the colour coding of the pathway end points is that of the hallmarks of cancer diagram 
from Hanahan and Weinberg (2011). Green referring to sustaining proliferative signalling, 
brown; evasion of growth suppressors, black; activation invasion and metastasis, blue; 
immortality, red; angiogenesis, grey; resisting cell death, purple; deregulating cellular 
energetics, pink; avoiding immune destruction orange; tumour-promoting inflammation and 
blue genome instability.  
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Figure 36. Verified GOIs Location in the Proteoglycans in Cancer pathway.  
Adapted from KEGG 2015, Genes of interest have been highlighted in red text. Hallmarks endpoints that are 
relevant to cancer have been highlighted with white text and a background linking the characteristic to a 
hallmark of cancer. In-between is known cellular processes as annotated by KEGG (2016). Refer to the key 
above for detail: 
 
The KEGG pathway figures depict the direct interactors with the GOIs as well as the consequent 
downstream effects in the context of cancer pathways. The reader is reminded that any gene or 
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protein or factor depicted in the diagram is not limited to the interactions seen. For focus, these 
are KEGG pathways of cancer only. 
 
Direct interaction of the GOIs: In the top left of Figure 36, Upon ligation, DCN (red text) is 
seen to activate IGF-1, TLR2 and 4, RTK’s and Met, or to have an inhibitory effect on TGF-
B1. IGF2 (red text lower left of Figure 36) binds and activates IGF-1R or GPC3. As Figure 37 
(below) is an adaptation of the KEGG Pathways in Cancer map; the tag EDNRA (red text) has 
been added onto the map in the place of a g-generic protein coupled receptor (GPCR) label that 
could be any or all of EDNRA, EDNRB, BDKRB2 or BDKRB1. These are shown to be ligated 
by Thrombin, Endothelin 1 or Angiotensin II but all effect by activation of GNAQ or GNA11 
a common transducer of transmembrane signals 
 
In the context of cancerous phenotypes: IGF2 signalling events to increased cell proliferation 
and cell survival cell signal cascade involving direct interaction and activation with IGF-1R 
which downstream signalling events in phosphorylation of ERK, a mitogen activated protein 
kinase, which has multiple actions causing a cellular activation cascade as mentioned above 
and documented in Hanahan and Weinburg (2011). 
 
DCN is also shown to activate cell survival and proliferation via either indirect activation of 
IGF-1R, PI3K then the mTOR signalling pathway, or by activation of EGFR, MAPKinases. 
Confusingly activation of the same pathway also initiates apoptosis, evading apoptosis is a 
hallmark of cancer. Finally DCN is seen to inhibit the VEGF angiogenesis signalling pathway, 
both by activation RTK to inhibit the activation of B-cadherin which would stimulation 
production of VEGFA, or by activation of THBS1 inhibiting MMP2 oro 9 then consequently 
VEGFA. This mixture of tumorigenic and anti-tumour characteristics echoes the conflicting 
findings of reported by Nash et al., (1999) and Bi and Yang (2013) when trying to understand 
the role of DCN in ovarian cancer. 
 
Figure 37 The GPCR denoted by EDNRA is seen to transduce an extracellular signal to 
intracellular signal cascade ending with sustained angiogenesis and cell proliferation. The 
cascade of activated proteins/ molecules triggered by EDNRA ligation diverges at several points 
however converge along the Ras – Raf - MEK - ERK cell activation pathway where 
phosphorylated ERK phosphorylates c-Jun, c-Fos, c-Myc or Ets1 which in turn glycosylates 
either VEGGF, MMPs or IL8 to stimulate angiogenesis, or, Cyclin D1 CDK4 to add to cell 
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proliferation signals. RAS also directly activates RASSF1 mutations in which have been linked 
to downstream mechanisms evading apoptosis 
 
All three KEGG figures highlight the complexity of systems of gene, protein and small 
molecule interactions they portray, and how being forced into a reductionist model for focus on 
one or a few genes or molecules to represent a large system for biomarker discovery is 
challenged to represent the full picture. 
 
Additionally, cropped from Figure below, KEGG has the function to limit the view of the 
pathway to one based on evidence for some select, specific cancers; colorectal, pancreatic, 
glioma, thyroid acute myeloid leukaemia, chronic myeloid leukaemia basal cell sarcoma, 
melanoma, renal cell carcinoma, bladder cancer, prostate cancer, endometrial cancer small cell 
lung cancer and non-small cell lung cancer. Ovarian cancer has not yet been mapped in this 
way. All KEGG figures here are generic to cancer. 
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Figure 37. Verified GOIs in the Pathways in Cancer pathway. Adapted from KEGG GOI and Hallmarks have been highlighted as in Figure 36 above. 
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In a wider, bioinformatic study of microarray data akin to that in Chapter 5, Zhang et al., (2013) 
conducted network analysis of gene expression of ovarian cancer, two of the genes found to be 
of interest DCN and EDNRA overlapped with the findings however focused on a different gene 
to verify their findings, FBN1. One data set used by Zhang et al., (2013) overlapped with those 
used above. This could be interpreted as promising, further validation of the differential 
expression of DCN and EDNRA together based on evidence from other methodologies and 
analysis techniques. 
 
From this brief review, Decorin and EDNRA were the favoured candidates for preliminary 
future work. The Human Protein Atlas (Pontén et al., 2008, Uhlen et al., 2010, Human Protein 
Atlas., 2014) was searched for existing experimental evidence of protein expression of the 
respective genes, specifically in normal ovarian, ovarian cancer or any other cancer.  
 
EDNRA was finalised as the available antibody contained the most validation literature with it. 
Proof of the specificity of an antibody to its ligand increases the confidence any further findings 
infer. 
 
Additionally, it was noted that EDNRA has several approved and one experimental antagonist 
drugs (GeneCards 2016, Drug Bank) where DCN only has one experimental listing. Non-of the 
PubMed links for any of the EDNRA drugs/compounds were considered with ovarian cancer 
although in a slightly expanded search, acetylsalicylic acid (Aspirin) (the mechanism of action 
on EDNRA is not listed) has been extensively investigated epidemiologically protective effects 
against several cancers (Tavani et al., 2000). These provide a direction for future work in the 
event that protein validation were to yield evidence supporting a link to ovarian cancer survival. 
If EDNRA were over activated in some ovarian cancers hypothetically this could be exploited: 
competitive antagonism of could block the binding of the native stimulatory ligand Endothelin-
1, stifling the angiogenic and cell proliferative downstream effects adding to Rosanò et al., 
(2011) cell line study reporting inhibition of EDNRA renders cell more susceptible to 
chemotherapy.  
 
EDNRA was rationalised to be the first candidate for verification of its protein expression in 
ovarian tissue: IGF2 is already well documented in ovarian cancer (Kanety et al., 1996, Sayer 
et al., 2005), as is BMP4 (Thériault et al., 2007, Laatio et al., 2011) thus further experimentation 
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was unlikely to yield novel information in relation to ovarian cancer. Thus EDNRA would 
provide interesting addition to current knowledge however. 
 
A common theme observed when collating information of the 7 genes of interest was EMT. The 
phenomena EMT, in which well differentiated epithelial cells revert back to a less differentiated 
form has previously been implicated cisplatin based drug resistance in ovarian cancer in cell 
line studies (Rosanò et al., 2011). The exact role of EMT in ovarian cancer and cancer in general 
is not fully characterised. Conflicting evidence has come to light in ovarian cancer, the presence 
of known EMT markers E-cadherin and SNAIL have been linked with invasive phenotypes of 
ovarian cancer (Park et al., 2008), whereas Miow et al., (2014) found that ovarian cancer cell 
lines with a more mesenchymal status were more susceptible to cisplatin than their epithelial 
counterparts. 
 
6.3.1. Protein Verification of EDNRA in Ovarian Tissue 
 
Hypotheses: 
 
H1-ix. Protein expression of EDNRA will be found to be different between different stages, 
grades and histologies of ovarian cancer samples. 
 
H0-ix. No difference in protein expression will be observed between different stages, grades 
and histology’s of ovarian cancer. 
 
6.3.2. Immunohistochemistry Method 
 
EDNRA was selected through a review of literature and web based databases (see section 6.3 
and Table 16 above). Anti-EDNRA antibody HPA014087 (Atlas Antibodies Stockholm, 
Sweden 2012) was sourced via the Human Protein Atlas Website (Human Protein Atlas, 2014), 
where, antibody quality and specificity is requisite. Product information document included 
data from IHC and western blot using a human cell lysate to demonstrate the antibodies quality 
and specificity (Atlas Antibodies 2012).  
 
The largest commercially available tissue MicroArray of ovarian cancer samples was purchased 
from Biomax (OV6161 from, UD Biomax inc). Further information is available at 
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http://www.biomax.us/tissue-arrays/Ovary/OV6161 (Biomax 2014). This high density 
microarray contains 616 specimens of paraffin embedded ovarian tissue mounded onto one 
glass slide. It contains; 280 cases of adenocarcinoma of varying stage and grade; 28 normal or 
normal adjacent tissue, 13 clear cell carcinomas and 1 transitional cell carcinoma. 
 
Alongside appropriate controls the TMA was deparaffinised then dehydrated by heating to 60°C 
for 10 min using a hot plate, then within 10 min the slides were transferred into a rack to fit the 
Leica Autostainer XL and pre-set function automated the following washes with gentle agitation 
and rinsing: two 5 min Xylene, followed by three two min washes in Industrial Methylated 
Spirit finished with 5 min in ddH20. For antigen retrieval, slides were boiled in in a citrate buffer 
(pH 6). Following this, slides were gradually cooled and gently re-introduced into ddH20 where 
the slides were carefully and manually loaded into the Sequenza staining system. As per the 
manufacturer’s recommendations care was taken to ensure no part of the slide ever dried, no 
micro-air bubbles appeared between the slide and the cover and a check was conducted that the 
speed the liquid drained past each slide was in a similar rate for all of the slides. The Novolink 
Polymer detection system (RE7200-CE, Leica Biosystems, Bucks, UK) was used for staining: 
This consisted of the following incubations each interspersed with two 5 min washes of tris-
buffered saline (TBS). Non-specific binding was minimised with room temperature 5 min 
peroxidase block, an 80 min room temperature incubation with the primary antibody 
HPA014087 (Atlas Antibodies Stockholm, Sweden) at a 1 in 40 dilution exposed the antigen to 
the antibody, a 30 min room temperature incubation in the post primary reagent containing 
secondary antibodies with conjugate peroxidase enzyme amplified the signal from any antigen-
bound primary antibody. The antigen-bound primary-secondary-conjugate construct catalysed 
the hydrogen peroxide into a localised brown stain during a 5 min room temperature exposure 
to freshly prepared 1 in 20 dilution of diaminobenzidine (DAB) working solution. Finally a 6 
min incubation with the haematoxylin reagent as a counterstain enabled visualisation of nucleic 
material and cell architecture. After staining the slides were fixed using sequential alcohol 
washes in reverse order as those described above for de-waxing and de-parafinisation. A glass 
coverslip was sealed on with DPX Mountant for permanent storage and histology.  
 
The concentration of the Anti-EDNRA primary antibody was determined by a prior 
optimisation experiment conducted on incomplete offcuts of a breast tissue TMA and one 
additional test slide of ovarian tissue purchased from Biomax. The negative control processed 
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alongside omitted primary antibody using purely antibody diluent in its place. This control 
ensured any staining observed in the test slide was a consequence of the primary antibody.  
 
To meet the criteria for the stained TMA to be scored a range of staining intensities was seen in 
tumour cells in cores across the slide. Cores had to contain 100 tumour cells to be considered 
viable for scoring. A trained technician blindly scored the TMA on a categorical basis assigning 
a number to the overall intensity of stain seen in the tumour (0 negative, 1 weak, 2 moderate 
and 3 intense). The scores were blindly validated and accepted by a pathologist familiar with 
ovarian malignancies who scored a proportion and found a significant consensus.  
 
6.3.3. Results and Discussion of Immunohistochemical Staining of EDNRA in Ovarian 
Tissue. 
 
To recap, a tissue microarray containing 616 cores of ovarian tissue was 
immunohistochemically stained for the coded protein of EDNRA; a gene whose expression was 
found to significantly associate with ovarian cancer patient survival time. A full range of 
staining intensity was observed across the TMA (Figure 38). The inclusion of appropriate 
controls ensured that the intensity of stain observed could be interpreted as the relative 
expression of the EDNRA protein.  
 
 
Figure 38. Range of Staining Intensity Observed in EDNRA Stained Ovarian Tumour Tissue from the 
Biomax OV6161 TMA.  
a) b1 adenocarcinoma scored as no stain seen b) b3 serous adenocarcinoma scored as weak c)b28 serous 
papillary adenocarcinoma scored as moderate d)b17 serous papillary adenocarcinoma scored as strong 
 
In brief, EDNRA protein expression was clearly increased in the later stage, higher grade 
disease (Figure 39,Figure 40 and Table 18 and Table 19). When separated by histology it was 
also an apparent difference in expression, however inconsistent sample numbers limited the 
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conclusions that could be drawn from this. Additionally it was noted that distinct staining 
patterns were seen.  
 
 
 
Figure 39. EDNRA Protein Expression in Ovarian Tissues of Different Stage.  
Bar graph of protein expression score and cancer stages. 
 
Table 18. T-test Results Comparing the Significance of Protein Expression Differences 
Between Cancer Stages. 
  Normal Stage 1 Stage 2 Stage 3 Stage 4 
 Normal   -  2.19741E-05 1.01E-08 2.20733E-11 1E-06 
 Stage 1  -   -  0.000137 8.50814E-08 0.000137 
 Stage 2  -   -   -  0.150605215 0.998291 
 Stage 3  -   -   -   -  0.316994 
 Stage 4 
 -   -   -   -   -  
 
Figure 39 and Figure 40 demonstrates that significantly more EDNRA was present in all 
cancerous ovarian tissue when compared with normal ovarian tissue. Stage 1 has significantly 
less than Stage 2, 3 and 4. In this data a clear increase in expression is observed from normal to 
Stage 1, 2 and 3, this trend plateaus, or marginally decreases at Stage 4. The change in trend 
observed in Stage 4 could be genuine/represent the larger population, however, the considerably 
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smaller sample number in this group should be noted devaluing the confidence in representing 
a larger population. 
 
 
Figure 40. EDNRA Protein Expression in Ovarian Tissues of Different Grades. 
A bar graph of protein expression score grades NAT=normal ovarian tissue. 
 
Table 19. T-test Results Comparing the Significance of Protein Expression 
Differences Between Cancer Grades. 
p-value All NAT All Grade 1 All Grade 2 All Grade 3 
All NAT  -  0.0053026 4.648E-06 1.36E-10 
All Grade 1  -   -  0.244156689 0.0075964 
All Grade 2  -   -   -  0.079898109 
All Grade 3  -   -   -   -  
 
When separated by grade, only the difference between Grade 1 and Grade 3 is statistically 
significant, however a clear upward trend is observed progressing through the grades (see 
Figure 40).  
 
A comprehensive set of T-tests comparing each of the cancer subtypes revealed a wide variation 
in expression (see Figure 41 and Table 20).  
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Figure 41. EDNRA Protein Expression in Ovarian Tissues of Different Histology. 
A bar graph of protein expression score and cancer histology (x axis). 
0.0
1.0
2.0
3.0
A
d
en
o
ca
rc
in
o
m
a
 (
n
 =
 1
4
)
A
d
en
o
ca
rc
in
o
m
a
(f
ib
ro
u
s 
ti
ss
u
e 
an
d
 b
lo
o
d
 v
es
se
l)
…
A
d
en
o
ca
rc
in
o
m
a
(n
 =
 1
3
)
C
an
ce
r 
ad
ja
ce
n
t 
n
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
e
(n
 =
 2
0
)
C
le
ar
 c
el
l 
ca
rc
in
o
m
a
(n
 =
 2
6
)
E
n
d
o
m
et
ri
o
id
 a
d
en
o
ca
rc
in
o
m
a
 (
n
 =
 2
2
)
E
n
d
o
m
et
ri
o
id
 c
ar
ci
n
o
m
a
(n
 =
 2
)
M
u
ci
n
o
u
s 
ad
en
o
ca
rc
in
o
m
a
 (
n
 =
 8
7
)
M
u
ci
n
o
u
s 
p
ap
il
la
ry
 a
d
en
o
ca
rc
in
o
m
a
(n
 =
 2
)
N
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
e
 (
n
 =
 6
)
N
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
e
w
it
h
 c
o
rp
u
s 
al
b
ic
an
s…
S
er
o
u
s 
ad
en
o
ca
rc
in
o
m
a
 (
n
 =
 3
3
9
)
S
er
o
u
s 
ad
en
o
ca
rc
in
o
m
a 
w
it
h
 n
ec
ro
si
s
 (
n
 =
 6
)
S
er
o
u
s 
p
ap
il
la
ry
 a
d
en
o
ca
rc
in
o
m
a
(n
=
6
8
)
T
ra
n
si
ti
o
n
al
 c
el
l 
ca
rc
in
o
m
a
(n
 =
 3
)
S
ta
in
in
g
 S
co
re
 (
0
=
n
eg
at
iv
e
-3
=
st
ro
n
g
)
EDNRA Intensity in Biomax TMA Sparated by Histology
A
d
en
o
ca
rc
in
o
m
a
(n
 =
 1
4
)
A
d
en
o
ca
rc
in
o
m
a(
fi
b
ro
u
s 
ti
ss
u
e 
an
d
 b
lo
o
d
 v
es
se
l)
(n
 =
 7
)
A
d
en
o
ca
rc
in
o
m
a
(n
 =
 1
3
)
C
an
ce
r 
ad
ja
ce
n
t 
n
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
e
(n
 =
 2
0
)
C
le
ar
 c
el
l 
ca
rc
in
o
m
a
(n
 =
 2
6
)
E
n
d
o
m
et
ri
o
id
 a
d
en
o
ca
rc
in
o
m
a
(n
 =
 2
2
)
E
n
d
o
m
et
ri
o
id
 c
ar
ci
n
o
m
a
(n
 =
 2
)
M
u
ci
n
o
u
s 
ad
en
o
ca
rc
in
o
m
a
(n
 =
 8
7
)
M
u
ci
n
o
u
s 
p
ap
il
la
ry
 a
d
en
o
ca
rc
in
o
m
a
(n
 =
 2
)
N
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
e
(n
 =
 6
)
N
o
rm
al
 o
v
ar
ia
l 
ti
ss
u
ew
it
h
 c
o
rp
u
s 
al
b
ic
an
s
(n
 =
 2
)
S
er
o
u
s 
ad
en
o
ca
rc
in
o
m
a
(n
 =
 3
3
9
)
S
er
o
u
s 
ad
en
o
ca
rc
in
o
m
a 
w
it
h
 n
ec
ro
si
s
(n
 =
 6
)
S
er
o
u
s 
p
ap
il
la
ry
 a
d
en
o
ca
rc
in
o
m
a
(n
=
6
8
)
T
ra
n
si
ti
o
n
al
 c
el
l 
ca
rc
in
o
m
a
(n
 =
 3
)
Validation Strategies 
182 
 
Table 20. T-test p-values Comparing EDNRA Protein Expression Between Cancer Histologies. p-values of  ≤ 0.05 are indicated in green italics, underline is added if still 
significant after Bonferroni correction is considered for the 98 tests p-values ≤  0.000512 
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(n
=
3
) 
Adenocarcinoma fibrous  
(n=14) 
 -  0.9111 0.1777 0.3656 0.0068 0.0551 0.0005 0.0708 0.1930 0.3490 0.0785 0.0058 0.8052 0.0000 0.0005 
Adenocarcinoma (fibrous 
tissue and blood vessel) (n=7) 
 -   -  0.0865 0.3726 0.0004 0.0115 0.0002 0.0124 0.2840 0.3312 0.0789 0.0001 0.7189 0.0000 0.0002 
Adenocarcinoma sparce 
(n=13) 
 -   -   -  0.0080 0.0236 0.3437 0.0092 0.3667 0.1108 0.5234 0.5244 0.0510 0.3413 0.0000 0.0092 
Cancer adjacent normal 
ovarian tissue (n=20) 
 -   -   -   -  0.0000 0.0004 0.0000 0.0003 0.4486 0.0702 0.0179 0.0000 0.2894 0.0000 0.0000 
Clear cell carcinoma  
(n=26) 
 -   -   -   -   -  0.0917 0.2783 0.0272 0.0362 0.0340 0.5868 0.0911 0.0201 0.2286 0.2783 
Endometrioid 
adenocarcinoma (n=22) 
 -   -   -   -   -   -  0.0482 0.9203 0.0773 0.2060 0.5868 0.3165 0.1234 0.0003 0.0482 
Endometrioid carcinoma 
(n=2) 
 -   -   -   -   -   -   -  0.0525  -  0.0004 0.0955 0.0561 0.0086 0.2568  -  
Mucinous adenocarcinoma 
(n=87) 
 -   -   -   -   -   -   -   -  0.0967 0.2528 0.8860 0.0586 0.1418 0.0000 0.0525 
Mucinous papillary 
adenocarcinoma (n=2) 
 -   -   -   -   -   -   -   -   -  0.0338 0.0955 0.0228 0.3153 0.0004  -  
Normal ovarian tissue 
(n=6) 
 -   -   -   -   -   -   -   -   -   -  0.1340 0.0535 0.6643 0.0001 0.0004 
Normal ovarian tissue with 
corpus albicans (n=2) 
 -   -   -   -   -   -   -   -   -   -   -  0.8530 0.2488 0.2030 0.0955 
Serous adenocarcinoma 
(n=339) 
 -   -   -   -   -   -   -   -   -   -   -   -  0.0202 0.0000 0.0561 
Serous adenocarcinoma 
with necrosis (n=6) 
 -   -   -   -   -   -   -   -   -   -   -   -   -  0.0000 0.0086 
Serous papillary 
adenocarcinoma (n=68) 
 -   -   -   -   -   -   -   -   -   -   -   -   -   -  0.2568 
Transitional cell carcinoma 
(n=3) 
 -   -   -   -   -   -   -   -   -   -   -   -   -   -   -  
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The small sample number in some subgroups detracts from the confidence of them to represent 
a larger population. Notable significant (p≤0.5) expression difference between subgroups of 
more sizable/comparable populations numbers include; the significant higher expression in 
Clear cell carcinoma (n=26) than Mucinous adenocarcinoma (n=87) and Adenocarcinoma 
(n=14). As patients with clear cell cancers have a poorer prognosis than those with a serous 
carcinoma (Matsuzaki et al., 2015), this result suggests a potential causative link between 
higher EDNRA expression and poor prognosis consequent of increased cell proliferation, 
resistance to platinum based chemotherapy and traits of EMT also observed in clear cell 
(Matsuzaki et al., 2015). It should be reiterated here that the data in (Chapter 5) selection criteria 
did not include clear cell carcinoma so this observational link can only be speculative.  
 
Significantly (p≤0.5) there was higher expression in Serous papillary adenocarcinoma (n=68) 
than Mucinous adenocarcinoma (n=87), Non-serous both fibrous and sparse adenocarcinomas 
(n=14 and n=13 respectively) and Non-papillary serous adenocarcinomas (n=339). Thus, a link 
between EDNRA expression and papillary formation could be deduced from this, though is also 
likely explained by the higher ratio of endothelial cells present in in papillae.  
 
IHC has so far been used for proteomic validation of one GOI, this is a very reductionist 
evaluation of what was a panel of genes, all found to be of interest and ranked accordingly. In 
time they could all be validated via IHC but at financial and significant resource cost. 
Additionally as mentioned earlier, Picotti et al., (2013) warns not to put immune-techniques on 
a pedestal and criticises that immune based or antibody reliant results are not reproducible when 
tested extensively as cross reactivity is common.  
 
A platform for proteomic validation that could negate large cost, lengthy time and low 
confidence/variability of antibodies would be more ideal, such as a mass spectrometry MRM 
based assay of all the GOIs on a large and appropriate data set available via collaboration. 
 
6.4. Discussion of Verification Strategies 
 
The aim of verification was to confirm or refute the significant association of 56 genes of 
interest to survival time from ovarian cancer identified in chapter 5.  
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Fifty six genes identified to be of interest from a biomarker discovery experiment (Chapter 5) 
were verified in a two stage approach. The majority were filtered out over a validation at 
genomic level using KM plotter to reproduce the findings in a larger sample cohort (Chapter 
6.2). The remaining 7 were then evaluated to prioritise an order of importance for verification 
by IHC. EDNRA was selected and IHC carried out one and work has begun on a second ovarian 
TMA.  
 
If any of the genes considered to be “of interest” in chapter 5 had been detected in the LC-
MALDI-MS analysis in chapter 3, a retrospective assessment of their presence / absence in 
cancer, control and benign groups could have made an interesting, though extremely limited 
proteomic validation. Considering the restricted number of potentially identifiable proteins (120) 
the chances of this list containing the coding proteins of the GOIs were slim. Further to this, the 
questionable confidence in those identities (Chapter 3 and 4) would have unfortunately further 
limited their value. 
 
Validation via KM-Plotter was a valuable approach, to access, collate and annotate this data 
without this web tool would not have been possible. However, the limitations of this are those 
that are inherent with microarray technology and combining cohorts of different origins. Put 
concisely, microarray technologies are limited to detect genes which match predesigned probes 
on the microarray chip. A novel oncogene will not be detected this way, only an association of 
a known gene to an available variable i.e. survival. Any gene is only represented by a number 
of probes on the array, and these vary in number and quality from array to array. The “full 
genome” microarray chips only represent the known genome, and do not accommodate 
detection of anything other than that on the chip such as single nucleotide polymorphisms (SNP) 
which may be key in identifying a patient subgroup within a cohort. Next generation sequencing 
of the same sample cohorts would be extremely insightful, especially if commonalities between 
microarray and next gen were present, however such data sets a far rarer and more complex. 
The sample cohorts available in KM-Plotter are extensive, selection options facilitate the 
filtering of the sample group and statistical parameter i.e. cut-off, however, full patient data is 
not accessible, infinite extraneous variable may unknowingly be effecting conclusions.  
 
For example, in KM plotter, when selecting an option to compare one treatment in a meta-
analysis of two cohorts there is no clarification of the proportion of which cohort has been 
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treated, thus the measurement may be of something between the cohorts – an extraneous 
variable e.g. ethnicity, and not the desired test parameter e.g. treatment used. 
 
IHC of EDNRA yielded significant findings associating its expression with ovarian cancer stage, 
grade and papillary histology. The TMA stained in chapter 6.3 could be explored more 
extensively, for example the scoring could be repeated using an H-Score to assign a continuous 
rather than categorical value for intensity. Using an H-score helps to weight a score if more than 
one staining intensity is observed in each case/core. The proportion of each intensity observed 
as a percentage is weighted by its strength i.e. the percentage observed as “high” would be 
multiplied by 3, “medium” by 2 and “low” by 1. This system is vastly more time intensive and 
is vulnerable to operator bias. Though appealing to apply to this study, repeating scoring using 
H-scoring may be of limited use. It may benefit the overall research strategy better it the 
potential time and resources were spent staining a TMA with survival data available, or, 
immunostaining for a different GOI, namely Decorin. 
 
Proteins coded by genes with multiple probes of interest that qualified for investigation as 
protein validation were: DCN, EDNRA IGF2, NAV3, TNFAIP6, WTAP and PPFIBP1. IGF2 
and WTAP were discounted from further IHC investigation as they are well reported in cancer 
and ovarian cancer (Sayer et al., (2005), Little et al., (2000)) thus not likely to generate novel 
information, however philosophically, outside of the remit of this project are still worth research 
endeavours. Just because a biomarker has already been reported it cannot be concluded from 
this that there is nothing more that can be learned from further investigation with a different 
focus. Comprehensive collaborative review articles often comment on the abundance of 
publications which implicate a gene or protein expression to ovarian cancer yet the distinct lack 
of follow-up, validation and weaving these findings into a larger biological story/ scene (Braem 
et al., (2011), Bowtell et al., (2015)). Bowtell et al., (2015) calls for describes how the ovarian 
cancer research area is now at the stage to move from a parts list to focus resources to a more 
comprehensive, integrated approach combining acquired knowledge resources. This project has 
highlighted the speed mass spectrometric protein analysis technology has advanced in recent 
years and minute protein concentration changes that were previously undetectable could now 
be possible, but reanalysis of the appropriate patient cohort with the correct detection system is 
key.  
 
Validation Strategies 
186 
 
For example Sayer et al., (2005) found IGF2 expression to associate with cancer progression 
however it was not significantly helpful in detecting early stage ovarian cancer – a core clinical 
question. It could be that a different detection method such as an MRM would help For a 
biomarker to be applicable in a clinical setting routine screening needs to be possible in a 
hospital lab at low cost. IGF2 overexpression has been shown in relation to the cancer 
progression (Sayer et al., 2005), thus is less likely to be a good biomarker of the early stage 
disease. However this depends on the sensitivity of the detection method applied. It is possible 
that there are currently unmeasurably small fluctuations in IGF2 expression in earlier stage but 
for now current investigations may be more informative if focused on its potential to guide 
treatment by predicting poor responders who develop a resistance to platinum therapy. Evidence 
from cell line studies have shown IGF2 as a possible therapeutic target (Sayer et al., 2005). 
 
Ganzfried et al., (2013) is an example of how mining databases of curated microarray data can 
be teamed with protein expression information to provide supporting evidence. In this example 
they match a trend of significantly lower survival time in ovarian cancer patients whose tumours 
have a higher expression of CXCL12, their hypotheses was from published data (Popple et al., 
2012 as referenced in Ganzfried et al., (2013)). However, on close inspection, out of a database 
of 21 cohorts mentioned the significant trend is reported only in three. It is not clear whether 
this is deliberate (i.e. the remaining 18 were not able to be assessed) or whether in these the 
result was not significant. 
 
Additionally, when KM Plotter is searched, none of the probes for CXCL12 were found to be 
significantly associated with survival time. Eight out of the ten cohorts on KM plotter are the 
same as in Ganzfried et al., (2013) leaving these finding ambiguous as they are not obviously 
reproducible.  
 
Researchers must take care not to bias results by ‘cherry-picking’ significant values, yet 
conversely not discount a potential finding as it does not meet a stringency criteria that has been 
arbitrarily set. 
 
If mass spectrometric verification were to be attempted, there is no guarantee that if the protein 
product of the gene of interest were to be present, even then, it still may not ionise or be 
detectable by mass spectrometry. The absence of detection could not count as a confirmed 
failure to verify genomic data. For example, as different peptides ionise with different 
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efficiencies on different sources (Greaves and Roboz 2014), researchers facing an absence of 
detection would be inclined to try a mass spectrometric method with a different source amongst 
other method development before accepting a null hypothesis. Additionally, said hypothetical 
biomarker may be present, but at a level below the limit of detection (Chapman et al., 2014), 
or be lost in source decay. 
 
There are several ways the verification stage of this study could be re-examined. If considered 
a worthwhile endeavour this could yield further insight or value to genes of interest and at low 
financial cost.  
 
For example KM plotter could be further explored by systematically cycling through the sample 
filters available in its interface. Using its filters to select subsets of samples an examination of 
a GOI could be investigated and focus the search to one attribute, namely drug treatments. For 
example, it may be possible to implicate a GOI to be linked to a platinum Chemoresistance 
pathway. If a high significance between long and short term survival were observed in a 
platinum treated subset and not in a subset treated by another drug. However, the feasibility of 
this has not been explored. KM plotter is a valuable tool, however its potential use is still 
confined by the limitations explored above (section 6.2.3.). 
 
6.5. Conclusion of Verification Strategies 
 
It was concluded that 7 of the 56 genes (DCN, EDNRA IGF2, NAV3, TNFAIP6, WTAP and 
PPFIBP1) of interest were verified to significantly associate with ovarian cancer when 
investigated using KM plotter. Only one of these genes were attempted to be verified by 
immunohistochemistry, EDNRA was shown to significantly associate with stage, grade and 
histology of ovarian cancer. 
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7. Discussions for Future Work and Overall Conclusions 
 
This thesis sought to identify markers of ovarian cancer using the available technology at that 
point in time. Through developments of MALDI, LC-MALDI and expression array platforms, 
a number of challenges were encountered. In some cases alternative method strategies were 
designed and implemented, in other cases recommendations for future work were made, or, 
reanalysis when upgraded technological platforms capable of accurate quantitation better 
placed to deliver this become available. 
 
The body of work presented here has taken a holistic/bottom-up approach avoiding the use of 
animal models, which do not best represent human disease (Vaughan et al., 2012) or cell lines, 
which do not reflect the vast diversity of the disease (Fleury et al., 2015).  
 
In summary, after a lack of assurance of the validity of results from protein biomarker 
investigations using MALDI-TOF-MS, a change of direction of the project was made to focus 
on the data mining of gene array experiments. A meta-analysis of two data sets using three 
analytical methods generated a focus list of 56 genes of interest. 
 
7.1. Ongoing Unmet Clinical Need and Future Work Required  
 
This project has explored and evaluated potential biomarker strategies for diagnostic and 
prognostic biomarkers of ovarian cancer. Several transcriptomic markers were verified in a 
larger cohort of samples, and one was verified at a protein level. Feasibility has been a common 
limitation throughout all approaches, thus the success and order of future work will be 
dependent on availability of resources. It is foreseeable to overcome some obstacles, namely, 
patient material appropriate to answer the designed clinical question, and some limitations are 
beyond the remit of any one individual researcher to tackle i.e. the availability and integration 
of gene and protein nomenclature, interaction or signalling pathway information. 
 
There are numerous possibilities for future work and a clearly defined and urgent unmet clinical 
demand (Bowtell et al., 2015). However, the obstacles hindering this research remain the same, 
namely, lack of sample cohorts relevant to the clinical question especially in the case of early 
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biomarker detection and the heterogeneity of the disease hindering classification and 
understanding. 
Recently Bowtell et al., (2015) reviewed and defined an international collaborative agreement 
to prioritise and steer future research in ovarian cancer, these include;  
 To move from a ‘parts list’ to a more integrated view. Meaning integration of existing 
and emerging evidence to further understanding. 
 Improving the currently used experimental models. 
 Understanding drug response as much as chemo-resistance. 
 Gain a deeper understanding of the tumour microenvironment. 
 Harnessing and exploiting the immune response and interaction within the tumour 
microenvironment. 
 Understanding clonal diversity, recurrent disease and exceptional responders. 
 Move to stratified trials of high grade serous ovarian cancer (HGSOC) subsets. 
 Implement strategies that could make a rapid impact on prevention and clinical care. 
 
Arguably the most important of these is to act on anything that could make a rapid impact on 
prevention or clinical care. Most poignant to the current body of work is the aim of achieving 
a wider integrated understanding of the disease as opposed to a ‘parts list’, this statement is an 
echo of Braem et al., (2011) 4 years prior, urging a move from biomarker discovery to 
investigation and verification. As this body of work has also shown, the discovery platforms 
and investigative tools are fast advancing, namely global protein expression and quantitation in 
different samples (Section 4.6.1., Law et al., 2013). The ability to compute and combine large, 
complex data sets is also advancing fast (Section 2.1.2., SCIEX 2016), the ability to marry 
significant genomic/transcriptomic biomarker observations to proteomic observations from the 
same samples would be highly insightful to the understanding on cellular processes in 
subgroups of ovarian cancer.  
 
The chance of attaining any future publication or funding to further the above body of research 
would be more successful if based around these collaboratively agreed guidelines of Bowtell et 
al (2015). The sentiment of some of the above points were bore in mind when undertaking this 
work, as discussed in section 4.6 where the call to re-examine existing data (Braem et al., 2011) 
influenced the work towards the analysis of microarray data, however sample availability or 
lack of, inadvertently steers research. Bowtell et al., (2015) emphasises the need to direct 
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research to answer the specific clinical questions, however, this is not possible without the 
appropriate data set. A well devised huge-scale prospective databank collection, such as 
UKCTOCS, is the only way to attain this.  
 
It is possible that much of the information needed to understand the complexities of ovarian 
cancer already is available as Braem et al., (2010) suggests, and that re-examining all existing 
information by an enormous-scale cross platform data mining of databases and integration of 
genomic, proteomic, transcriptomic, cell line or aetiological studies could unearth additional 
and relevant information. However, this is not likely to attract funding/support due to the large 
amount of resources needed to conduct, for an undefined potential final measurable outcome.  
 
7.1.1. Targeted Protein Mass Spectrometry Based on Transcriptomic Discovery as a 
Strategy for Future Work. 
 
An MRM/SRM experiment could be designed for the coded proteins of the verified genes of 
interest generated from transcriptomic data in Chapter 5.  A seemingly appropriate potential 
data set that could be re-examined this way does now exist (Russell et al., 2016), this study 
incorporates patient cohorts which are sourced from the UKCTOCS investigation conducted in 
2001 to 2005 (Jacobs et al., 2015), however their raw data is not yet publicly available for re-
analysis. 
 
The biomarker discovery strategies explored in Chapter 3 and 4 were found to be of insufficient 
quality to be used as a biomarker discovery tool. However, other mass spectrometric approaches 
could be more strategically employed should more time, funding, resources become available. 
With current, more advanced technology, the protein transcripts of the gene markers of interest 
generated in the above chapters could be explored. The genomic validation step from KM 
plotter (Chapter 6.2) filtered the interest list down to seven genes, a number suitable for a 
targeted mass spectrometry strategy as recommended by Marx (2013) (Chapter 4). As 
evidenced by Morcavello et al., (2014) DCN, one of the seven GOIs, is able to exist in the 
extracellular space, and its ligand role to IGF2 makes it a particularly interesting focus for 
potential targeted mass spectrometry experiments such as MRM/SRM or SWATH (see section 
4.6). In such a method the expected fragment m/z values from each peptide fragment could be 
calculated using the known amino acid sequence the protein of the genes of interest (available 
via Uniprot) and an appropriate software such as Skyline, which is also freely available. From 
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this, a selective reaction monitoring experiment could be set up with an appropriate mass 
spectrometer to selectively measure the quantity, if any, of each of the fragments in the sample 
with both accuracy and high sensitivity. 
 
Using the targeted MRM/SRM/SWATH mass spectrometric approach for protein verification 
is advantageous over immuno-body based techniques (Marx 2013, Baker 2015) it is arguably 
cost effective, and accurate both qualitative and quantitative accuracy of measurement, 
increasing the size of experiment possible: If the capital equipment is in place (as antibodies, 
or designed kits do not need to be purchased) it is possible to assay more target molecules for 
the same cost. Additionally the accuracy of antibodies compared to MRM experiments for 
confirmation of target protein presence has been discussed (Marx 2013, Baker 2015), it would 
be possible to confirm and quantify all of the coded proteins of the genes of interest. For an 
example the reader is referred to Russell et al., (2016), who, utilise the latest data independent 
tandem mass spectrometry technology for ovarian cancer biomarker verification. The data 
independent SWATH method applied in this study negated designing a specific MRM 
experiment. All peptide fragments from the digested serum were quantified, then algorithms 
applied to assign which fragment data matched to the values of their genes of interest. A higher 
number of potential biomarkers can be investigated using a SWATH data independent approach 
as all peptide fragments in the analyte are directed through all quadrupoles in the mass 
spectrometer to the detector where they are measured. This moderately decreases the sensitivity 
when compared directly to a specific MRM experiment as signal at the detector is distributed 
across all the other fragments hitting it at any given time, but does still provide high quality 
quantitative data. 
 
As discussed in Chapter 4.6.2, the serologic proteomic analysis of the samples available to this 
study (see chapter 4.6) was found to be a suboptimal use of resources in a research landscape 
including such studies as Russell et al., (2016), who, both utilise the next generation of MS 
technology and have greater sample numbers. Instead/ moreover, should the opportunity arise 
the raw data acquired in the Russell et al., (2016) could be utilised to add to the body of evidence 
built in the current study: the raw/SWATH data could be mined to quantitate the calculated 
transition values of DCN, EDNRA, IGF2, NAV3, TNFAIP6, PPFIBP1 and WTAP proteins 
providing translational verification. For example if the raw/SWATH data was made available 
via a resource such as PRIDE. As patient survival information is available and the sample 
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number is comparative or larger, this would be a highly relevant and appropriate translational 
validation of the genes of interest arising from the present study (Chapter 6.1). 
 
7.1.2. Clarity and Cohesiveness of Current Resources Challenge Future Work 
 
As discussed in section 5.4.5. and demonstrated above, re-exploration of publically available 
genomic or transcriptomic large data sets is an endeavour with potential to generate both novel 
results, and, a novel perspective on existing data. Moreover, meta-analyses to increase both 
sample number and the scope of type of data analysed, adds rigor to any results generated. 
Hence this should be continued to be incorporated into future study design. Data sets found to 
be comparable/akin to those used in the Chapter 5 and those of utilised in (Ganzfried et al., 
2013) would be most relevant to continue research with a goal of subcategorising subpopulation 
of ovarian cancers.  
 
Encouragingly, more resources are constantly becoming available as discussed in section 5.4.5. 
However, if this work were to be conducted care must be taken to clarify the source of data 
before is used as discussed in section 2.2.3. It is important to note that in the spirit of data 
sharing data from the same sample may be represented by numerous databases for example the 
ICGC sources data from TCGA and CPTAC. Before utilising one we need to untangle where 
each source their data. For example the Cancer Genome Project (CGP) originated from the 
Human Genome Project at the Sanger Institute and, The International Cancer Genome 
Consortium (ICGC), the Cancer Genome Atlas (CGA) and the Clinical Proteomic Tumour 
Analysis Consortium (CPTAC). It must be considered that the/this multiple representation of 
the same data by a different title/name could transpire to misinterpreted or misrepresented 
findings and even further bias the emphasis on that data. Misrepresentation double reporting of 
data is a potential problem: for example, a researcher conducts a novel experiment to generate 
a list of genes or proteins of interest in relation to a cancer, a logical progression of this research 
would be to compare to already published results then proceed to validation. They may find 
two pieces of evidence on data repositories linking a gene to the cancer where: Firstly, it may 
not be obvious without a significant amount of secondary research that the two pieces of 
information came from the same sample. Secondly, after reporting their results, the role of the 
already associated genes to the cancer may be exaggerated by over reporting and the genes that 
are not or ambiguously linked via literature search, though potentially relevant, may remain 
unmentioned or under reported.  
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7.1.3. Integration of Cross-Platform Data Challenges Future Work 
 
As discussed above, the concept of using one or a few biomarkers to detect and monitor a 
complex system, such as a tumour surviving within a host disease has been argued to be a 
reductionist, or overly simplistic (Strimbu et al., 2011) measurement, however, a measurable 
factor from an easily attainable patient sample is key to improving patient prognosis. As 
outlined by Hanahan and Weinburg (2011), Strimbu et al., (2011) suggests biomarkers will only 
be able to be implemented as accurate measurements of clinical endpoints once normal cellular 
function and physiology has been fully mapped out, which it has not yet been. Gil et al., (2015) 
points out, the technical platform or computing power to attain this does not currently exist. 
 
This study contributes to a growing body of evidence or each of the thousands of genes 
investigated, not just those that were shown to have a significant relation to survival time. The 
relevance of each gene in relation to survival time from ovarian cancer contributes to an ever 
expanding body of evidence connected through online resources mapping out cellular function 
under diseased and normal conditions such as STRING, Reactome, KEGG and more. In chapter 
6 the three of the finalised GOIs are placed in two cellular pathways already known to manifest 
some hallmark phenotypes of cancer, this offered insight into their relevance and whether they 
may be of use as future biomarkers or targets of therapy. However, the KEGG database from 
which these were created, though extensive, is not yet comprehensive. An integration of data 
acquired at all levels of cellular function is called for.  
 
As Hanahan and Weinburg (2011) and Strimbu et al., (2011) elude to, an ideal-scenario-tool for 
an integrated research model, that is not currently logistically fathomable/foreseeable would 
enable the analysis to be expanded across acquisition platforms. More specifically encompass 
genomic transcriptional and proteomic translational data, and as software becomes available, 
to integrate measurements from all experimental platforms: genomic, proteomic, metabolomics 
lipidomic etc. The overall goal being a quantified ‘ome’ from multiple derivatives of each 
sample. For example, cancer tissue, sera, plasma, saliva, urine, white blood cells and more from 
each patient of a cohort, ideally the cohort would contain over 1000 cases. 
 
A realistic best-case scenario using currently available platforms would include experimental 
measurements of the genome as measured by de-novo next generation sequencing (Koboldt et 
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al., 2013), and these measurements easily matched to and compared against the translated 
proteome as measured by a data independent de-novo sequenced platform data which included 
all post translational modifications, and any future platforms of measurement based in place of 
probing of known or matching to known factors.  
 
Other considerations for future work: 
 To reiterate what is discussed in section 6.5, some genes were found to associate with 
survival time from ovarian cancer, IGF2 and WTAP were discounted from further 
verification for this work as the previous reporting was counted as verification (Sayer 
et al., (2005), Little et al., 2000). However these genes and proteins should not be 
discounted from future validation or investigation. Although their association has 
already been reported their role each tumour microenvironment still remains to be 
expanded, and made part of a larger biological story/ scene (Braem et al., 2011, Bowtell 
et al., 2015). 
 If a biomarker is recognised to be a suitable drug target this may still be of limited use. 
A drug designed to target one component in the molecular pathway, it is likely that 
inhibiting/blocking one pathway component the other components of the pathway 
compensate. To further complicate the matter, these are not necessarily of tumour origin 
and are more likely in or related to the tumour microenvironment. (Vaughan et al., 
2012). A full system of up or down regulated genes or proteins would need to be isolated 
and targeted. 
 Though limited cell lines of well characterised histopathological origins are reported to 
be needed. New technologies such as three-dimensional growth platforms are available 
to better recapitulate the micro-tumours growth pattern and signalling (Vaughan et al., 
201, Hickman et al., 2016). 
 Immunofluorescence to view subcellular localisation of genes of interest would be 
insightful.  
 
7.2. Overall Summary and Conclusions 
 
The purpose of this study was to meet an ongoing unmet clinical need to detect and diagnose 
subpopulations to effectively treat ovarian cancer (Wilson and Junger (1968) in Nossov et al., 
(2008), Vaughan et al., 2012, Menon et al., 2014, Bowtell et al., 2015). As the stage of an 
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ovarian cancer at diagnosis is the key prognostic indicator (Erickson et al., 2014). Thus, the 
strategic clinical question to address first was to discover novel serologic protein biomarkers 
for early detection of ovarian cancer. Thus, the study began with this aim.  
 
Chapter 3 and 4 investigated the merit and reliability of MALDI TOF MS/MS as a biomarker 
generation platform. It was concluded that the instrumentation used had limited applicability in 
the biomarker discovery process. In Chapter 5 a meta-analysis of serous Stage 3 ovarian cancer 
samples generated a list of 56 genes paired with evidence from three analyses, Cox univariate, 
ANN and T-test, implying their significant association with survival time of patients with 
ovarian cancer. Finally in Chapter 6 the results were validated on a larger cohort of microarray 
data narrowing the interest list down to 7 genes. One of the genes was further verified at a 
protein level and evidence supporting its differential protein suppression between cancer stage 
and grade and histopathology were shown to be significant. 
 
In Chapter 3 a preliminary, bottom-up MALDI-TOF-MS based analysis of serum protein was 
conducted on a sample cohort collected in a manner addressing criticisms of peer research at 
the time. Unique patterns in protein expression in the sera were detected by MALD-TOF-MS 
and ANNs and were used in an attempt to distinguish cancer from control on a blinded 
validation set. Unfortunately insufficient data or evidence linked the m/z of the peptide peaks 
expressed differentially in the tested serum to protein identities by matching them to data from 
linked LC-MALDI-MS with the MS profiles. The full panel of peptide peaks could not be 
identified so full validation of the biomarker panel could not be attempted. 
 
In Chapter 4 the next generation of MALDI-MS analysis platform was evaluated for use as an 
ovarian serum protein biomarker detection tool. It was concluded that the intensity values of 
MALDI-TOF-MS data can be used to indicate relative protein quantity within a sample, 
however it was noted that the accuracy of this type of analysis was low and did not allow a 
robust and meaningful comparison to be made between samples. One sample preparation 
technique resulted in generating more reproducible peptide identities than others. The 
differences in the LC-MALDI-MS profiles of serum samples produced under different 
conditions was shown using a qualitative and semi-quantitative method and neither yielded list 
of proteins large or consistent enough to contribute with novelty to serum protein biomarker 
discovery. 
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Evidence was also provided to suggest that, both sample processing workflows tested reduced 
the number of reproducible identities attained from samples and clinical samples should be run 
in at least triplicate to reduce the number of false identities attained. Of the two methods of data 
export and analysis conducted, different conclusions can be drawn from the raw data collected. 
Most importantly from this evaluation it was concluded that this sample platform was not 
reproducible enough to warrant the use of limited, rare sample cohort and resulted in modifying 
the research focus to include different data sources and the application of bioinformatic data 
mining of publicly available data sets in an attempt to discover valid ovarian cancer biomarkers.  
A meta-analysis of mRNA microarray data from two cohorts of serous Stage 3 ovarian cancer 
samples generated a list of 56 genes paired with evidence from three analyses; Cox univariate, 
ANN and T-test implying their significant association with survival time from ovarian cancer. 
 
Within the listed caveats of the material available for study, 56 genes were found to significantly 
and consistently associate with survival from ovarian cancer. The meta-analysis tactic added 
confidence to the 56 inferred associations. Verification of the 56 genes was conducted on a 
wider sample cohort using a freely available web tool. Evidence confirmed the association of 
the following genes expression with survival time from Stage 3 serous ovarian cancer: DCN, 
EDNRA, IGF2, NAV3, TNFAIP6, WTAP and PPFIBP1. Literature review was used to select 
one of these genes, EDNRA, for preliminary protein verification, using immunohistochemical 
staining of a TMA of ovarian tumour tissue. The results correlated EDNRA expression with 
ovarian stage, grade and cancer histology. 
 
This study generated evidence supporting the role of several genes effect on survival time from 
ovarian cancer at a transcriptomic level and one at both gene and protein. These results 
contribute to current knowledge and provide substantial evidence to base future investigation 
upon.
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